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SUMMARY
Exposure of endothelial cells (EC) and blood vessels to elevated 
glucose elicits the formation of reactive oxygen species, resulting in NO 
insufficiency and vascular dysfunction. Oxidative loss of 5,6,7,8- 
tetrahydrobiopterin (BH4), an essential endothelial NO synthase (eNOS) 
cofactor, has been implicated as a mechanism of diabetes-associated NO 
insufficiency. Experiments examined the possibility that intracellular 
accumulation of catalytically-incompetent 7,8,-dihydrobiopterin (BH2) 
effectively competes with BH4 for eNOS occupancy, driving uncoupled 
superoxide production in lieu of NO. BH2 was undetectable in murine EC 
cultured in low glucose (5 mM), but comprised 40% of total pterin (BH4 and 
more oxidized species) after 48 h exposure to diabetic glucose levels (30 mM) 
-  high glucose did not attenuate total pterin. Concomitant with BH2 
accumulation, A23187-evoked NO activity was dampened and superoxide 
production was accelerated -  this was accompanied by evidence of 
peroxynitrite formation, via reaction of NO with superoxide. Superoxide 
overproduction was abolished with a selective NOS inhibitor and with eNOS 
gene silencing, implicating uncoupled eNOS as the source. BH4 oxidation in 
EC was prevented by supplementation with glutathione (GSH) and 
accelerated by GSH depletion, linking thiol reserves to intracellular pterin 
redox status. Progressive BH4 oxidation and protein tyrosine nitration were 
recapitulated in vivo in the Zucker Diabetic Fatty rat model of type II diabetes 
and the atherosclerotic ApoE knockout mouse. These findings implicate 
diminished intracellular BH4:BH2, rather than depletion of BH4 per so, as the 
trigger of endothelial cell dysfunction in chronic vascular conditions such as
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diabetes and atherosclerosis, where oxidative stress is a feature. Therapeutic 
approaches that can transiently re-couple eNOS would provide a means to 
break the cycle of endothelial dysfunction and lead to long-term reinstatement 
of vascular health. These data show that, N“ -hydroxy-L-arginine (NOHA) 
reacts with superoxide and other reactive oxygen species, releasing NO 
and/or NO-related species. Notably, while unable to synthesize NO from its 
normal substrate arginine, BH2-bound eNOS is still able to synthesize NO 
from the reaction intermediate NOHA. Administration of NOHA to our high 
glucose endothelial cell model is effective in restoring NO synthesis while 
simultaneously reducing O2', thus restoring BH4 levels and normal endothelial 
function.
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1.0 INTRODUCTION
1.1 Nitric Oxide: The discovery of a new biological 
messenger
Nitric oxide (NO) is a small, lipophilic, free radical gas discovered by 
Joseph Priestly in 1772. Since the 1970’s NO was known to be produced by 
certain bacteria (Iwasaki and Matsubara, 1972), but the importance of NO in 
mammalian biology was originally considered to be exclusively as an 
environmental toxin. Following the discovery that endothelial cells are 
required for acetylcholine-induced (ACh) relaxation of vascular smooth 
muscle, it was proposed that ACh causes the release of a labile substance 
from the endothelium resulting in arterial vasodilation. This substance, 
termed endothelial-derived relaxing factor (EDRF) (Furchgott and Zawadzki, 
1980) was shown to stimulate the conversion of GTP to cyclic GMP (cGMP) 
(Holzmann, 1982) via the activation of soluble guanylate cyclase (sGC) 
(Forstermann et al., 1986; Ignarro et al., 1986), causing smooth muscle 
relaxation through activation of cGMP-dependent protein kinase.
In 1978 Murad and coworkers studied the endothelium-dependent 
vasodilatory effects of azides and other nitrogen-containing compounds such 
as glyceryl trinitrite and sodium nitroprusside (Murad et al., 1978), 
demonstrating that these compounds elicit relaxation of vascular smooth 
muscle via activation of sGC and consequent cGMP-dependent protein 
phosphorylation (Fiscus et al., 1983). In 1987 two groups showed 
experimentally that EDRF is indistinguishable from NO (Ignarro et al., 1987; 
Palmer et al., 1987). This discovery supported the earlier proposal by
1
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Furchgott and Ignarro that NO is a biological messenger in the cardiovascular 
system (Furchgott, 1988; Ignarro et al., 1988a).
Although evidence for the identity of EDRF as NO was compelling, 
acceptance of the hypothesis was slow due to the lack of an identifiable 
pathway for mammalian NO biosynthesis. However, evidence for the 
existence of a biosynthetic pathway was actually reported as early as 1916 
with the finding that urine of rats, pigs and humans contain more nitrite than 
they ingest (Mitchell, 1916) and furthermore, that nitrite levels are elevated 
during infection (Stuehr and Marietta, 1985; Wagner et al., 1983). 
Subsequent studies then showed that murine macrophages, 
immunostimulated with Escherichia coli lipopolysaccharide (LPS) and 
interferon gamma (IFNy) synthesize nitrite (NO2 ), nitrate (NOa") (Stuehr and 
Marietta, 1987) and citrulline, from L-arginine via the oxidation of one of the 
two chemically equivalent guanido nitrogens (Hibbs et al., 1987b; Iyengar et 
al., 1987; Stuehr and Marietta, 1987). In 1988, the amino acid L-arginine was 
first shown to be a precursor for the synthesis of NO and L-citrulline in 
vascular cells (Palmer et al., 1988a; Sakuma et al., 1988). Endothelial cells 
cultured in the absence of L-arginine were observed to have a decrease in the 
amount EDRF released in response to either calcium lonophore (A23187) or 
bradykinin. This decrease could be fully restored with L-, but not D-arginine, 
and was inhibited by N-guanadino-substituted arginine analogues such as N°- 
methyl-L-arginine (L-NMA) (Palmer et al., 1988b). Neuroscientists finally 
joined the toxicologic, immunologic and cardiovascular fields in 1991, when 
experiments in brain slices were reported showing that treatment with 
excitatory neurotransmitters stimulated sGC via NO (Garthwaite, 1991).
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Nitric oxide synthase (NOS), the enzyme responsible for the production 
of NO from arginine, was purified from brain and characterized in 1990 (Bredt 
and Snyder, 1990). The widespread distribution of three distinct NOS 
isoforms in a variety of cell types is known to mediate the diverse biological 
functions of NO and impact on virtually all organ systems. The pioneering 
work by Furchgott, Ignarro and Murad on the role of NO in the cardiovascular 
system was recognized in 1998 when they shared the Nobel Prize for 
Physiology or Medicine.
1.2 Physiology and pathophysiology of NO
NO has been shown to mediate numerous important physiological 
functions. From the original discovery of NO/EDRF as a physiological 
regulator of vascular tone (Furchgott, 1988; Ignarro et al., 1988b; Palmer et 
al., 1987), evidence now shows important roles for NO in suppressing platelet 
aggregation (Furlong et al., 1987; Radomski et al., 1987b) and contributing 
importantly to innate immunity (Hibbs, 2002; Hibbs et al., 1987a; Hibbs et al., 
1987b; Marietta et al., 1988), inflammation (Harbrecht et al., 1995), 
neurotransmission (Bredt and Snyder, 1989; Garthwaite, 1991), learning and 
memory (Bohme et al., 1993; Estall et al., 1993; Holscher and Rose, 1992), 
penile erection (Adaikan et al., 1992; Ignarro et al., 1990), gastric emptying 
(Plourde et al., 1994; Takakura et al., 1997), hormone release (McCann et al., 
1997; Seilicovich et al., 1995), cell differentiation (Morbidelli et al., 1996), cell 
migration (Noiri et al., 1997), and apoptosis (Albina et al., 1993; Sarih et al., 
1993; Yoshioka et al., 2003) . More recent advances in the NO field have 
implicated NO, or more specifically NO signaling by protein S-nitrosylation, in
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the regulation of oxygen delivery by hemoglobin (Gow et al., 1999; McMahon 
and Stamler, 1999; Singel and Stamler, 2004).
The cardiovascular system
The endothelial L-arginine/NO pathway plays a pivotal role in the 
homeostatic regulation of vascular tone and blood pressure. Endothelial- 
derived NO is produced by the vascular endothelium under basal conditions, 
and its production is increased in response to a variety of vasodilatory stimuli 
including bradykinin, ACh, histamine, purines, estrogen and vascular shear 
stress. Endothelial-derived NO is a major endogenous vasodilator, 
counterbalancing vasoconstriction imposed by the sympathetic nervous 
system and the renin-angiotensin system. As noted above, NO-induced 
vasodilation results from stimulating sGC and increasing cGMP in vascular 
smooth muscle cells (Forstermann et al., 1986; Rapoport et al., 1983). 
Administration of arginine analogues, such as L-NMA, inhibits NOS and leads 
to peripheral vasoconstriction in all mammalian species studied (Aisaka et al., 
1989; Tresham et al., 1991). Moreover, endothelial NOS (eNOS) knockout 
mice have been shown to be hypertensive and have impaired vasodilatory 
responses to ACh, confirming a physiological role for endothelium-derived NO 
in vasoregulation (Shesely et al., 1996).
In addition to its vasodilatory actions, endothelial NO has 
vasoprotective and anti-atherosclerotic properties. NO is a potent inhibitor of 
platelet aggregation and adhesion to the vascular wall (Radomski et al., 
1987a; Radomski et al., 1987c), protecting the vessel from thrombosis and 
preventing the release of platelet-derived growth factors that stimulate smooth 
muscle cell proliferation. NO has been shown to decrease the expression of
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genes involved in atherogenesis, including the chemoattractant protein MCP- 
1 (Tsao et al., 1997), cell surface adhesion molecules such as CD11/CD18 
(Arndt et al., 1993; Kubes et al., 1991), P-selectin (Gauthier et al., 1995), 
VCAM-1 and ICAM-1 (Tsao et al., 1996). Decreased expression of these 
proteins protect against the early phases of atherogenesis by preventing 
leukocyte migration and adhesion to the vascular wall.
A number of disorders are associated with a reduced bioavailability of 
vascular NO, as well as elevated production of the reactive oxygen and 
nitrogen species, superoxide anion (O2') and peroxynitrite (ONOO), 
respectively. Such conditions include diabetes mellitus (Du et al., 2001; 
Shimizu et al., 2002), hypertension (Landmesser et al., 2003), 
hypercholesterolemia (d'Uscio et al., 2001) and vascular defects associated 
with chronic tobacco smoking (Higman et al., 1996; Ueda et al., 2000). 
Endothelial dysfunction is the failure of the endothelium to subserve its normal 
role in vascular homeostasis. It has been shown to be responsible for the 
reduced vascular reactivity observed in these conditions (Anderson, 2003; 
Bautista, 2003; De Mattia et al., 2003; Ihlemann et al., 2003), although the 
cause and mechanisms remain unclear.
Whereas, endothelial dysfunction is associated with a reduced 
bioavailability of NO, septic shock is a condition that is associated with NO 
overproduction. Septic shock results from systemic bacterial infections when 
host defenses are overwhelmed. Evidence indicates that the cytokine- 
mediated induction of iNOS is a key event in the etiology of septic shock, 
resulting in continuous production of large quantities of NO. This excess NO 
leads to extreme hypotension and progressive failure of the circulation to
Mark J. Crabtree BH4 oxidation in models of vascular disease 2005
provide oxygenated blood to vital organs, causing death in over 50% of cases 
(Bone, 1994; Thomas et al., 2003; Titheradge, 1999).
1.3 Nitric oxide synthase isoforms and their regulation
The three isoforms of nitric oxide synthase (NOS) are encoded by 
distinct mammalian genes (Xie and Nathan, 1994). Two of the three isoforms 
are constitutively expressed in cells and synthesize NO primarily in response 
to transient elevations in intracellular Ca '^" levels, a process mediated by 
binding of calcium-calmodulin (CaM) (Fleming et al., 1998). These 
constitutive enzymes are designated neuronal NOS (nNOS or NOS I) and 
endothelial NOS (eNOS or NOS III) after the cell type and order in which they 
were discovered. The third isoform, or inducible NOS (iNOS or NOS II), is 
typically synthesized in response to inflammatory stimuli, but has been shown 
to be constitutively expressed in some tissues, such as lung epithelium 
(Dweik et al., 1998). The main difference between iNOS and the constitutive 
NOS isoforms is the high-affinity binding of CaM to iNOS such that it remains 
bound even at subnanomolar levels of Ca^  ^(Cho et al., 1995).
The first NOS to be isolated, nNOS, was purified from rat brain (Bredt 
and Snyder, 1990). nNOS was found to be dimeric, with each monomer 
consisting of an N-terminal oxygenase domain and a C-terminal reductase 
domain, bridged by a short (approximately 30 amino acid) calmodulin binding 
peptide. The oxygenase domain contains binding sites for heme, 
tetrahydrobiopterin (BH4) and L-arginine, forming the active site where NO 
synthesis takes place. The reductase domain shares approximately 40% 
sequence homology with NADPH cytochrome P450 reductase (Bredt and
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Snyder, 1990) and contains binding sites for FMN, FAD and NADPH (Bredt et 
al., 1992; Stuehr and Ikeda-Saito, 1992). During NO synthesis the flavins in 
the reductase domain of NOS serve to transfer electrons from NADPH to 
heme iron in the oxygenase domain (triggered by CaM binding in nNOS and 
eNOS), allowing the activation of heme-bound molecular oxygen for NO 
synthesis (Masters et al., 1996a; Masters et al., 1996b). Subsequent 
purification and cloning of the two other NOS isoforms showed that they share 
the same basic bidomain structure where each is an obligate dimer, with the 
reductase domain of one monomer supplying electrons to the oxygenase 
domain of the other (Figure 1.1).
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Figure 1.1 Comparison of the domain structure and cofactor binding 
features of the three mammalian nitric oxide synthase isoforms. Note 
that the N-termini of each isoform is unique and serves the function of isoform 
specific subceilular targeting.
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1.3.1 Inducible nitric oxide synthase (iNOS)
The inducible form of the NOS enzyme has been shown to play a 
prominent role in host defence and is a major mediator of innate immunity. 
iNOS was first isolated from macrophages where its activity was found to be 
inducible in response to proinflammatory cytokines, including IL-1 (Kilbourn et 
al., 1992), IL-2 (Kilbourn and Griffith, 1992), TNFa (Kilbourn et al., 1990a) and 
bacterial LPS (Kilbourn et al., 1990b). Despite the beneficial role NO plays in 
host defence, immunostimulant-induced increases in vascular NO have been 
shown to be responsible for the severe and potentially lethal hypotension 
exhibited in septic shock (Kilbourn et al., 1993).
The importance of iNOS-derived NO for protection against specific 
pathogens was characterized in iNOS knockout (iNOS -/-) mice. It was shown 
that the lethal dose (LD50) of Listeria monocytogenes was 10 fold lower in 
iNOS -/- mice, in comparison to wild type mice (MacMicking et al., 1995), 
suggesting that iNOS contributes to host survival following infection with this 
bacteria. Conversely, after inoculation with Influenza A, iNOS -/- mice 
demonstrated better survival rates than wild type mice, indicating that the 
inflammation associated with iNOS induction was of greater harm to the host 
than the initial viral infection (Akaike et al., 1996). Hence, it was concluded 
that the relative benefit of iNOS-derived NO in the control of infection is 
dependent on both the type of pathogen and immune response evoked.
1.3.2 Neuronal nitric oxide synthase (nNOS)
nNOS is encoded by one of the most structurally diverse human genes; 
extensive post-transcriptional regulation occurs via alternative mRNA splicing
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(Wang et al., 1999a; Wang et al., 1999b). There are four principal nNOS 
splice variants known as nNOSa, nNOSp, nNOSy and nNOSp (Brenman and 
Bredt, 1996; Huang and Lo, 1998). The factors determining the alternative 
splicing events and the biological significance of the splice variants remain 
poorly understood, although it has become apparent that the alternative splice 
variants are expressed in a tissue-specific manner. The principal nNOS 
variant in the brain is nNOSa, with nNOSp being expressed predominantly in 
the heart and skeletal muscle (Huang et al., 1993).
The N-terminal 220 amino-acids of nNOS are unique to this NOS 
isoform; notably, variants a and p contain a PDZ domain (multifunctional 
protein-interaction motif) that targets nNOS to distinct membrane patches in 
brain and skeletal muscle (Brenman et al., 1996; Christopherson et al., 1999).
The phenotype of nNOS knockout animals has highlighted the 
significance of nNOS in a variety of biological functions. In the cerebellum, 
Ca '^" influx through NMDA receptor-gated channels mediates the activation of 
nNOS, resulting in NO production from the postsynaptic neuron 
(Christopherson et al., 1999) that plays a role in learning and memory. In 
skeletal muscle, nNOS co-localizes with nicotinic ACh receptors at the motor 
end-plate and is activated upon membrane depolarization where it directs 
increased blood flow to sites of muscle activity (Mang et al., 2002).
1.3.3 Endothelial nitric oxide synthase (eNOS)
Transcriptional regulation
In recent years, the regulation of eNOS gene expression has been 
shown to be influenced by a variety of factors and
10
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physiological/pathophysiological conditions. The eNOS promoter contains 
response elements which appear to confer transcriptional regulation by NF- 
kB, p53, Sp1, NF-1, shear stress, cAMP and Interferon y (IFNy) (Fleming and 
Busse, 2003). The functional relevance of these response elements is not 
fully established, however, mutation of the putative Sp1 binding site was 
shown to reduce basal eNOS promoter activity by 85% (Zhang et al., 1995). 
Shear stress, the frictional force exerted on the vascular endothelium by 
flowing blood, upregulates eNOS expression in part by stabilizing eNOS 
mRNA in a calcium-dependent, G-protein-mediated manner that is potentiated 
by PI3K inhibitors (Sessa et al., 1994; Xiao et al., 1997). Additionally, six 
shear stress response elements have been identified in the eNOS gene 
promoter (Nishida et al., 1992; Sessa et al., 1992).
Although classically associated with the transcriptional upregulation of 
iNOS, immunostimulants have also been found to modulate eNOS protein 
expression. Notably, expression of eNOS is upregulated by some 
inflammatory cytokines (Iwase et al., 2000; Navarro-Antolin et al., 2000) and 
both the activity and mRNA levels of eNOS have been reported to increase 
following administration of the adenylyl cyclase activator forskolin (Kiss et al., 
1998). LPS has been implicated in upregulation of eNOS mRNA levels in 
brain astrocytes (Iwase et al., 2000) and paradoxically, the
immunosuppressant cyclosporine has been reported to induce eNOS gene 
transcription in bovine endothelial cells (Navarro-Antolin et al., 2000).
Post-translational modification of eNOS
In addition to the transcriptional regulation of eNOS, post-translational 
modifications have become accepted as the major regulatory mechanism in
11
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the control of stimuli-evoked eNOS activity. Regulation of eNOS-derived NO 
production is perhaps the best characterized, and most complex, of the three 
isoforms. Extensive studies have been done on both the transcriptional and 
post-translational regulation of eNOS, illustrating that although eNOS is 
constitutive in many cell types, both activity and protein expression levels are 
regulated to meet local demands.
Intracellular localization
The eNOS isoform was originally characterized as a membrane 
associated protein and purified from a detergent soluble fraction of endothelial 
cells (Pollock et al., 1991). However, it is now appreciated that targeting to 
distinct subcellular loci, including the plasma membrane, is an important 
mechanism in the modulation of eNOS activity and subsequent signal 
transduction. Functional eNOS has been detected predominantly in two 
cellular compartments, the plasma membrane (Meeker et al., 1994), 
concentrated in plasmalemmal caveolae (Goligorsky et al., 2002; Liu et al.,
1995) and the golgi apparatus (Sessa et al., 1995). eNOS is unique among 
the three NOS isoforms as it is dually acylated by the fatty acids myristate and 
palmitate (Robinson et al., 1996) restricting expression to cellular membranes 
(Busconi and Michel, 1993). Myristoylation is an essentially irreversible lipid 
modification, catalyzed by N-myristoyltransferase and occurs cotranslationally 
on an NH2 terminal glycine residue (Liu and Sessa, 1994). Site directed 
mutagenesis of the myristoylation site of eNOS demonstrated that myristic 
acid incorporation was abolished and that eNOS becomes predominantly 
cytosolic. Additionally, myristoylation of eNOS is critical for subsequent 
cysteine palmitoylation (Sessa et al., 1993).
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Palmitoylation occurs posttranslationally and involves the reversible 
formation of a fatty-acyl thioester bond between palmitoyl-CoA and the thiol 
group of cysteine residues 15 and 26 within eNOS (Liu et al., 1995). 
Palmitoylation can occur in response to extracellular stimuli, providing a 
mechanism for the dynamic regulation of protein localization (James and 
Olson, 1989). Interestingly, a mutant exhibiting deficient palmitoylation also 
exhibits an impaired ability to produce NO, suggesting that correct subcellular 
targeting is required to bring eNOS into close proximity with its substrates and 
perhaps other factors that allow for efficient signal transduction (Liu et al.,
1996). Through their combined hydrophobic interactions with membrane 
lipids, N-myristoylation and palmitoylation play a key role in the anchoring of 
eNOS to the endothelial plasma and golgi membranes.
Classically, NOS isoforms have been designated as either constitutive 
or inducible, based on whether their activation is regulated by reversible 
Ca^VCaM binding or transcription, respectively. CaM binding to eNOS 
displaces an autoinhibitory loop (a unique polypeptide insert in the FMN 
binding domain), facilitating the flux of NADPH-derived electrons from the 
reductase domain to the oxygenase domain (Salerno et al., 1997). Ca^^-
independent activation of eNOS is elicited by stimuli such as vascular shear 
stress. In this case, activation of 3-phosphatidylinositol kinase (PI3K) and 
downstream kinases, Akt and cAMP-dependent protein kinase (PKA), result in 
phosphorylation-evoked eNOS activation (see below for a discussion of eNOS 
phosphorylation) (Dimmeler et al., 1999; Fisslthaler et al., 2000; Fulton et al., 
1999; Go et al., 2001).
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eNOS phosphorylation
The role of protein kinases in the regulation of eNOS is one of intense 
investigation. In vitro and in wVo experiments have determined that the 
catalytic activity of eNOS is augmented by phosphorylation of a C-terminal 
serine residue (Ser-1177 or Ser-1179, in human and bovine eNOS, 
respectively) mediated via the PI3K/Akt pathway. The involvement of eNOS 
phosphorylation in vascular function was demonstrated using adenoviral gene 
transfer of Akt. Transduction of rabbit femoral arteries with constitutively 
active Akt increased NO-mediated vasodilation in response to ACh. 
Interestingly, transduction with dominant-negative Akt attenuated this effect 
(Luo et al., 2000). Mutation of eNOS serine 1179 to alanine in bovine (or the 
corresponding serine 1177 residue in human) endothelial cells prevented 
phosphorylation at this site and resulted in decreased NO production 
(Dimmeler et al., 1999; Fulton et al., 1999). In addition, brâdykinin was 
demonstrated to increase Akt-dependent eNOS phosphorylation (Bernier et 
al., 2000). In bovine eNOS, phosphorylation of threonine 497 within the CaM 
binding domain has also been described. Phosphorylation of Thr497 seems 
to be inhibitory since de-phosphorylation at this site, in response to 
bradykinin, is associated with increased in eNOS activity (Michell et al., 2001).
1.4 NOS catalysis
All NOS isoforms synthesize NO from one of the chemically-equivalent 
guanidino nitrogens of L-arginine, consuming 1.5 NADPH and 2 O2 for each 
NO formed. The reaction is a two-step, sequential, 5-electron overall oxidation
14
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of nitrogen (Palmer et al., 1988b; Sakuma et al., 1988; Stuehr, 1999). In the 
first step, hydroxylation of arginine forms N®-hydroxyarginine (NOHA) as a 
stable intermediate. The second step converts NOHA into the terminal 
reaction products, NO and citrulline (Marietta et al., 1988; Stuehr et al., 
1991b). The flow of electrons within NOSs and the two-step reaction are 
depicted in figures 1.2 and 1.3, respectively.
During NO synthesis, electron flux within the dimer occurs in a trans 
fashion, whereby the flavins in the reductase domain of one monomer transfer 
NADPH-derived electrons to the heme iron located in the oxygenase domain 
of the other monomer. In the constitutive, Ca^'^-dependent NOSs, CaM- 
binding promotes electron transfer to the heme by altering the conformation of 
the reductase domain to allow electron flow through the flavins.
In addition to the flavins, several other cofactors are essential for 
production of NO by NOSs. Both the shared chemistry of their catalysis and 
the presence of a flavin-containing electron transfer domain, suggested the 
involvement of a P450-type heme. iNOS was the first NOS isoform to be 
shown to contain a P450-like heme with the characteristic absorbance 
maximum at 446 nm, following reduction in the presence of CO; other NOS 
isoforms were later shown to contain heme with similar spectral 
characteristics. The heme is held in position by an axial thiol of a conserved 
cysteine residue which has been mapped to positions 184, 200 and 415 in 
bovine eNOS (Chen et al., 1994), murine iNOS (Cubberley et al., 1997) and 
rat nNOS (McMillan and Masters, 1995), respectively. Mutation of these 
conserved Cys to Ala or His residues abolishes NOS catalytic activity. 
Studies using recombinantly expressed iNOS oxygenase domains suggest
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that although dimers can be formed, they are unable to convert arginine to 
citrulline in the absence of a reductase domain. However, oxygenase dimers 
can convert the reaction intermediate, N®-hydroxy-L-arginine, to NO and 
citrulline, but only in the presence of H2O2 , a substitute for molecular oxygen 
(Ghosh et al., 1997). Thus, in the absence of the reductase domain, the 
oxygenase domain appears to retain partial catalytic activity.
Early studies with iNOS showed that the low molecular weight pterin, 
(6R) 5,6,7,8- tetrahydrobiopterin (BH4) was essential for NOS activity. Having 
been well established as an obligate cofactor in reactions catalyzed by the 
aromatic amino acid hydroxylases (AAAHs), it was first thought that BH4 
would act in an identical catalytic manner (Kaufman, 1963). However, a role 
for BH4 as an electron donor, as known in the AAAHs, was ruled out by 
stoichiometric analysis of the catalysis of isolated iNOS. This revealed that 
>15 moles of citrulline were produced for each mole of consumed BH4 
(Giovanelli et al., 1991). Although the exact function of BH4 in NO synthesis 
has yet to be fully elucidated, recent evidence suggests it may play both 
allosteric and electron cycling roles.
High resolution X-ray crystallographic structures of all three isoforms of 
NOS show a zinc thiolate (ZnS4) cluster at the dimer interface, formed by a 
zinc ion coordinated in a tetrahedral conformation with pairs of symmetrically 
oriented and conserved cysteine residues (Li et al., 1999; Ludwig and 
Marietta, 1999; Raman et al., 1998). Mutation analysis of these sites 
suggests that stabilization of the dimer by the zinc cluster is key for NOS 
catalytic activity (Zou et al., 2002).
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Figure 1.2 Path of electron transfer in a NOS dimer. The reductase 
domains transfer electrons from NADPH, via the flavins, to the heme located 
in the adjacent subunit. Note: Electron transfer between reductase and 
oxygenase domains on the same subunit does not occur. Taken from 
(Stuehr, 1999).
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Figure 1.3 Enzyme catalyzed NO synthesis from arginine.
Hydroxylation of L-arginine generates NOHA as an intermediate. . In the 
second step, NO and citrulline are formed.
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1.5 Tetrahydrobiopterin
(6R) 5,6,7,8- Tetrahydrobiopterin (BH4) is a pteridine, defined by its 
unique heterocyclic ring structure (Figure 1.4). The biological synthesis of 
pteridines was first discovered in 1889, when Sir Fredrick Gowland Hopkins 
isolated the yellow pigments from the wings of English butterflies (Hopkins, 
1889). The identity of these compounds was not established until the 1940s, 
when three compounds were isolated and shown to share a novel pyrimidine 
ring system. The name pterin was given to these compounds after the Greek 
name Ptera, meaning wing, for the source from which these molecules were 
isolated.
Biopterin is defined as the pteridine analogue in which the heterocyclic 
ring is substituted with amino, carbonyl oxygen and 1,2-di hydroxy propyl at the 
2, 4 and 6 positions, respectively. The redox state of this substituted ring has 
profound effects on chemical, spectral and biological activity, existing as fully 
oxidized (biopterin), partially reduced (BH2), or fully reduced (BH4) forms.
1.5.1 Biological functions of BH4
A report by Kaufman and coworkers in 1963 first demonstrated a 
cofactor function for BH4 in mammalian biology. BH4 was shown to be an 
essential cofactor for the metabolism of phenylalanine to tyrosine by 
phenylalanine hydroxylase in the liver (Kaufman, 1963). BH4 was later found 
to also play a similar cofactor role for the two other mammalian AAAHs, 
tyrosine hydroxylase and tryptophan hydroxylase (Brenneman, 1964; 
(Nagatsu et al., 1964). These findings implicated BH4 in the biosynthesis of 
epinephrine, norepinephrine, dopamine and 5-HT. The role of BH4 in AAAH
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catalysis is well established to include redox-based activation of molecular 
oxygen and allosteric stabilization of the enzyme (Walter et al., 1998). The 
enzymatic reactions of the AAAHs also have a strict requirement for oxygen 
and iron. During catalysis, BH4 is oxidized to the intermediates, BH4-4a- 
carbinolamine (Haavik and Flatmark, 1987) and quinonoid-BH2 (q-BH2) 
(Rebrin et al., 1995). In AAAHs, one mole of BH4 is able to support a single 
catalytic turnover; continued catalysis is dependent upon the NADPH- 
mediated regeneration of the BH4 cofactor by the enzyme dihydropteridine 
reductase (DHPR).
The observation that BH4 synthesis is dramatically induced in 
mammalian cells by cytokines puzzled researchers for many years, as there 
was no known enzyme that was both inducible and BH4-dependent. This led 
to the discovery that BH4 is an essential cofactor for iNOS activity (Kwon et 
al., 1989a; Tayeh and Marietta, 1989). It was naturally assumed that the 
function of BH4 in NOSs was identical to that shown for the AAAHs. 
However, it is now appreciated that while BH4 is essential for activity of all 
NOS isoforms, it is not utilized in the same way as for the AAAHs.
In addition to serving as a cofactor for AAAH and NOS catalysis, BH4 
was reported to have growth factor and proliferative actions on hematopoetic 
cells (Tanaka et al., 1989; Thony et al., 2000). Another function may be 
scavenging O2' as shown in experiments with both xanthine/xanthine oxidase 
and rat macrophage/phorbol myristate acetate O2' generating systems 
(Kojima et al., 1995). Indirect support for this role came in another set of 
experiments where endothelial cell death induced by the NO donor S-nitroso-
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N-acetyl-D,L-penicillamine (SNAP) could be prevented by increasing 
intracellular BH4 levels (Shimizu et al., 1998).
1.5.2 BH4 biosynthesis
De novo synthesis
BH4 is formed de novo from GTP, via a sequence of enzymatic steps 
carried out by GTP cyclohydrolase I (GTPCHI), 6-pyruvoyl tetrahydrobiopterin 
synthase (PTPS) and sepiapterin reductase (SR) (Werner-Felmayer et al.,
2002) (Figure 1.4). In the first, and rate-limiting step, guanosine 5’ 
triphosphate (GTP) is reduced to 7,8-dihydroneopterin 3’ triphosphate (DNTP) 
by GTPCHI (not to be confused with the unrelated enzyme GTP 
cyclohydrolase II, that catalyzes the second step in riboflavin biosynthesis by 
microorganisms) (Burg and Brown, 1968). GTPCH-catalyzed formation of 
DNTP is a common initial step in the biosynthesis of unconjugated pterins, 
folates and riboflavin, but not molybdopterin (a cofactor of sulfite oxidase, 
xanthine dehydrogenase and aldehyde oxidase in man). GTPCH is the rate- 
limiting enzyme in BH4 biosynthesis and its activity is regulated at the 
transcriptional, translational and post-translational levels (Gross et al, 2000).
GTPCH protein levels have been shown to be induced by H2O2 in 
oxidative stress (Shimizu et al., 2003) and bacterial LPS elicits a 2-3-fold 
increase in GTPCH activity in a variety of rat tissues that constitutively 
express GTPCH, including cerebellum, liver, spleen and the adrenal gland. 
Macrophages, dermal fibroblasts and tumour cell lines all demonstrate a 
profound increase in GTPCH activity after treatment with IFNy and TNFa; LPS 
and IFNy has also been observed to increase activity and act in a synergistic
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manner (Gross et al., 1993; Hattori and Gross, 1993). BH4 synthesis by 
GTPCH is subject to feedback inhibition by BH4 and other reduced pterins via 
a mechanism that requires a regulatory protein known as GTPCH feedback 
regulatory protein (GFRP) (Milstien et al., 1996). This inhibition of GTPCH by 
BH4/GFRP can be reversed by high levels of phenylalanine (Milstien et al., 
1996; Yoneyama et al., 1997).
The conversion of DNTP to 6-pyruvoyl tetrahydropterin (PTP) is 
catalyzed by the zinc-dependent metalloprotein, PTPS. Although GTPCH is 
rate-limiting to BH4 synthesis in most cells, PTPS has been suggested to be 
rate-limiting in some, most notably human hepatocytes. PTPS may become 
rate-limiting in other tissues and cells, following stimulation with cytokines and 
other immunological stimuli that induce BH4 synthesis by upregulation of 
GTPCH expression (Thony et al., 2000). The final steps in the biosynthesis of 
BH4 are two successive propyl side-chain reduction reactions, catalyzed by 
SR. Present in all cells that produce BH4, SR has not yet been revealed as a 
site for regulation of BH4 synthesis.
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Figure 1.4 The de novo pathway for BH4 synthesis from GTP and its 
end product inhibition. Abbreviations: AR, aldose reductase; CR, carbonyl 
reductase; GFRP, GTPCH feedback regulatory protein; GTPCH, GTP 
cyclohydrolase I; PTPS, 6-pyruvoyl tetrahydropterin synthase; SR, sepiapterin 
reductase
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Figure 1.5 Chemical structures of the essential NOS cofactor BH4 and 
increasingly more oxidized non-cofactor derivatives: q-BH2, 7,8-BH2 and 
biopterin.
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Synthesis of BH4 via the pterin salvage pathway
Distinct from the recycling of BH4 by DHPR, a pathway is present in 
cells to recycle BH4 after its oxidation to qBH2 (Nichol et al., 1985). 
Sepiapterin and 7,8-BH2 are produced non-enzymatically when BH4 is 
subject to an oxidative environment and can be ‘salvaged’ as BH4 at the 
expense of NADPH by SR and dihydrofolate reductase (DHFR). The actions 
of SR in the salvage pathway are different to those in the de novo synthesis 
pathway, catalyzing the reduction of sepiapterin to 7,8-BH2. DHFR has been 
widely studied and is better known for its ability to reduce 7,8-dihydrofolates to
5,6,7,8-tetrahydrofolates. DHFR does not recycle BH4 from q-BH2 and 
therefore does not have detectable DHPR activity (Gross et al, 2000; Nichol et 
al., 1985). Intracellular pools of sepiapterin arise from the oxidation of 
intermediates formed during the de novo synthesis of BH4 and can be 
reduced to active BH4 by this ‘salvage’ pathway.
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Figure 1.6 Salvage pathway of BH4 synthesis from sepiapterin and 7,8- 
BH2. SR, sepiapterin reductase: DHFR, dihydrofolate reductase.
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1.5.3 The role of BH4 in NOS catalysis
Following the discovery of BH4 as an essential cofactor in NOS 
catalysis, it was assumed that the redox function in oxygen activation was 
operative for NOS enzymes as for AAAHs. However, it became clear that 
BH4 adopted a different role in NOS catalysis when it was discovered that 
NOS contained a cytochrome P450-type heme, a moiety able to support the 
activation of oxygen without the need for a pterin cofactor. The main 
evidence against a direct redox role for BH4 came from the observation that 
citrulline formation is not stoichiometric with BH4 consumption and the fact 
that BH4 had little effect on the initial rate of NOS catalysis (Giovanelli et al., 
1991). Comparison of eNOS (Fischmann et al., 1999; Raman et al., 1998), 
iNOS (Crane et al., 1998) and nNOS (Raman et al., 2000) oxygenase 
domains with crystal structures of the AAAHs has revealed fundamental 
structural differences between the BH4 binding sites. In NOSs, BH4 functions 
in part as an allosteric modulator of arginine binding. Binding of BH4 to NOS 
elicits a conformational change that increases the affinity for binding of 
arginine-based ligands (Klatt et al., 1994; Liu and Gross, 1996). Support for 
an allosteric role of BH4 was confirmed by spectrophotometric and electron 
paramagnetic resonance (ERR) studies, which show that BH4 binding 
converts the heme iron from a low-spin to a high-spin state (Gorren et al., 
1996). Another possible role of BH4 was thought to be in dimer assembly 
(Ghosh and Stuehr, 1995). Although proven not to be essential for dimer 
assembly (Rodriguez-Crespo et al., 1996), BH4-binding does play a role in 
dimer stabilization (Klatt et al., 1995).
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The above mentioned allosteric effects do not fully explain the essential 
role of BH4 in NO synthesis and electron donation from BH4 to the heme iron 
remains almost certain. Indeed, only fully reduced pterins such as 
tetrahydrobiopterin have ever been shown to support catalysis (Presta et al., 
1998; Riethmuller et al., 1999; Vasquez-Vivar and Kalyanaraman, 2000). 
Moreover, tetrahydrobiopterins with modifications that would cause them to be 
redox silent are unable to catalyze NO synthesis (Hevel and Marietta, 1992; 
Werner et al., 1996). Spectral and ERR studies have revealed the presence 
of a trihydrobiopterin («BHs) radical intermediate, which strongly supports a 
redox role for BH4 in NOS catalysis and may explain the ability of eNOS- 
bound BH4 to limit the release.of oxygen as O2 ' (Bee et al., 1998).
1.6 Oxidative stress and endothelial dysfunction
Oxidative stress is defined as an “imbalance between oxidants and 
antioxidants in favour of the oxidants, potentially leading to damage" (Sies, 
1991). This occurs when the generation of reactive oxygen species (ROS) in 
a system exceeds the rate at which they can be neutralized or eliminated. 
Such an imbalance can result from diminished antioxidant defenses or an 
increase in the production or distribution of ROS. If not adequately controlled, 
the excess ROS can damage lipids, protein or DNA, inhibiting physiological 
functions. Oxidative stress has been implicated in a growing list of human 
diseases, as well as in the ageing process. There are multiple sources by 
which ROS is generated in cells. Most ROS arise as by-products of essential 
metabolic reactions, such as energy generation from mitochondria and 
detoxification reactions involving the cytochrome R-450 enzyme system in the
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liver. Exogenous sources include exposure to cigarette smoke, environmental 
pollutants, excessive consumption of alcohol, exposure to ionizing radiation 
and activation of oxidant production by bacterial, fungal or viral infections.
The endothelium is a major regulator of vascular homeostasis and 
maintains the equilibrium between vasodilation and vasoconstriction. When 
this balance is disturbed by excess ROS, endothelial dysfunction occurs. 
Endothelial dysfunction, defined as ‘the failure of the vascular endothelium to 
subserve its normal role in vasodilation and/or vascular homeostasis’ is 
recognized as a cardiovascular disease risk factor in individuals with 
atherosclerosis and hypercholesterolemia (d'Uscio et al., 2001; Landmesser 
et al., 2000), hypertension (Landmesser et al., 2003), diabetes (Cai et al., 
2005) and smokers (Heitzer et al., 2000a).
1.6.1 Uncoupled NOS, a peroxynitrite synthase?
It is hypothesized that BH4 availability determines whether eNOS 
produces O2' or NO. In BH4 deficient NOS, L-arginine oxidation becomes 
uncoupled from O2 reduction, resulting in the production of O2" and 
subsequently H2O2 , rather than NO (Figure 1.7)(Pou et al., 1992). This finding 
was later directly confirmed by EPR studies (Vasquez-Vivar et al., 1998). 
Moreover, addition of BH4 to eNOS was shown to simultaneously increase 
NO production and decrease O2 ' generation (Wever et al., 1997). Production 
of O2' from recombinant eNOS can be blocked by heme-ligands and arginine 
antagonists that also interact with heme (nitro arginine methyl ester, L- 
NAME), indicating that heme, rather than FMN or FAD, is the primary source 
of O2*, implicating BH4 in preventing the release of heme-iron bound dioxygen 
as the O2' anion (Vasquez-Vivar et al., 1998; Xia et al., 1998).
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The capacity of eNOS to produce O2' in vivo was first reported by 
Pritchard et al. 1995, demonstrating that incubation of endothelial cells with 
LDL causes the release of O2 ' that is inhibited by the addition of L-NAME 
(Pritchard et al., 1995). Basal O2' production was also detected and shown to 
be inhibitable by L-NAME, suggesting that even under normal physiological 
conditions eNOS may produce both NO and O2'. As all NOS isoforms exist as 
dimers, it is conceivable that NOS may consist of one BH4-free (or 7,8-BH2/q- 
BH2 bound), and one BH4-containing subunit. Simultaneous production of 
NO and O2" by NOS, and the near diffusion-limited rate for the reaction 
between O2" and NO, would predictably result in the formation of peroxynitrite 
(ON0 0 ) , a much more potent oxidant than either NO or O2'. Notably, 
peroxynitrite can oxidize both BH4 (Milstien and Katusic, 1999) and the zinc 
thiolate complex in eNOS, resulting in disabled NO biosynthesis (Zou et al.,
2002). In summary, exposure of eNOS to oxidants, including ONOO', causes 
enzymatic uncoupling and generation of O2' and/or ONOO* which can 
contribute to further endothelial cell oxidant stress (Cosentino et al., 1997; 
Cosentino et al., 1998). Several potential sources of ROS production are 
depicted in Figure 1.8 and all may play a role in the initiation and/or 
propagation of endothelial dysfunction.
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BH4
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NADPH
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NADPH ONOO
NO
Figure 1.7 Schematic depicting the potential for peroxynitrite 
production by uncoupied eNOS. In BH4 deficient eNOS (or BH2-bound 
eNOS), L-arginine oxidation becomes uncoupled from O2 reduction, resulting 
in the production of ONOO' and H2O2 instead of NO.
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OXIDATIVE
STRESS:
Diabetes
Hypercholesterolemia 
Hypertension 
Atherosclerosis 
Ischemia/reperfusion 
Inflammation 
Smoking
NADPH 
^OXIDASE
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EDUCTASE/V.W-'»
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OXIDASE ONOOURIC ACID
eNOS
Figure 1.8 Schematic depicting four major possibie sources of 
endothelial-derived 0 { : Xanthine Oxidase, NADPH Oxidase, uncoupled 
aerobic (mitochondrial) respiration and uncoupled eNOS.
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1.6.2 Tetrahydrobiopterin oxidation and endothelial dysfunction in
response to high levels of glucose
Endothelial dysfunction is a causal factor of vascular complications 
associated with type II diabetes and is characterized by diminished levels of 
bioavailable NO (Drexler and Hornig, 1999). Diminished NO bioactivity has 
been reproduced in cell culture models of diabetes by the addition of 
hyperglycemic levels of glucose (30 mM) to the growth media. Despite a 
marked decrease in NO levels with high glucose, eNOS protein levels may be 
paradoxically increased (Hink et al., 2001). High glucose is also capable of 
direct NO scavenging, via formation of an NO-glucose adduct, and may cause 
a significant blunting of the NO response to both calcium ionophore and 
bradykinin (Brodsky et al., 2001). One effect of chronic exposure to 
hyperglycemia is the formation of advanced glycation end products by a non- 
enzymatic reaction between glucose and proteins/lipoproteins in arterial walls 
(Brownlee et al., 1988).
A great deal of evidence indicates that hyperglycemia may also 
compromise natural antioxidant systems that serve to maintain BH4 in its fully 
reduced form. GSH, vitamin 0 and vitamin E are among those antioxidant 
systems whose overwhelmed activity has been reported in diabetic patients 
vs. non-diabetic subjects (Wolff, 1993; Yoshida et al., 1995b), potentially 
leading to increased intracellular oxidative stress and oxidation of BH4. In 
cultured endothelial cells treated with L-ascorbic acid (vitamin C), an increase 
in NOS enzyme activity was found and attributed to the chemical stabilization 
of BH4 (d'Uscio et al., 2003).
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The role of BH4 deficiency in mediating endothelial dysfunction and 
vascular disease is one of great interest in the NO field today. BH4 
supplementation in human patients with vascular conditions has 
demonstrated beneficial effects for reversing impaired endothelium-dependent 
vasodilation in association with hypercholesterolemia (Stroes et al., 1997a), 
diabetes (Pieper, 1997; Shinozaki et al., 2000b), tobacco smoking (Higman et 
al., 1996) and ischemia-reperfusion injury (Tiefenbacher et al., 1996). In 
aortae of mice with deoxycorticosterone acetate-salt (DOCA)-induced 
hypertension, ROS production from NO synthase was shown to be markedly 
increased and BH4 oxidation was evident. Treatment of these mice with oral 
BH4 attenuated vascular ROS production, increased NO production and 
blunted hypertension compared to control animals (Landmesser et al., 2003).
Pharmacological manipulation of the redox status of BH4 and/or the 
levels of free radicals may provide an effective strategy for upregulating NOS 
enzyme function and NO bioavailability in pathophysiological conditions.
1.6.3 Clinical significance of endothelial dysfunction in vascular
disease
The endothelium is a complex organ that regulates normal vascular 
homeostasis by exerting anti-atherogenic and anti-thrombotic tone. Under 
pathological conditions where the role of the endothelium is compromised (i.e. 
endothelial dysfunction) the endothelium facilitates inflammation, thrombosis, 
vasoconstriction and atherosclerotic lesion formation. In human patients, this 
poor endothelial function manifests prior to the development of cardiovascular 
disease and is an apparent underlying factor in the etiology of atherosclerosis.
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hypercholesterolemia, hypertension and diabetes mellitus. Only recently has 
the clinical significance of endothelial dysfunction become appreciated in the 
prognosis of increased cardiovascular risk and advanced vascular disease. In 
the past, links between endothelial function and clinical progression of 
atherosclerosis were purely circumstantial. Although largely retrospective, 
research is ongoing into the value of endothelial function as a hallmark of 
cardiovascular risk. In 2000, small retrospective studies by two groups firmly 
placed endothelial function as a reliable predictor of cardiovascular events 
such as infarction and stroke (Schachinger et al., 2000). More recently, 
Quyyimi and colleagues conducted a large scale study and investigated the 
relationship between coronary endothelial function and the occurrence of 
unpredictable cardiovascular events (cardiovascular death, myocardial 
infarction, stroke and unstable angina) (Halcox et al., 2002). They tested 
vascular responses to endothelium-dependent (ACh) and endothelium- 
independent (SNP and adenosine) vasodilators in 308 patients. Of the 35 
ischemic cardiovascular events observed, all were independently associated 
with attenuated endothelium-dependent dilation, whereas no change in 
endothelium-independent vasodilator responses was seen. Other groups 
confirmed this conclusion in studies of brachial arterial circulation and forearm 
blood flow using both invasive and non-invasive approaches (Brevetti et al.,
2003).
Assessment of endothelial function in both coronary and peripheral 
circulation of patients with cardiovascular disease provides telling prognostic 
information about future cardiovascular risk. Reversing endothelial 
dysfunction and restoring NO bioavailability will predictably provide major
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therapeutic benefit in diverse conditions where endothelial function is an 
established indicator of cardiovascular risk.
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2.0 AIMS AND OBJECTIVES
Previous in vitro studies in our lab revealed that recombinant eNOS 
binds BH4 and its more oxidized counterpart BH2, with similar affinity, 
although only BH4 supports NO synthesis (Figure 3.1). As describéd above, 
it is established that BH2-bound eNOS becomes ‘uncoupled’ and produces 
O2' instead of NO. It is therefore postulated that it is the intracellular ratio of 
BH4:BH2, rather than the absolute amount of BH4, that determines the 
balance between the alternative eNOS products, NO and O2'. Simultaneous 
production of NO and O2' promotes the formation of a more harmful oxidant, 
ONOO', while simultaneously scavenging bioactive NO. Both O2' and ON0 0 ' 
play a potential role in the onset of endothelial dysfunction.
The focus of this thesis research is to elucidate the role of BH4 in the 
initiation and propagation of oxidative stress associated with hyperglycemia 
and vascular disease, and how this leads to impaired of levels of bioactive NO 
and endothelial dysfunction. It is envisioned that any stimulus that initiates 
BH4 oxidation in endothelial cells (EC) can trigger O2' synthesis by eNOS, 
resulting in a feed-forward cascade of BH4 oxidation to BH2 and a further 
increase in the rate of O2' production. Therapies that reduce the underlying 
oxidative stress and protect BH4 from oxidation, preserving eNOS coupling, 
may offer potential therapeutic approaches in vascular disease states. 
Preliminary studies in our lab have shown that BH2-bound eNOS can support 
the synthesis of NO and citrulline from NOHA, but not arginine (Figure 5.1). 
Conversion of NOHA to NO can occur by eNOS-mediated catalysis as well as 
by direct reaction with O2* (including O2' from uncoupled eNOS). In the 
context of endothelial dysfunction, NOHA could be employed as a O2 -
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dependent NO releaser, to support NO production by EC that express high 
ratios of BH2:BH4, while simultaneously reducing levels of cellular O2' and 
allowing antioxidant defence mechanisms to reinstate BH4 levels.
The potential of NOHA and Ebselen (shown to react rapidly with 
ONOO' in vitro, acting as a glutathione peroxidase mimic and general 
antioxidant), as therapeutic agents against the observed endothelial 
dysfunction, will be investigated. Success in these studies would offer 
potential therapeutic benefit for the treatment of endothelial dysfunction, 
associated with a wide range of vascular diseases and pathophysiological 
conditions.
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3.0 Cell culture models of oxidative stress and 
endothelial dysfunction
3.1 Introduction
Nitric oxide (NO),is a biological messenger that is produced by the NO 
synthase gene family, comprising endothelial (eNOS), inducible (iNOS) and 
neuronal (nNOS) isoforms. In the vasculature, eNOS-derived NO plays a 
pivotal role in the physiological regulation of vessel tone, patency, blood flow, 
and inflammatory status (Tojo et al., 1999). Diminished bioavailability of 
eNOS-derived NO is common to chronic vascular disorders that share 
endothelial dysfunction as a hallmark, e.g., diabetes (Drexler and Hornig, 
1999; Pieper et al., 1997; Zanetti et al., 2000), hypertension (Landmesser et 
al., 2003) and atherosclerosis (Landmesser et al., 2003; Stroes et al., 1997b). 
While the mechanistic basis for this deficiency in NO bioavailability is 
uncertain, both attenuated NO synthesis and increased NO scavenging by 
ROS have been implicated (Cohen, 2005). In contrast, levels of eNOS 
protein are typically unchanged or even paradoxically increased (Hink et al., 
2001). Oxidative stress, imposed by excessive ROS production, constitutes a 
unifying feature and likely generic trigger for endothelial dysfunction in chronic 
vascular conditions -  the precise molecular mechanisms await elucidation.
The redox sensitive NOS cofactor BH4 is essential for NO synthesis by 
all NOS isoforms. Whereas fully-reduced tetrahydropterins can support 
catalysis by NOSs, oxidized pterin species are catalytically incompetent (e.g.,
7,8-dihydrobiopterin; BH2) (Gross et al., 1991; Kwon et al., 1989b; Tayeh and 
Marietta, 1989). EPR studies showed that in the absence of BH4 (or
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presence of BH2), O2' and NADP^ are the sole products of pure recombinant 
eNOS (Vasquez-Vivar et al., 1998). This is explained by the mechanistic role 
of BH4 in the donation of a single electron to ferrous-dioxygen in the eNOS 
active site as a first step in L-arginine oxidation (Hurshman et al., 1999). In 
the absence of BH4, electron transfer between eNOS dimers becomes 
“uncoupled” from L-arginine oxidation, and ferrous-dioxygen releases O2 ' 
(Vasquez-Vivar et al., 1998).
Notably, BH4 is prone to oxidation, occurring readily in laboratory 
solutions unless opposed by the addition of a thiol reductant (Davis et al., 
1988; Kirsch et al., 2003). BH4 oxidation may also occur in vascular EC in 
the setting of oxidative stress associated with hypertension (Landmesser et 
al., 2003), atherosclerosis (Laursen et al., 2001) and diabetes (Meininger et 
al., 2000). Importantly, depletion of BH4 in oxidatively-stressed EC can result 
in product switching from NO to O2 '. Simultaneous production of NO and O2' 
by vascular cells is particularly undesirable, given that consumption of 
beneficial NO is accompanied by formation of cytotoxic ONOO’ (Vasquez- 
Vivar et al., 2001), a more reactive oxidant than either of its parent species 
(Pryor and Squadrito, 1995). Uncoupled eNOS can initiate a futile feed­
forward cascade whereby the production of ONOO' elicits BH4 oxidation 
(Kuzkaya et al., 2003; Milstien and Katusic, 1999), further eNOS uncoupling 
(Zou et al., 2002) and a downward spiral in levels of vascular NO bioactivity.
Oxidant stress, such as that associated with hyperglycemia, can 
potentially overwhelm the natural antioxidant defense mechanisms that serve 
to maintain BH4 in its fully reduced form, preventing endothelial dysfunction. 
Glutathione (GSH), vitamin 0  and vitamin E are among those systems, and
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diminished levels of these important antioxidants are evident in diabetic 
patients (Wolff et al., 1993; Yoshida et al., 1995a). Treatment with L-ascorbic 
acid (vitamin C) was shown to increase eNOS activity in EC, apparently via 
chemical stabilization of BH4 (d'Uscio et al., 2003; Huang et al., 2000). Direct 
augmentation of endothelial BH4 levels following adenoviral-mediated gene 
transfer of GTPGH, the rate-limiting enzyme for BH4 synthesis, was 
demonstrated to restore eNOS activity in cultured human EC following 
exposure to high glucose (Cai et al., 2005) and in rodent blood vessels of 
ApoE knockout (Schock et al., 2004) and streptazotocin models (Ono et al.,
2003) of atherosclerosis and diabetes, respectively. Direct supplementation 
of BH4 was similarly shown to acutely improve endothelial function in chronic 
smokers (Higman et al., 1996) and patients with hypercholesterolemia (Stroes 
et al., 1997b), diabetes (Pieper et al., 1997; Shinozaki et al., 2000a), or 
following ischemia-reperfusion injury (Tiefenbacher et al., 1996). In aortae of 
mice with deoxycorticosterone acetate salt-induced (DOCA-salt) 
hypertension, production of NOS-derived ROS is markedly increased and 
BH4 oxidation is evident. Treatment of DOCA-salt-treated mice with oral BH4 
acutely attenuated vascular ROS production, increased NO levels and blunted 
hypertension in comparison to non-hypertensive control mice (Landmesser et 
al., 2003).
It was hypothesized that oxidative stress-induced accumulation of BH2 
may bind to eNOS in EC and hence, rather than act as an inert product of 
BH4 oxidation, directly suppress eNOS activity. If so, the intracellular ratio of 
BH4 to BH2, rather than the absolute level of intracellular BH4, would be the 
key determinant of eNOS-derived NO vs. O2' production. To test this
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hypothesis, experiments examined the influence of pterin oxidation status on 
eNOS-binding affinity and the extent to which pterin oxidation occurs in ECs 
and animal tissues following exposure to diabetic levels of glucose. These 
data show that eNOS binds both BH4 and BH2 with identical affinity and that 
BH2 can displace eNOS-bound BH4 in vitro. Exposure of EC to elevated 
levels of glucose elicits a progressive decrease in NO and GSH levels and 
accelerates eNOS-derived O2' and peroxynitrite formation. These effects are 
concomitant with intracellular BH4 oxidation, with no observable decrease in 
total pterin levels. Studies identified eNOS as the major source of ROS, 
responsible for BH4 oxidation as a result of glucose-induced oxidative stress. 
Decrease of intracellular BH4:BH2 ratio changed the profile of eNOS products 
(in favor of O2' production) concomitant with pterin redox status, not absolute 
BH4 levels. Increased oxidant generation and BH4 oxidation is also found in 
vivo, in tissues of the ZDF rat model of type II diabetes. Together, these 
findings indicate that intracellular BH4;BH2 ratio, not BH4 amount, is the key 
in vivo determinant of eNOS product formation. Pterin redox balance is 
suggested to be the fundamental molecular link between endothelial 
dysfunction and oxidative stress in diabetes and other chronic 
vasoinflammatory conditions.
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3.2 Methods
All chemicals, unless otherwise stated were purchased from Sigma 
Chemical Co (St. Louis, MO). Water used for HPLC mobile phase and 
sample preparation was from a MilliQ water purification system (Millipore, MA) 
and >18 MQ resistance.
Cell culture
The sEnd.1 murine endothelial cell line was cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Gibco Life Technologies, MD), 
supplemented with 10% fetal bovine serum (FBS). This cell line was a gift 
from Dr. Patrick Vallance (University College London) and originally 
established from a mouse skin capillary endothelioma, immortalized with a 
retrovirus harboring an insert that encodes polyoma middle T antigen 
(Williams et al., 1988). Cells were grown to confluence in T75 flasks or 6-well 
plates and harvested immediately prior to use. RFL-6 fibroblasts were a gift 
from Dr. Ferid Murad (University of Texas at Houston) and grown in Ham’s F- 
12 medium (Invitrogen, CA) containing 10% FBS. All cells were maintained at 
37°C in a humidified atmosphere of 95% air and 5% CO2 . All culture media 
were supplemented with 2 mM glutamine, 100 U/ml penicillin, and 0.1 mg/ml 
streptomycin (Invitrogen, CA).
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Determination of protein content using the BioRad assay
Sample protein content was measured using the BioRad Dc protein 
assay reagent (BioRad, CA). Briefly, 5 pi sample was transferred to a 96 well 
plate and BioRad reagents added as per manufacturer’s instructions. 
Unknown protein levels were quantified by comparison with bovine serum 
albumin (BSA) standards, ranging from 20 -  1000 pg/ml. The plate was read 
at ODysonm usIng a Versa MAX spectrophotometric plate reader (Molecular 
Devices, CA).
Pterin binding studies
Purification o f recombinant eNOS. Bovine eNOS was purified from 
BL21 E. coll harboring both pGroELS and pCW-eNOS expression plasmids 
(Martasek et al., 1996; McMillan et al., 1992). Doubly-transformed bacteria 
were grown in terrific broth (0.5 L) containing ampicillin (100 pg/ml) and 
chloramphenicol (35 pg/ml) in 2.6 L Fernbach Flasks at 37°C and shaken at 
250 rpm. When Aeoo reached 0.8-1.2, ô-aminolevulinic acid (450 pM) was 
added and, after an additional 1 h incubation, isopropyl p-D-thiogalactoside 
(0.5 mM), riboflavin (3 pM) and ATP (1 mM) were added. Growth was 
continued at 23°C in the dark for 40-48 h. Bacteria were harvested by 
centrifugation at 2500 x g for 20 min at 4°C. Pellets were stored at -70°C for 
up to 3 weeks prior to eNOS purification.
Purification of eNOS from cell pellets was performed following 
resuspension in 30 ml lysis buffer [Tris-HCI pH 7.4 (100 mM), glycerol (10%), 
dithiothreitol (1 mM), EDTA (1 mM), phenylmethylsulfonyl fluoride (1 mM),
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leupeptin (5 pg/ml), pepstatin A (5 pg/ml), chymostatin (5 pg/ml)], followed by 
pulse sonication (Fisher Scientific sonicator Model 550, @ 80% power for 4 
min). The bacterial lysate was centrifuged at 100,000 x g for 70 min at 4° C 
and the supernatant was applied to an 8 ml 2’,5’-ADP-sepharose 4B column 
(GE Healthcare, UK) that had been pre-equilibrated with Buffer A [Tris-HCI pH 
7,6 (50 mM), Glycerol (10%), dithiothreitol (0.1 mM), EDTA (0.1 mM), NaCI 
(100 mM)]. After sample application, the column was washed with 10 
volumes of Buffer A, followed by 10 volumes of Buffer A containing NaCI (500 
mM), but excluding EDTA, and then eluted with 5 ml of buffer A containing 
NADPH (10 mM), CaClz (100 pM) and excluding EDTA. Eluted eNOS from 
the 2’,5’-ADP-sepharose column was then applied to a calmodulin-sepharose 
column (Sigma, MO), followed by column-washing with 10 volumes of Buffer 
B [Tris-HCI pH 7.6 (50 mM), glycerol (10%), dithiothreitol (0.1 mM), CaCb 
(100 pM), NaCI (100 mM)]. This was followed by another column wash with 
10 volumes of Buffer B that additionally contained 500 mM NaCI. Elution of 
purified eNOS was achieved with 15 ml Buffer B containing 10 mM EGTA, 
without CaCl2 . Eluted fractions were dialyzed to remove EGTA, concentrated 
using Centriprep 30 filtration units (Millipore, MA) and analyzed for protein 
content by the Bradford method (BioRad, CA). Purified eNOS was assayed 
for enzyme activity based on N0% accumulation using the Griess assay 
method (Weissmann, 1998) and was shown to be at least 90% pure by 
Coomassie staining of polyacrylamide gels (data not shown). The 
concentration of heme-incorporated eNOS protein was determined based on 
heme absorption. Toward this end, sodium metabisulfite was added to eNOS 
in a saturated solution of carbon monoxide and the resulting change in
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absorption at 444 and 500 nm was used to determine NOS concentration, 
calculated based on the extinction coefficient AE444-500 = 74 mm'^cm'^ 
(Martasek et al., 1996; Roman et al., 1995).
[^H]BH4 synthesis. To quantify and characterize BH4 binding (6R)- 
[^H(6)]BH4 was custom synthesized by complete reduction of 7,8-BH2 with 
sodium borotritide (New England Nuclear/Perkin Elmer, MA). Although the 
initial product was (6R,6S)[^H(5,6)]-BH4, exchange of N5 tritium on the 
biopterin ring with solvent protons, followed by HPLC purification by cation 
exchange chromatography on a Partisyl 10 SCX column, provided purified 
[^H]BH4 stereoisomers labeled specifically at the 6-position. The R- 
stereoisomer was used in the present study. [^H]BH4 was stored as a 1 mM 
stock solution in equimolar HCI at -70°C.
[^H]BH4 binding to eNOS. [^H]BH4 binding assays were performed 
using PVDF membrane-bottom 96 well filtration plates (Millipore, MA). Prior 
to the assay, filtration membranes were sequentially washed under vacuum 
once with 100 pi ethanol/water (50%), then twice with 200 pi Tris (50 mM) pH 
7.6. All binding reactions contained Tris (50 mM) pH 7.6, DTT (ImM), eNOS 
(10 pmol), desired concentration of [^H]BH4 and other additions comprising a 
final volume of 100 pi. Equilibrium binding was analyzed after sample 
incubation for 15 min at 22°C. Binding reactions were initiated by the addition 
of eNOS. For measurements of association rate, binding was initiated by 
addition of [^H]BH4. In dissociation experiments, eNOS (10 pi) was added to 
a 90 pi binding mixture including [^H]BH4; after a 15 minute preincubation
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period, dissociation was initiated by addition of unlabeled BH4 to give a 100 
pM final concentration. Displacement binding assays were performed after 
preincubation of [^H]BH4 with eNOS for 15 min, followed by incubation with 
desired concentrations of BH2 or BH4 for a further 30 min then quantification 
of residual [^H]BH4/N0S complexes. All binding reactions were terminated by 
rapid filtration of samples in the 96-well filterplate, followed by three washes 
with iced-Tris buffer (50 mM, pH 7.6). Plates were air-dried for 30 min 
followed by addition of 25 pi scintillation cocktail (Optiphase, Wallac, MA) and 
counted using a MicroBeta plus scintillation counter (Perkin Elmer, MA).
Analysis o f fH ]B H 4 binding. Equilibrium binding data, as well as 
association and dissociation kinetics, were analyzed using Prism (Graphpad 
Software Inc., CA) and Ligand (Biosoft, Cambridge, UK) programs. Binding 
isotherms were calculated based on the equation:
B = (5max+ T + Kd)l2—'l[Brci'ày^ T + Kd! 2]^ -  jBmaxT
Where 8  is the concentration of bound ligand, Bmax is the total eNOS 
concentration, T is the total ligand concentration and Kd is the concentration 
of [3HJBH4 that gives half-maximal binding. This formula derives from the 
basic equilibrium equation: [L][R]/[LR] = Kd, when L (total ligand
concentration) is not equal to the free ligand concentration.
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Handling of tetrahydrobiopterin
BH4 used in all assays and experiments was dissolved in equimolar 
HCI. Stock solutions where rapidly aliquoted, flash-frozen in liquid nitrogen 
and stored at -70°C. BH4 was thawed immediately prior to use and was 
always the last constituent of buffers used for binding and activity assays. 
BH4 was not used after being thawed and retained on ice for more than one 
hour.
Electrochemical detection of NO
Cells, cultured as described above, were seeded into 96-well culture 
plates. After 24 hours the media was replaced with fresh media containing 
low (5 mM) or high (30 mM) concentrations of D-glucose in the presence and 
absence of NMA. After a further 48 hours, the media was removed and cells 
were gently washed with Dulbecco's phosphate-buffered saline and incubated 
for 1 h at 37°C in 100 pL of Krebs Ringer buffer (145 mM NaCI, 4.86 mM KCI, 
0.54 mM CaCl2 , 1.22 mM MgS0 4 , 5.7 mM Na2HP0 4 , and 5.5 mM glucose). 
NO concentration was then measured using an electrochemical sensor and 
Apollo 4000 free radical analyzer (World Precision Instruments, FL). 
Calibration of the electrode was performed using varying concentrations of the 
NO donor S-nitroso-A/-acetyl-DL-penicillamine (SNAP), as recommended by 
the electrode manufacturer.
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Detection of endotheiiai-derived NO using an RFL-6 ceii cGMP 
reporter bioassay
Following treatment of sEnd.1 EC with drugs, or exogenous pterins 
where appropriate, endothelial-derived NO bioactivity in the culture medium 
was measured based on the increase in cGMP elicited in RFL-6 reporter cells 
(Ishii et al., 1991). Briefly, sEnd.1 and RFL-6 cells were each grown to 
confluence in 6-well plates. sEnd.1 cell medium was removed, cells were 
washed twice with arginine-supplemented Krebs Ringer phosphate glucose 
buffer (145 mM NaCI, 5.7 mM sodium phosphate, 4.86 mM KCI, 0.54 mM 
CaCl2 , 1.22 mM MgS0 4 , 5 mM glucose, 1 mM arginine, pH 7.4) and then 
allowed to equilibrate in 1 ml of the same buffer in the absence or presence of 
3 mM NMA for 20 min. SOD was added 5 min prior to eNOS activation with 
A23187 (5 pg/ml) for 20 min. An aliquot of the sEnd.1 cell-conditioned 
medium was removed and transferred to confluent RFL-6 cells that had been 
pre-incubated with the same Krebs Ringer buffer, but additionally containing 
3-isobutyl-1 -methylxanthine (IBMX, 300 pM). After 5 minutes, buffer was 
removed and ice-cold HCI (0.1 M) was added to the culture wells. RFL-6 cell 
extracts were harvested and analyzed for cGMP content using an ELISA kit 
(Cayman Chemical, Ml) as per the manufacturers instructions. Experiments 
were repeated in the presence of the NO donor, SNAP (100 pM) and a 4-fold 
elevation in cGMP generation was observed.
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Western blotting
Cells were suspended in RIPA lysis buffer (20 mM Tris-HCI, 150 mM 
NaCI, 1 mM Na2pDTA, 1 mM EGTA, 1% Triton, 0.1% SDS, 0.1 sodium 
deoxycholate, pH 7.4), that additionally contained a cocktail of protease 
inhibitors, and subjected to four freeze-thaw cycles in liquid nitrogen. Protein 
concentration was determined by the Bradford method (BioRad, CA). Sample 
protein (30 pg) was resolved by polyacrylamide gel electrophoresis (10-20%) 
and transferred to nitrocellulose membranes by wet electroblotting for 90 min. 
Nonspecific protein binding was blocked by incubation of the membranes with 
blocking buffer (10 mM Tris, 150 mM NaCI, 0.05% Tween 20, 5% nonfat milk, 
pH 7.4). After washes in TBS, rabbit polyclonal IgG to eNOS (1:2500, 
Transduction Laboratories, NJ), phospho-PKC (specific to phosphorylation on 
Ser660; 1:1000, Upstate, VA), GTPCH (1:10000) or GFRP (1:10000) was 
incubated with membranes overnight, at 4°C. Membranes were washed in 
TBS and then incubated with HRP-conjugated anti-rabbit secondary antibody 
(1:2000) for 60 min at room temperature. Membranes were rewashed and 
visualized using LumiGLO Chemiluminescent Substrate (Cell Signaling 
Technology, Inc., MA).
Pterin analysis by CouiArray electrochemical detection
Cells: After treatment, sEnd.1 cells were harvested by scraping into 
PBS buffer and centrifuged at 2000 x g for 1 minute. The supernatant was 
discarded and 300 pi ice cold acid precipitation buffer (0.1 M Phosphoric acid, 
0.23 M TCA) was added to the cell pellet. Samples were then mixed and
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centrifuged (12,000 x g at 4°C) for a further 1 minute. Two aliquots of 
supernatant (120 pi) were removed into HPLC vials for the analysis of total 
biopterin, BH4, qBH2 and 7,8-BH2 (Heales and Hyland, 1989).
To the first vial, 1 pi sodium bisulfite (final concentration 3 mM) was 
added immediately followed by 1 pi dithioerythritol (DTE, 6 mM final). To the 
second vial, DTE (6 mM final) only was added. Samples were then injected 
onto an HPLC system configured with sequential multi-channel 
electrochemical CoulArray (ESA inc., MA) and fluorescence detection. 
Pterins were resolved isocratically with a 100 mm C-18 column (Microsorb- 
MV, Varian, CA) running mobile phase, comprising: 50 mM sodium acetate, 5 
mM citric acid, 48 pM EDTA and 0.3 mM DTE, pH 5.2 at a flow rate 0.75 
ml/min and temperature at 30°C. The optimum potential for detection of BH4 
was determined to be +125 mV. Two additional electrodes were set 
sequentially at -350 mV and +700 mV to initially restore the BH4 (via 
reduction) and then oxidize all pterins within the sample, respectively, allowing 
for confirmation of BH4 presence and detection of all pterins, irrespective of 
their redox state. Quantitation of q-BH2 was done by subtracting the value of 
sample 1 (BH4 only) from sample 2 (BH4 + qBH2). 7,8-BH2 and biopterin 
was quantified by fluorescence detection, as depicted in Figure 3.1. 
Quantitation of BH4, 7,8-BH2 and biopterin was done by comparison with 
external standards after normalizing for sample protein content. An example 
chromatogram is shown in Figure 3.2.
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(modified from Heales and Hyland, J. Chromatog., 1989)
Figure 3.1. Schematic depleting the HPLC~EC method used for 
quantitation of BH4, q-BH2 and 7,8-BH2. Briefly, two aliquots of each 
sample are taken. Sample 1 is treated with sodium bisulfite (3 mM) prior to 
DTE (6 mM), while sample 2 is treated with DTE (6mM) only. Samples are 
then injected onto an isocratic HPLC system with multi-channel 
electrochemical CoulArray and fluorescence detection. BH4 appears as a 
peak at approximately 4.5 minutes, while quantitation of q-BH2 is done by 
subtracting peak area of sample 1 from sample 2. 7,8-BH2 is quantified by 
fluorescence detection linked to the fourth channel of the electrochemical 
detector.
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Figure 3.2. Example chromatogram depicting BH4 oxidation at 37°C. 
BH4 (25 pmol) was prepared in PBS and incubated at 37°C for 0, 15 and 30 
minutes and analyzed for pterin content in A, B and C, respectively. In each 
panel, the second trace reflects BH4 content (+125mV) and the top trace 
reflects 7,8-BH2 content (Fluorescence excitation 350 nm, emission 450 nm) 
Complete oxidation of BH4 to BH2 was observed within 30 minutes.
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Superoxide quantitation by luminol chemiluminescence
The production of ROS in response to elevated levels of glucose was 
measured by luminol (5-amino-2,3-dihydro-1,4-phthalazinedione) 
chemiluminescence. After incubation of sEnd.1 cells in high or low glucose 
media for 48 hours, cells were washed with a modified Krebs buffer (145 mM 
NaCI, 5.7 mM sodium phosphate, 4.86 mM KCI, 0.54 mM CaCb, 1.22 mM 
MgS04, 5.5 mM glucose, pH 7.35) and media was replaced with fresh 
medium that was either unmodified or contained L-NAME (3 mM), DPI (10 
pM), or CuZn-SOD (1000 U/ml). After 2 hours further incubation, cells were 
rewashed and harvested in modified Krebs buffer. Cell suspensions (100 pi) 
were added to Krebs buffer containing luminol (100 pM; 100 pi) and placed in 
a luminometer cuvette. After 5 minutes, luminol-enhanced 
chemiluminescence was quantified using a TD-20/20 luminometer (Turner 
Designs, Sunnyvale, CA).
Amplex Red™ assay for hydrogen peroxide
A highly sensitive probe for H2O2 , Amplex Red, was used to quantify 
the production of H2O2 from EC exposed to low or high levels of glucose 
(Calbiochem, CA). In the presence of horseradish peroxidase (HRP), Amplex 
Red reacts with H2O2 to produce fluorescent resorufin with a 10 pmol limit of 
spectrophotometric detection at 560nm. In 96 well plates, H2O2 production 
from sEnd.1 EC was measured in phenol red-free DMEM (100 pi). Using a 
kinetic protocol, 100 pi of the Amplex Red - HRP working solution was added
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and assayed for H2O2 content over time using a Molecular Devices 
Thermomax microplate reader at 37°C.
Protein incorporated 3-nitrotyrosine quantification by 
CoulArray electrochemical detection
Cells were washed three times, harvested into ice-cold phosphate- 
buffered saline (pH 7.2-7.4) and pelleted at 2,000 x g. A buffer consisting of 
50 mM Tris, 150 mM NaCI, 0.1 mM EDTA and 20 mM CHAPS (pH 7.4) was 
added (300 pi) to the cell pellet and agitated gently without vortexing. After 
centrifugation, (12,000 x g for 5 min) the supernatant was transferred to a new 
tube and ice-cold acid precipitation buffer (0.1 M phosphoric acid, 0.23 M 
TCA), added to a 100 pi portion of the sample (3:1 v/v). The extract was 
incubated for 5 min at room temperature and then recentrifuged for 15 min 
(12,000 X g at 4°C). To quantify free 3-NT, the supernatant was removed and 
placed in HPLC autoinjector vials.
A second 100 pi aliquot of the cell homogenate, was subjected to 
proteolytic digestion for analysis of the extent of protein incorporated 3-NT. 
Proteinase K (1U/10 mg protein) was added to the tissue homogenate and 
incubated for 8 hours at 55°C. Samples were allowed to come to room 
temperature before the addition of the precipitation buffer and further 
preparation as above.
An isocratic HPLC system with multi-channel electrochemical 
CoulArray (ESA inc., MA) detection was used to effectively resolve 3-NT from 
background species using a 100 mm C-18 column (Microsorb-MV, Varian,
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CA) running mobile phase (90 mM sodium acetate, 35 mM citric acid, 130 pM 
EDTA and 460 pM sodium octane sulfonate, pH 4.35) at a flow rate of 0.75 
ml/min and temperature of 30°C (Crabtree et al, 2003; Maruyama et al., 
1996). The optimum potential for detection of 3-NT was found to be +800 mV. 
For maximum selectivity of the system for 3-NT, two other electrodes were set 
either side of the optimum potential for 3-NT detection, at +700mV and +900 
mV respectively. Compounds that have the same retention time, but have a 
different optimum electropotential will not be detected. Confirmation of the 
identified species as 3-NT was established by silencing of the 3-NT signal 
when sodium hydrosulfite (10 mM) was added to the sample. This treatment 
chemically reduces 3-nitro- to 3-amino-tyrosine, silencing the electrochemical 
signal.
Microtiter plate GSH assay
For quantitation of GSH, a modified microtiter plate enzymatic recycling 
assay was used, adapted from a commonly used enzyme recycling assay 
(Griffith, 1980). In this procedure, cellular GSH is oxidized by 5,5’-dithiobis-(2- 
nitrobenzoic acid) (DTNB) and continuously reduced by NADPH in the 
presence of glutathione reductase. A reaction buffer containing sodium 
phosphate (125 mM) and EDTA (1 mM) in assay solution (2.8 ml of ImM 
DTNB, 3.75 ml of 1 mM NADPH, 5.85 ml of buffer, and 20 U GSH reductase) 
was freshly prepared. GSH standards and cell homogenates (50 pi) were 
added to wells in a 96-well microtiter plate. Immediately, 100 pi of the 
reaction mixture was added and the rate of 2-nitro-5-thiobenzoic acid 
formation was quantified at 412 nm over a 2 minute period.
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Glucose quantification in cell media
Cells grown in 6 well plates were treated with low (5 mM) or high (25 
mM) levels of glucose and glucose consumption measured overtime was 
measured using an Amplex Red assay kit. The Amplex Red Glucose/Glucose 
Oxidase Assay Kit provides a sensitive one-step method for detecting glucose 
or glucose oxidase (Invitrogen, CA). The Amplex Red reagent (10-acetyl-3,7- 
dihydroxyphenoxazine) is a colorless and stable peroxidase substrate. In the 
assay, glucose oxidase reacts with D-glucose to form D-gluconolactone and 
H2O2 . In the presence of horseradish peroxidase (HRP), the H2O2 then reacts 
with the Amplex Red reagent in a 1:1 stoichiometry to generate the red- 
fluorescent oxidation product, resorufin. The limit of detection is 3 pM D- 
glucose when read using the fluorescence excitation and emission maxima of 
approximately 571 nm and 585 nm, respectively.
eNOS knockdown by RNAI
Design and synthesis o f eNOS-specific siRNA dupiexes. The
Qiagen “HiPerformance siRNA Design Algorithm” technology was used for the 
selection of specific siRNAs for sequence-specific targeting of mouse eNOS 
mRNA (Qiagen inc., CA). The siRNAs for each sequence were used as a 
pool of two specific siRNA duplexes with the target sequences listed below.
Duplex 1 - CAC GTG GAT GAG CCA GCT CAA 
Duplex 2 - CCG GCG CTA CGA AGA ATG GAA
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The resulting sequences for the two siRNA primers were:
Duplex 1 - CGU GGA UGA GCC AGC UCA A-dTdT
Duplex 2 - GGC GCU ACG AAG AAU GGA A-dTdT
The 21 nt RNA oligonucleotides are predicted to form a 19 bp duplex core 
(average duplex MW = 14890 g/mol). siRNA duplexes were resuspended in 1 
ml siRNA diluent (Roche, Basel, Switzerland) and aliquots were stored at - 
20°C. siRNA duplexes were handled and stored using RNase-free conditions 
and solutions.
Transfection o f sEnd.1 ceils with eNOS-specific siRNA. sEnd.1 
cells were grown in DMEM containing 10% fetal bovine serum and 1% 
penicillin/streptomycin at 37°C and 5% CO2 . The day before transfection, 
cells were seeded onto 6 well plates for subsequent Western blot analysis 
and BH4 measurement. When the cells reached -50% confluency they were 
transfected with 100 nM of eNOS-specific siRNA or nonspecific pooled duplex 
control SiRNA. For each well, 3 pg of siRNA was diluted in 50 pi OptiMEM 
(Invitrogen, CA) and mixed with 15 pi X-tremeGENE siRNA transfection 
reagent (Roche, Basel, Switzerland) diluted to 50 pi in OptiMEM (Invitrogen, 
CA). The SiRNA transfection mixture (final volume 100 pi) was incubated for 
5 min at room temperature (1:5 ratio of siRNA (pg) to transfection reagent, 
(pi)). During this incubation, fresh antibiotic-free DMEM was added to the 
sEnd.1 cells. The siRNA transfection mixture was added dropwise to the cells 
in a final volume of 2 ml. As a control for specificity, cells were also incubated
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with siRNA only, transfection reagent only, non-specific scrambled siRNA (1 
pg: Qiagen, CA), MARK siRNA (1 pg: Qiagen, CA) or left untreated. Cells 
were cultured for 2 days at 37°C and 5% CO2 . RNA silencing was detected 
by Western blotting for eNOS protein expression in cell lysates.
Establishing an eNOS overexpressing EC line
sEnd.1 cells were grown in low glucose DMEM supplemented with 
10% (v/v) fetal bovine serum (FBS), penicillin (100 U/ml), streptomycin (100 
pg/ml), and L-glutamine (2 mM). Cells were freshly seeded and grown to 50- 
60% confluency in serum-free media, 48 h prior to transfection. Transfections 
were carried out using FuGENE 6 according to the manufacturer’s instructions 
(Roche, Basel, Switzerland). Briefly, 776 pi of low serum (4%), OptiMEM 
medium (Invitrogen, CA) was added to sterile tubes. 24 pi of FuGENE 6 
reagent was then added and allowed to stand at RT for 5 min. 10 pg of 
pcDNA3.1-eN0S was added to the OptiMEM/FuGENE mix and complexes 
were gently tapped to mix contents. After a further incubation for 25 min at 
RT, the complex mixture was added to the cells dropwise and evenly 
dispersed. Cells were returned to the incubator for 7 h, after which the media 
was replaced with fresh media containing 10% FBS.
Statistics
Data are expressed as means ± SEM. All data were analyzed and 
compared using either an unpaired Student’s t-test or one way AN OVA with
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Tukey’s post hoc test, where appropriate. Differences were considered to be 
significant at P<0.05.
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3.3 Results
I^H]BH4 binding to eNOS. Studies were performed by a previous 
graduate student in our lab, Dr Caroline Smith, to characterize the binding of 
[^H]-BH4 to pure recombinant bovine eNOS and the ability of unlabelled 
pterins to compete. Binding assays were performed in the presence of 0.1 
mM DTT to minimize oxidation of [^H]BH4 during incubation. As shown in 
Figure 3.3A, under test conditions (50 nM [^H]-BH4 and 10 pmol eNOS, at 
22°C), pH]BH4 association with eNOS was half-maximal after 5.3 ±1.4  min 
(n=5) min and reached saturation within 30 min. The dissociation of 
preformed [^H]BH4-eN0S complexes was monophasic, with T1/2 = 28.1 ± 2.5 
min (n=3, inset to Figure 3.3A). Pseudoequilibrium binding of pH]BH4 to 
eNOS at 22°C was analyzed after a 20 min incubation of 10 pmol purified 
eNOS with the indicated concentrations of [^H]BH4. As shown in Figure 3.3B, 
binding was saturable and fit to a single class of sites with an apparent "^"^Kd 
of 82.1 ± 17.8 nM. Competition binding studies were performed to compare 
the ability of non-radiolabelled pterins to vie for pH]BH4 binding to eNOS. 
Most importantly, the binding affinities of BH4 and BH2 were found to be 
indistinguishable, with EC50 values of 59.3 ± 19.0 nM and 67.4 ±11.1 nM, 
respectively (Figure 3.3C). In contrast, tetrahydropterin (PH4), an analog of 
BH4 that differs only in the lack of a 6-position dihydroxypropyl side-chain, 
bound eNOS with >1000-fold lower affinity (EC50 = 112 pM). These results 
demonstrate that partial oxidation of the biopterin ring does not influence 
pterin binding to eNOS, whereas the 6-position side-chain is essential for high 
affinity binding.
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Given that BH2 binds eNOS with high affinity and dissociation of BH4- 
eNOS occurs with relative rapidity, it was hypothesized that BH2 can 
efficiently substitute for BH4 in complexes with eNOS. To test this possibility, 
I^H]BH4-eN0S complexes were preformed, then desired concentrations of 
BH2 were added and residual [^H]BH4-eN0S complexes quantified following 
a further 30 min incubation. As shown in Figure 3.3D, as much as 80% of 
[^H]BH4 in eNOS complexes was displaced by BH2 in this experimental 
paradigm; notably, half-maximal [^H]BH4 displacement was observed when 
concentrations of added BH2 and [^H]-BH4 approached equivalence (50 nM). 
Taken together, these in vitro binding studies indicate that if BH2 was to 
accumulate in EC, it would efficiently compete with BH4 for occupancy of the 
eNOS pterin binding site and thereby promote eNOS uncoupling.
The stability o f BH4 is dependent on temperature. BH4 is
susceptible to auto-oxidation. Experiments were performed to assess the 
lifetime of BH4 in physiological buffer at different temperatures. At 4°C more 
than 90% of total BH4 remains after a 60 minute incubation, whereas only 
23% and 3% remain at 22°C and 37°C, respectively (Figure 3.4).
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Figure 3.3. Characterization of I^H]BH4 binding to purified recombinant 
bovine eNOS and competition by pterin analogues. Panel A: Kinetics of 
association an(d (dissociation (panel insert) of pH]BH4 biniding (50 nM) to 
eNOS (10 pmol). For (dissociation stu(dies, [^H]BH4-eN0S complexes were 
formed during a 15 min preincubation and dissociation of complexes was 
quantified at varying times after addition of a 2,000-fold molar excess of 
unlabelled BH4. Panel B: Pseudoequilibrium binding of [^H]BH4 to eNOS (10 
pmol) following 15 min incubation. The calculated apparent ®^ "^ Kd = 82.1 ± 
17.8 nM (n = 3). Panel C: Competition of unlabelled pterins for [^H]BH4 
binding to eNOS. [^H]BH4 (50 nM) and eNOS (10 pmol) were incubated with 
indicated concentrations of BH2, BH4 or tetrahydropterin (PH4) -  binding was 
terminated and analyzed after 15 min. Panel D: Displacement of pH]BH4 
from pre-formed eN0S-[^H]BH4 complexes by BH2. Complexes were formed 
by preincubating eNOS (10 pmol) with [^H]BH4 (50 nM) for 15 min and 
residual complexes were quantified 30 min after addition of indicated 
concentrations of BH2. All binding reactions were conducted at 22°C. Points 
are means ± SEM of triplicate determinations.
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Figure 3.4. The rate o f BH4 oxidation is temperature dependent. BH4
(25 pmol) was incubated at different temperatures (4°C, 22°C and 37°C) and 
the time-dependent degradation was assessed by HPLC-EC. Points are 
means ± S.E.M (n=3).
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Attenuation o f NO production by elevated glucose. NO bioactivity 
was measured in the culture medium of murine EC (sEnd.1 line), following a 
20 min incubation with calcium ionophore (A23187; 5 pg/ml). Quantification of 
NO bioactivity was based on electrochemical detection (Panel A) as well as 
by the rapid increase in cGMP content elicited in phosphodiesterase-inhibited 
RFL-6 reporter cells, following 5-min exposure to EC-conditioned medium 
(Panel B). By both measures ionophore-elicited NO bioactivity was 
diminished by >50% after treatment of EC for 48 h with 30 mM vs. 5 mM 
glucose (P<0.05). Whereas a progressive decrease in NO bioactivity was 
observed with increasing glucose concentrations in the range of 5-30 mM, 
responsivity of RFL-6 reporter cells to NO was not attenuated by high 
glucose, as indicated by their unaltered response to the NO donor SNAP.
Attempts to detect glucose-induced changes in eNOS or BH4 
synthetic/regulatory proteins. The possibility that suppression of NO 
synthesis by high glucose-containing media arises from diminished levels of 
eNOS or key BH4 biosynthetic and/or regulatory proteins was considered. To 
test this possibility, western blots were performed using specific antibodies to 
probe for expression of eNOS, GTP cyclohydrolase (GTPCH; the rate-limiting 
enzyme in de novo BH4 synthesis) and GTP cyclohydrolase feedback 
regulatory protein (GFRP; an allosteric protein that binds GTPCH and inhibits 
activity). As shown in Figure 3.6, and replicated in three additional 
experiments, high glucose-associated changes in expression levels of these 
proteins was not detected.
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Figure 3.5. Giucose-induced attenuation o f NO production by EC.
sEnd.1 cells were treated with increasing concentrations of glucose for 48 
hours and levels of bioactive NO measured after treatment with A23187 (5 
pg/ml) in the absence or presence of NMA (3 mM) using A) an NO electrode, 
and B) cGMP accumulation in RFL-6 reporter cells. High levels of glucose 
(30 mM) significantly attenuated endothelial-derived NO levels, in comparison 
to levels observed with low glucose (5 mM) (*P<0.05). Treatment of RFL-6 
cells with the NO donor, SNAP elicited a four fold increase in cGMP 
accumulation (***P<0.001). Data are means ± SEM (n=3).
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Figure 3.6. eNOS, GTPCH and GFRP protein levels are unchanged after 
exposure o f sEnd.1 EC to high glucose fo r 48 hours, immunoblots of cell 
lysates for A: eNOS, B: GTPCH, C: GFRP show that protein levels remain 
unchanged after exposure of cells to Low (5 mM) vs. High (30 mM) levels of 
glucose. Depicted blots are representative of three replicate experiments.
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High glucose-elicited Intracellular BH4 oxidation In EC. The BH4
redox status in EC was analyzed by HPLC, using combined electrochemical 
and fluorescence detection (Heales and Hyland, 1989). Absolute amounts of 
total pterin (BH4 + BH2 + biopterin) were indistinguishable between high and 
low glucose-treated cells. However, the level of BH4 in EC after exposure to 
high glucose for 48 h was diminished by 40-50%, with a reciprocal increase in 
BH2 content (P<0.01) (Figure 3.7). This accumulated BH2 was almost 
exclusively 7,8-BH2 and did not contain a significant component of the 
quinonoid tautomer, q-BH2. Neither fully-oxidized BH4 (i.e., biopterin), nor 
the side-chain cleaved product, pterin was observed in detectable amounts.
BH4 oxidation to BH2 in EC increased progressively with the duration 
of exposure to high glucose (Figure 3.7A) and as a function of glucose 
concentration (Figure 3.7B). High glucose-elicited oxidation of BH4 was more 
than 50% prevented by co-treatment with the NOS-specific inhibitor, L-NAME 
(3 mM), and abolished by an inhibitor of flavoproteins, DPI (10 pM: Figure 
3.7C). These findings suggest a key role for O2 and/or derived species from 
uncoupled eNOS in the oxidation of BH4 (Figure 3.7C).
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Figure 3.7. High glucose promotes the oxidation o f BH4 to BH2 in a 
time, concentration, and eNOS-dependent manner. sEnd.1 EC were 
exposed to , indicated levels of glucose for 24 or 48 hours. Panel A: 
Intracellular BH4 and BH2 measured as a function of time of incubation in low 
(5 mM) and high (30 mM) glucose concentrations. Panel B: Intracellular BH4 
and BH2, measured after 48 h incubation in the indicated glucose 
concentration. Panel C: Influence of the NOS inhibitors L-NAME and DPI on 
low (5 mM) and high (30 mM) glucose associated biopterin status. High 
glucose conditions caused significant (*P<0.05) oxidation of BH4 to BH2 by 
24 hours, which was worsened by 48 hours. Addition of L-NAME (3 mM: 
*P<0.05) or DPI (10 pM: ***P<0.001) significantly attenuated the oxidation 
(BH2 accumulation, white bars) observed under high glucose conditions, 
while promoting a minor degree of oxidation under low glucose conditions. 
Bars represent means ± S.E.M. (n= 4 or 5).
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High glucose-elicited production o f reactive oxygen and reactive 
nitrogen species in EC. BH4 insufficiency is an established trigger of eNOS 
uncoupling, resulting in eNOS-derived O2" production. Such uncoupling may 
elicit a feed-forward cascade, wherein BH4 oxidation in EC leads to eNOS 
uncoupling, resulting in increased O2' production, increased ONOO' formation 
and consequently further BH4 oxidation. Consistent with this scenario, 
findings presented in Figure 3.8 indicate that exposure to high glucose does 
indeed elicit eNOS uncoupling in EC. Treatment of EC with high glucose (30 
mM) elicited significant increases in the release of H2O2 (30% increase, panel 
A), O2' (300% increase, panel B) and 3-NT incorporation into EC proteins 
(300% increase. Panel C). Notably, 3-NT is a hallmark of peroxynitrite 
formation, via the near diffusion limited, radical-radical reaction of NO with O2' 
(McMillan et al., 1992). Authenticity of detected O2* is supported by its 
removal upon addition of Cu, Zn-SOD (2000 U). The fact that the high 
glucose-induced increase in O2' production derives from uncoupled eNOS is 
supported by the finding that it is abolished by the NOS inhibitor, L-NAME 
(Figure 3.8B). Moreover, an almost identical degree of inhibition was 
observed with diphenyleneiodonium (DPI), an agent that inhibits O2' 
production from NOS and other flavoprotein sources, most notably NADPH 
oxidase. Thus, products derived from uncoupled eNOS are sufficient to 
explain the observed high glucose-associated increases in EC production of 
superoxide, contributing to elevated levels of H2O2 and OONO*.
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Figure 3.8. Glucose-Induced ROS formation In EC. EC were exposed to 
high (30 mM), or low (5 mM) levels of glucose, and markers of oxidative 
stress were measured after 48 hours. Panel A: H2O2 production, quantified 
using the Amplex Red assay. High glucose treated cells produced markedly 
more H2O2 when compared to low glucose control cells. (*P<0.05). Panel B: 
O2 production, determined by luminol chemiluminescence. High levels of O2' 
were produced after exposure of EC to elevated levels of glucose in 
comparison to low glucose treated control cells. This elevated ROS formation 
was totally inhibited by DPI (10 pM), L-NAME (3 mM) and SOD (2000 U/ml). 
Panel 0: Protein incorporated 3-NT, an indicator of peroxynitrite formation, 
quantified by HPLC-EC. High levels of 3-NT were shown to accumulate in 
cells treated with high, but not low levels of glucose (*P<0.05, **P<0.01, 
***P<0.001). Points and bars are means ± SEM (n=5-8).
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Supplementation o f Intracellular pterin by exogenous BH4 or BH2.
Experiments sought to determine the extent to which supplementation of EC 
with exogenous BH4 or BH2 would change the intracellular ratio of BH4:BH2, 
and how these changes would impact on eNOS-derived NO and O2' 
production. Supplementation of low glucose treated EC with either BH4 or 
BH2 (10 pM) for 24 hours, significantly increased the levels of both BH4 and 
BH2 (Figure 3.9) and resulted in an overall >8-fold increase in total 
intracellular biopterins. Significant amounts of BH2 and BH4 accumulated in 
EC following treatment with BH2, demonstrating the operation of pterin 
recycling pathways. The presence of high glucose in the culture medium 
exacerbated BH2 formation in BH4 treated cells (P<0.05), whereas elevated 
levels of glucose appeared to have no significant effect on BH4:BH2 balance 
in cells treated with BH2.
Studies next investigated the influence of biopterin supplementation on 
high-glucose impaired NO production and accelerated superoxide production. 
Shown in Figure 3.10, supplementation with either BH4 or BH2 elicited an 
increase in NO production, as measured by the accumulation of cGMP in an 
RFL-6 reporter cell line (P<0.05). However, in the presence of high levels of 
glucose, NO production by EC was markedly blunted (P<0.05). Notably, BH4 
supplementation of high glucose treated EC resulted in a markedly greater 
decrease in NO bioactivity than observed under basal conditions or with BH2 
treatment (P<0.05). Oxidation of supplemented BH4 to BH2 may explain 
some previous paradoxical reports showing a detrimental effect of BH4 
supplementation on NO-mediated vasorelaxation (Tsutsui et al., 1996; 
Vasquez-Vivar et al., 2002a). Reciprocal to the decreased NO bioactivity.
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BH4 supplementation elicited a 7-fold increase in O2' production. Whereas 
BH2 modestly diminished the production of O2' by EC in the presence of high 
glucose, these agents markedly increased O2 ' production in low glucose 
treated cells (P<0.05, Figure 3.10). Pterin supplementation had no significant 
effect on levels of intracellular GSH (Figure 3.11).
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Figure 3.9. Effect o f supplementation o f EC with exogenous BH4 o r  
BH2. EC were incubated with DMEM supplemented with BH4 or BH2 (10 pM 
in each case). After 24 hours, intracellular levels of BH4 and BH2 were 
determined by HPLC. Filled bars = BH4, open bars = BH2. Incubation of low 
glucose EC with BH2 elicited a 3.5-fold increase in BH4 levels and 
accumulation of an equivalent amount of BH2. The presence of high glucose 
in the culture medium exacerbated BH2 formation in BH4 treated cells 
(P<0.05), whereas elevated levels of glucose appeared to have no significant 
effect on BH4;BH2 balance in cells treated with BH2. Bars represent means ± 
S.E.M (n=5).
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Figure 3.10. Pterin supplementation o f high glucose treated EC. Cells 
were grown in high (30 mM) or low (5 mM) glucose containing media and BH4 
or BH2 (10 pM) were added at 24 hours. After a further 24 hours, NO and O2 ' 
production were measured as shown in panels A and B, respectively. A) NO 
production from both low and high glucose-treated cells was increased by 
supplementation with BH2, but not BH4 (*P<0.05). Treatment of high glucose 
EC with BH4 further diminished NO production (*P<0.05). B) O2 ' production 
was enhanced five-fold by exposure of cells to high levels of glucose 
(**p<0 0 1 ). This was blunted by the addition of BH2, but further exacerbated 
by BH4. BH2 markedly increased the formation of O2 ' from cells exposed to 
low levels of glucose (*P<0.05), but to a much lesser degree than observed 
with the addition of BH4. Data are shown as mean ± S.E.M. (n=5).
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Figure 3.11. Supplementation with exogenous pterin does not affect 
Intracellular GSH levels. Cells were grown in high glucose (30 mM) 
containing media and BH4 or BH2 (10 pM) were added at 24 hours. After a 
further 24 hours, GSH was measured. No difference in intracellular GSH was 
observed when cells were treated with either BH4 or BH2. Data are shown as 
means ± S.E.M. (n=6).
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GSH levels determine the extent o f BH4 oxidation by glucose In
EC. Since GSH is the major EC reservoir of reduced thiols, whether glucose- 
elicited BH4 oxidation is concomitant with GSH oxidation was investigated. 
As shown in Figures 3.13A and 3.13B, a 48 h treatment with 30 mM glucose 
resulted in a 35-40% relative decrease in both intracellular GSH and BH4, in 
comparison to levels observed with 5 mM glucose. Repletion of intracellular 
GSH levels to 220% of that observed with low glucose, occurred following 
treatment with GSH ester (Figures 3.12 and 3.13A). This level of GSH 
repletion in EC afforded complete protection against glucose-elicited BH4 
oxidation and prevented glucose-induced GSH loss (Figure 3.13B). 
Reciprocally, depletion of GSH to 20% of basal levels in cells cultured in low 
glucose was obtained after treatment with a selective y-glutamyl-cysteinyl 
synthase inhibitor, buthionine sulfoximine (BSO; Figure 3.13C). This extreme 
level of GSH depletion markedly accentuated high glucose-induced BH4 
oxidation to >85% (compared to 40%, without BSO) and was sufficient to elicit 
BH4 oxidation on its own in low glucose media (20%), where BH4 oxidation is 
not otherwise observed.
GSH depletion with BSO increased the susceptibility of BH4 to 
oxidation by H2O2 . ECs were treated with H2O2 (100 pM) for 24 hours and 
pterin redox status was measured by HPLC. H2O2 , unable to elicit pterin 
oxidation on its own, resulted in 80% oxidation of BH4 to BH2 after 
intracellular GSH levels were already compromised by treatment with BSO 
(100 pM) (Figure 3.14).
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Figure 3.12. Supplementation o f Intracellular GSH by glutathione mono 
ethyl ester (GSH-MEE). sEnd.1 EC were incubated overnight with GSH- 
MEE at the indicated concentrations and the level of intracellular GSH was 
measured by a modified microtiter plate assay. GSH-MEE (1 mM) resulted in 
a 220% increase in the levels of intracellular GSH. Bars are means ± SEM, 
*P<0.05 (n=3). Similar results were seen in two replicate experiments.
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Figure 3.13. Intracellular GSH levels are depleted by high glucose 
treatment (30 mM) and correlate with BH4 levels. Cells were cultured in 
normal (5 mM) or high glucose (30 mM) for 48 hours in the presence and 
absence of either glutathione mono ethyl ester {Panels A and B; GSH-MEE, 1 
mM), or an inhibitor of GSH synthesis, buthionine sulfoximine (Panels C and 
D; BSO, 100 pM). Cells were then harvested and GSH (Panels A and C) and 
biopterin (Panels B and D) were quantified. A 2.2-fold elevation of 
intracellular GSH levels was achieved by supplementation of cell culture 
media with GSH-MEE (1 mM). This enhancement of intracellular GSH totally 
prevented oxidation of BH4 to BH2 upon treatment of EC with high levels of 
glucose. The opposite was also true, an 80% reduction of intracellular GSH 
pools was observed following BSO treatment. This markedly potentiated the 
oxidation of BH4 to BH2 after treatment of EC with high glucose (30 mM) 
(*P<0.05). Assessment of the pterin redox state was done by HPLC-EC, 
showing an approximate 80% reduction in the amount of BH4 and a reciprocal 
increase in levels of BH2 (**P<0.01). All values are means ± SEM (n=5).
80
Mark J. Crabtree BH4 oxidation in models of vascular disease 2005
D)
100
® 75
S 25
Figure 3.14. The Influence o f Intracellular GSH on the susceptibility o f 
BH4 to oxidation by H2O2. EC were pretreated with either BSO (100 pM) or 
vehicle (DMSO) for 24 hours prior to experiment. Cells were then exposed to 
H2O2 (500 pM) for a further 24 hours and pterin redox status assessed by 
HPLC-EC. H2O2 alone had no effect on BH4 levels in EC. After pretreatment 
with BSO, at a concentration that decreases intracellular GSH by >80%, H2O2 
significantly increased the susceptibility of BH4 to oxidation (***P<0.001). All 
values are means ± SEM (n=3).
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The role o f the pterin salvage pathway. As 7,8-BH2 can be recycled 
to BH4 by DHFR, inhibition of DHFR by methotrexate (MTX; 10 pM) could 
cause accumulation of BH2 under physiological conditions and potentiate the 
glucose-induced oxidation of BH4. After 48 hours in high glucose media, the 
previously seen -40% loss of BH4 was observed vs. low glucose cells (Figure
3.15). In the presence of MTX, significant amounts of BH2 accumulated in 
cells even when grown in low glucose media (P<0.05). MTX treatment of 
cells that had been stressed by high glucose, further exacerbated the 
increase in BH2 levels and reciprocally diminished BH4 levels by 4-fold. 
These data support a key role for DHFR mediated BH4 recycling in the 
regulation of BH4 redox status in EC.
The contribution o f eNOS uncoupling to BH4 oxidation. Any
stimulus that initiates pterin oxidation in EC would predictably trigger O2 ' 
production by eNOS. Notably, this could result in a feed-forward cascade of 
further oxidation of BH4 to BH2 and an escalating rate of O2' production. This 
possibility was supported by the earlier observation that pharmacological 
inhibition of eNOS blocks glucose-induced BH4 oxidation. This possibility 
was tested using a molecular approach for suppression of eNOS activity. 
Towards this end, eNOS gene silencing in EC, using RNAi technology was 
utilized to assess the contribution of eNOS to BH4 oxidation by elevated 
glucose levels. eNOS-specific siRNAs were designed and synthesized as 
described in Materials and Methods. To determine the selectivity of the eNOS 
siRNAs, sEnd.1 EC were transfected with eNOS-specific siRNAs and the 
knockdown of eNOS protein was determined by Western blotting (Figure
82
Mark J. Crabtree BH4 oxidation in models of vascular disease 2005
3.16). A knockdown of «70% of detectable eNOS protein was obtained with 
eNOS-specific siRNA, whereas scrambled, non-specific and control siRNAs 
had no observable effect. To ensure that eNOS-siRNA induced changes in 
pterin levels were not associated with unforeseen non-specific gene silencing 
events, membranes were additionally probed with antibodies specific for the 
p47phox subunit of NADPH oxidase and GTPCH protein. As expected, non­
specific gene knockdown was not observed with either eNOS-specific or 
eNOS non-specific siRNAs (Figure 3.16).
With the specificity and efficiency of our eNOS siRNA system 
confirmed in EC, the effect of suppressed eNOS-derived O2' by siRNA on 
BH4 oxidation was assessed (Figure 3.17). In contrast to the -50% inhibition 
of glucose-elicited BH4 oxidation observed with L-NAME (Figure 3.7), 
incubation with eNOS specific siRNA resulted in -70% inhibition of BH4 
oxidation. As expected, in untreated, transfection reagent only and non­
specific siRNA-treated control cells, knockdown of eNOS protein did not occur 
and intracellular pterin levels were unaffected. As the level of protection 
afforded by eNOS siRNA is comparable to the observed degree of eNOS 
knockdown, experiments conclude that BH4 oxidation by glucose is almost 
totally dependent on eNOS-derived ROS production.
Having found that eNOS gene silencing protects against glucose- 
mediated BH4 oxidation, an eNOS transfected cell line was employed to 
explore the effect of eNOS overexpression on glucose-induced BH4 oxidation. 
Transiently transfected sEnd.1 EC were prepared using the mammalian 
expression vector, pcDNA3.1-eN0S, as outlined in the Materials and 
Methods. Overexpression of eNOS in sEnd.1 cells resulted in exacerbated
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accumulation of intracellular BH2 following exposure of cells to hyperglycemic 
levels of glucose (Figure 3.18). Moreover, intracellular BH4:BH2 ratio was 
decreased dramatically when cells were incubated in high glucose media for 
48 hours, beginning 6 hours post transfection with pcDNA31-eNOS. 
Surprisingly, eNOS overexpression in cells cultured in low glucose media also 
resulted in a decrease in BH4:BH2 ratio.
Interestingly, as eNOS protein was overexpressed, so too was the level 
of GTPCH as shown by Western blot analysis and the dramatic (>3-fold) 
elevation of total pterin levels (Figure 3.18). Although not reported in prior 
literature, this finding is in accord with multiple reports of active eNOS in 
eNOS transfected cells that are normally devoid of any NOS isoform (Liu et 
al., 1996; Sessa et al., 1995). eNOS inhibition with L-NAME was effective in 
preventing both the accumulation of BH2 with low and high glucose, as well 
as the induction of increased GTPCH protein expression.
Taken together, these data evidence a key role for eNOS-derived O2 ' in 
BH4 oxidation and deficiency that arises as a consequence of EC exposure to 
high glucose.
84
Mark J. Crabtree BH4 oxidation in models of vascular disease 2005
100
B  75-
D)
B 25-
LOW HIGH LOW HIGH
+ MTX
Figure 3.15. Inhibition o f BH4 recycling by DHFR potentiates BH4 
oxidation. sEnd.1 EC were exposed to low (5 mM) and high (30 mM) levels 
of glucose for 48 hours, in the absence or presence of MTX (10 pM, added at 
24 hours). Addition of MTX promoted oxidation of BH4 in low glucose treated 
cells, which was further exacerbated after exposure of cells to high levels of 
glucose (*P<0.05). All values are means ± SEM (n=5).
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Figure 3.16. Endogenous eNOS expression in sEnd.1 EC is attenuated 
by eNOS-specific siRNA. sEnd.1 cells were transfected with eNOS-specific 
and control, MARK and scrambled nonspecific siRNA, as described in 
Materials and Methods. Cell lysates were prepared and 30 pg protein 
samples were subject to Western blot analysis with anti-eNOS (1:2500), actin 
(1:20,000), the p47phox subunit of NADPH oxidase (1:1000), GTPCH 
(1,10000) and MARK (1:1000) antibodies. Quantification by densitometry 
illustrates that expression of eNOS monomer is knocked-down by 
approximately 70% using eNOS-specific siRNA, although expression is 
unaffected by either control non-specific or MARK siRNA. Blots shown are 
representative of at least five other experiments.
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125
Figure 3.17. eNOS gene siiencing prevents eNOS-induced pterin  
oxidation in EC. sEnd.1 cells were transfected with eNOS-specific, control 
MARK or scrambled nonspecific siRNA, as described in Materials and 
Methods. eNOS-specific siRNA elicited an average of 70% knockdown of 
eNOS, as shown in Figure 3.16. Following 48 h incubation in low or high 
glucose containing media, intracellular BH4 was quantified by electrochemical 
detection. eNOS RNAi diminished intracellular BH2 levels by 70%, nearly the 
same as the degree of eNOS knockdown. Treatment with non-specific, and 
MARK control siRNA had no effect of pterin oxidation status (data not shown). 
Results are means ± S.E.M. (n=5).
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Figure 3.18. eNOS transfection promotes eNOS uncoupling and GTPCH 
upregulation. sEnd.1 EC were transiently transfected with pcDNA3.1-eN0S 
and after 6 hours media was replaced with supplemented DMEM containing 
high or low glucose. After a further 48 hours, cells were harvested for 
Western blot analysis for eNOS (1:2500), GTPCH (1:10000) GFRP (1:10000) 
and actin (1:20,000) (Panel A) and pterin quantitation (Panel B). L-NAME 
was added where indicated, 18 hours prior to cell harvest (Right panels). 
eNOS transfection resulted in 3-fold increases in both eNOS and GTPCH 
protein expression. L-NAME had no effect on eNOS protein levels, but 
reduced GTPCH protein. Concomitant with GTPCH expression, following 
eNOS overexpression, total pterin levels are increased by 3-fold. Significant 
amounts of BH4 {filled bars) oxidation and BH2 accumulation {open bars) are 
now detected, not observed in control cells. L-NAME treatment significantly 
reduced intracellular levels of BH2 in EC (P<0.05).
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Attempts to determine alternative sources o f ROS that contribute 
to BH4 oxidation in EC. Having established eNOS-derived O2 ' as a major 
contributor to BH4 oxidation and the diminished NO production observed with 
high glucose-treated EC, experiments sought to examine the potential role of 
other sources of ROS and the extent to which they may additionally affect 
BH4 oxidation and NO bioactivity. In one line of investigation, the possibility 
that activation of NADPH oxidase by hyperglycemic levels of glucose could 
lead to BH4 oxidation and subsequent eNOS uncoupling was explored. As 
shown in Figure 3.19A, PKC, a known activator of ROS production by NADPH 
oxidase (Hink et al., 2001; Inoguchi et al., 2003), was activated by addition of 
phorbol 12-myristate 13-acetate (PMA; 5 pM) to the culture media. The 
predicted phosphorylation of PKC was confirmed (Figure 3.19), however this 
was not associated with BH4 oxidation in EC. Whereas modest BH4 
oxidation was evident in the presence of MTX (10 pM), NADPH oxidase- 
derived ROS did not contribute to further oxidation of BH4 (Figure 3.19).
The mitochondrial electron transport chain is known to be a significant 
source of ROS in physiology and this may be upregulated by oxidative stress. 
Indeed, it is well known that high glucose triggers metabolic excess of 
mitochondrial-derived ROS (Nishikawa et al., 2000; Srinivasan et al., 2004). 
O2' production from the mitochondria was inhibited by incubation of high 
glucose-stressed cells with either rotenone (2 pM), or thenoyl-trifluoroacetone 
(TTFA; 5 pM), inhibitors of complexes I and II of the electron transport chain, 
respectively. Surprisingly, rotenone completely prevented the pterin oxidation 
effects of hyperglycemia, implicating mitochondria in the genesis of NO 
insufficiency (Figure 3.20).
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Figure 3.19. Activation o f NADPH oxidase by PKC does not lead to BH4 
oxidation in EC. Panel A: PMA-induced phosphoactivation of PKC. EC 
were incubated with PMA (0-10 pM) for 2 hours and the phosphorylation 
status of PKC was measured by Western blotting. Cell lysates were 
prepared, normalized for protein content, and 30 pg samples were subject to 
Western blot analysis. An anti-pPKC antibody specific to PKC 
phosphorylated at Ser660 was used (1:1000). Panel B: PMA (10 pM) does 
not elicit BH4 oxidation in EC. Experiments were repeated in the absence 
and presence of MTX (10 pM) and pterin redox status assessed by HPLC-EC. 
NADPH activation by PMA only induced BH4 oxidation in the presence of 
MTX, suggesting that NADPH oxidase is not involved in the glucose-induced 
BH4 deficiency. Bars represent means ± SEM (n=5).
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Figure 3.20. Protection against high glucose-induced BH4 oxidation by  
inhib itors o f m itochondrial electron transport. Cells were grown in high 
glucose containing media for 48 hours. Rotenone (2 pM) or TTFA (5 pM), 
inhibitors of complexes I and II of the mitochondrial electron transport chain, 
respectively, were added. After 24 hours cells were harvested for assay of 
BH4 and BH2 after a further 24 hours. BH4 (filled bars) oxidation to BH2 
(open bars) was attenuated by both TTFA and rotenone treatment (P<0.01). 
Bars represent means ± SEM (n=3).
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3.4 Discussion
Diminished NO bioactivity is a significant predictor of cardiovascular 
risk (Britten et al., 2003; Schachinger et al., 2000) and a hallmark of 
endothelial dysfunction (Heitzer et al., 2001). NO insufficiency has been 
implicated in the etiology and progression of major chronic vasoinflammatory 
conditions, including diabetic vasculopathy and, hypertension (Warnholtz et 
al., 2004). Mitochondrial O2' overproduction provides a common trigger, 
eliciting the principal metabolic derangements implicated in the appearance 
and/or progression of diabetic complications (Brownlee, 2001). While 
scavenging of NO by O2' offers a simple explanation for consumption of NO 
bioactivity in diabetic blood vessels, the peroxynitrite product of this reaction 
can further compromise vascular function via oxidation of BH4, leading to 
eNOS uncoupling. Notably, oxidation of BH4 and eNOS uncoupling has 
recently been described in the Goto-Kakizaki genetic rat model of type II 
diabetes (Bitar et al., 2005).
These findings argue for a revised mechanistic view regarding the role 
of BH4 oxidation in endothelial dysfunction. Studies described herein indicate 
that the fundamental determinant of endothelial NO bioactivity is the balance 
between intracellular BH4 and its primary two-electron oxidation product, BH2 
- not absolute quantities of BH4 as had been previously thought. This 
conclusion is implied by in vitro analysis of [^H]-BH4 binding to purified 
recombinant eNOS and supported by studies of cultured vascular EC 
exposed to elevated glucose levels. Notably, a prior report by Vasquez-Vivar 
and colleagues provided indirect evidence of BH2 binding to recombinant 
eNOS in vitro, based on EPR detection of increased O2' formation in the
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presence of BH2, which was quenched following the addition of excess BH4 
(Vasquez-Vivar et al., 2002). Direct binding analyses described herein reveal 
that catalytically-incompetent BH2 binds eNOS with an identical affinity to that 
of the fully reduced BH4 cofactor. Moreover, when present in equimolar 
amounts, BH2 exchanges with BH4 on pre-formed BH4-eN0S complexes in 
vitro, achieving equal occupancy (50% of eNOS binding sites) within 15 min at 
22°C -  this exchange is likely to be more rapid at 37°C in intact cells. Levels 
of glucose found in diabetic patients are known to elicit oxidant stress to an 
extent that markedly perturbs EC pterin redox balance in favor of BH2 
accumulation. . Accumulated BH2 in EC increases in accord with the 
concentration of glucose in the extracellular milieu, is progressive with time 
(for a given glucose concentration) and is coupled to levels of intracellular 
GSH. Our findings indicate that the accumulated BH2 in high glucose treated 
EC is a cause of eNOS uncoupling.
Uncoupling of eNOS is demonstrated by a reciprocal, high glucose- 
elicited, decrease in stimulus-evoked NO bioactivity and increase in O2' 
production; O2' production is eradicated following exposure to a NOS- 
selective inhibitor (L-NAME), identifying eNOS as the source. Indeed, eNOS 
overexpression, as sometimes observed in diabetic vessels (Alp and 
Channon, 2004), did not attenuate, but potentiated the glucose-induced BH4 
oxidation to BH2 in cultured cells (Figure 3.18). In support of our data, Ozaki 
et al hypothesized that, as eNOS-derived NO is regarded as a protective 
factor against atherosclerosis, augmentation of eNOS expression or NO 
production by pharmacological intervention will inhibit atherosclerotic 
progression. In fact, in transgenic ApoE knockout mice crossed with eNOS-
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overexpressing (eNOS-Tg) mice, they observed chronic overexpression of 
eNOS does not retard, but accelerates, atherosclerosis under 
hypercholesterolemic conditions (Ozaki et al., 2002). This, in addition to the 
inhibition of BH4 oxidation that accompanies eNOS gene silencing using 
eNOS-specific siRNAs, provides evidence to confirm eNOS as the dominant 
source of ROS responsible for BH4 oxidation and hence, NO deficiency.
In contrast to a prior study (Landmesser et al., 2003), this study 
demonstrates no significant role for NADPH oxidase as a mediator of high 
glucose-elicited pterin oxidation. However, attenuation of mitochondrial- 
derived ROS did have a great impact on BH4 redox status, implying that 
increased flux through the electron transport chain and activation of 
mitochondrial ROS production lie upstream of BH4 oxidation and eNOS 
uncoupling. This was shown by the inhibitory action of rotenone and TTFA, 
inhibitors of mitochondrial electron transport, on glucose-elicited BH4 
oxidation. This view of mitochondrial O2' production as being a key initiator of 
the pathological changes in EC is supported by a recent publication stating 
that diminishing the levels of mitochondrial reactive oxygen species prevents 
glucose-induced activation of PKC, formation of advanced glycation end- 
products, sorbitol accumulation and NF^B activation (Nishikawa etal., 2000).
Accelerated peroxynitrite formation, inferred from increased 3-NT 
incorporation into EC proteins, provides further support for a switch in eNOS 
catalysis toward oxidant generation, rather than NO. Peroxynitrite is likely to 
be the biologically-relevant oxidant of BH4 in high glucose treated EC. 
Although O2' reacts with BH4 in vitro, the rate constant is >10,000-fold slower 
(3.9 X 10® mol-L'^-s'^) (Vasquez-Vivar et al., 2001) than its near-diffusion
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limited reaction with NO (6.7 x 10® mol-L'^-s'^) (Huie and Padmaja, 1993). 
Accordingly, NO should easily outcompete BH4 for reaction with O2'. 
Peroxynitrite, formed by the NO/O2 ' reaction, could then oxidize BH4 (Laursen 
et al., 2001; Milstien and Katusic, 1999) and thereby promote eNOS 
uncoupling. Notably, the reaction of peroxynitrite with BH4 occurs via the 
intermediacy of the BH3 radical cation and with a first-step rate constant that 
is several times faster than the reaction with thiols (6 x 10® mol-L'^-s'^) 
(Kuzkaya et al., 2003). In as much as intracellular thiol levels ( 5 - 1 0  mM) far 
exceed estimated levels of BH4 in EG (0.05 -  0.2 pM), thiol oxidation should 
predominate over BH4 oxidation. This competition between thiols and BH4 
for reaction with peroxynitrite provides an explanation for our observation that 
the extent of glucose-elicited BH4 oxidation in EC is directly-related to GSH 
levels (Figure 3.13).
The finding that BH2 avidly binds eNOS and engenders uncoupling has 
important implications for potential BH4-based therapies for endothelial 
dysfunction. Prior studies have suggested the therapeutic potential of BH4 
supplementation for reversal of endothelial dysfunction. While high doses of 
BH4 have been shown to acutely restore endothelial-dependent (NO- 
mediated) vasoactivity (Gori et al., 2001; Heitzer et al., 2000a; Higashi et al., 
2002; Setoguchi et al., 2002; Stroes et al., 1997b), studies have not yet 
addressed the long term consequences of chronic BH4 treatment. Results 
reported herein suggest that ongoing oxidative and nitrosative stress can elicit 
significant BH2 accumulation in EC that oppose the desired NO-restoring 
action of administered BH4. Thus, desensitization to the benefits of BH4 
administration, or frank worsening of vascular function, would result if BH2
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was to progressively accumulate in EC with repeated BH4 treatments. 
Accumulation of BH2 and consequent eNOS uncoupling also provides a likely 
explanation for paradoxical reports of BH4 treatment worsening endothelial 
function in ex wVo vessel segments (Tsutsui et al., 1996) and animals 
(Vasquez-Vivar et al., 2002a). While BH4 is generally considered to be an 
anti-oxidant, it can also function as a pro-oxidant. Indeed, BH4 undergoes 
auto-oxidation via its reaction with molecular oxygen, generating O2 ' along 
with BH2 in this process (Kirsch et al., 2003) -  enzymatic regeneration of BH4 
via dihydrofolate reductase would occur in cells at the expense of reduced 
pyridine nucleotide, thereby consuming cell reducing equivalents. Thus, 
results reported here suggest that BH4 treatment may have limited long-term 
benefit in improving eNOS coupling, despite the promise of reports from acute 
studies.
To investigate the potential beneficial effects of pterin supplementation 
on improving eNOS uncoupling, EC pterin levels were supplemented by 
treatment with equal concentrations of BH4 or 7,8-BH2. The intracellular ratio 
of BH4:BH2 in glucose-induced BH4 deficient EC was studied and 
experiments tested whether this would have subsequent effects on both NO 
and O2' production. The significance of this experiment extends to the 
conflicting results observed in studies where exogenous pterins were tested 
for their therapeutic potential (Heitzer et al., 2000b; Katusic, 2001; Vasquez- 
Vivar et al., 2002a). Conflicting results were observed suggesting that BH4 
has both beneficial and detrimental effects depending on experimental 
conditions and duration of exposure.
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These data firmly support the hypothesis that the intracellular BH4:BH2 
ratio is the pivotal determinant of whether EC produce NO or O2' (when eNOS 
is saturated with pterin cofactor). After supplementation of EC with 
exogenous BH4 or BH2, intracellular BH4 levels were increased by equal 
amounts, 3.5-fold. While, BH2 levels were also increased, the extent differed 
for BH4 and BH2 supplementation and was reflected by the observed 
BH4:BH2 ratios («0.68 in BH4 vs. «1.08 in BH2 treated EC). Given the equal 
enhancement of BH4 levels observed with either of these two treatments, if 
total BH4 amount was the deciding factor for NO production, an equivalent 
level of NO production would be expected. However, if as hypothesized, BH2 
displaces BH4 from eNOS and therefore the ratio of intracellular BH4 to BH2 
is the key determinant in eNOS product formation, a more pronounced 
increase in NO levels following BH2 in comparison to BH4 supplementation 
would be expected. Indeed, this was the case, NO production was increased 
by ~40%, in BH2 compared with BH4 treated EC. This was concomitant with 
the degree to which the BH4:BH2 ratio is higher in BH2 vs. BH4 
supplemented EC. O2' production was attenuated in a reciprocal manner, the 
addition of exogenous BH2 was more efficient than BH4 at preventing the 
synthesis of O2' (P<0.05). High glucose led to an attenuation of NO 
production compared to low glucose control cells.
Paradoxically, these data reveal that BH4 can worsen, rather than 
improve glucose-induced eNOS uncoupling. Taken together, these findings 
recommend the following model for the initiation and progression of 
endothelial dysfunction in the setting of chronic vasoinflammation: 1) 
Exposure of the vascular endothelium to a pro-oxidative stimulus (including
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but not limited to diabetic levels of plasma glucose), triggers O2' 
overproduction. Our data suggests that for elevated glucose, this O2' may 
derive from electron transport “leak” from mitochondria (driven by accelerated 
glucose metabolism) but not NADPH oxidase. 2) Accelerated reaction of O2' 
with eNOS-derived NO leads to increased peroxynitrite synthesis. A fraction 
of this peroxynitrite contributes to BH4 oxidation, and accumulation of BH2. 
3) Accumulated BH2 competes with BH4 for occupancy of the pterin binding 
site on eNOS promoting uncoupled O2' production by eNOS. At this stage, 
even with full resolution of the initiating oxidative insult, uncoupled eNOS 
would predictably sustain the production of peroxynitrite, promote BH4 
oxidation, and self-limit NO biosynthesis. According to this view, therapeutic 
approaches that can transiently recouple eNOS would provide a means to 
break the cycle of endothelial dysfunction and lead to long-term reinstatement 
of vascular health.
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4.0 In vivo examples of endothelial dysfunction
4.1 Introduction
Atherosclerosis is the major source of morbidity and mortality in the 
developed world, claiming more lives than all types of cancer combined. 
Characterized by the accumulation of cholesterol deposits in the vessel wall, 
macrophages, smooth muscle cell proliferation, blockage of arteries and 
obstruction of blood vessels, atherosclerosis is a major cause of heart attack 
and stroke. Many factors have been linked with the onset of vascular 
disease, including: age (Wilson et al., 1998), gender (Barrett-Connor and 
Bush, 1991), obesity (Wilson et al., 1999), smoking (Doll and Hill, 1956), 
hypertension (Collins et al., 1990; MacMahon et al., 1990),
hypercholesterolemia (Gotto and Grundy, 1999), and diabetes melitus
(Bierman, 1992). This chapter describes in vivo studies of BH4 deficiency 
and endothelial dysfunction in genetic models of diabetes/metabolic syndrome 
and atherosclerosis. Data presented herein extends our in vitro evidence for 
BH4 oxidation as a molecular basis for high glucose-induced NO insufficiency 
to the in vivo setting, and suggests that BH4 oxidation occurs with oxidative 
stress and underlies endothelial dysfunction in many chronic 
vasoinflammatory conditions.
A growing population, approaching epidemic proportions in the 
developed world, is at risk of developing the vascular complications 
associated with type II diabetes (non-insulin dependent diabetes, NIDDM). 
Estimates based on data from 134 countries put the number of people with
clinically diagnosed diabetes in the 20-79 year age group at 151 million
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(Gadsby, 2002) and this is predicted to double by 2010 (Amos et al., 1997). 
The current prevalence extrapolates to 4.6% of the population worldwide, but 
apparently due to dietary factors, diabetes may be much more prevalent in 
developing countries. Most type II diabetes will be treated with dietary advice 
and oral hypoglycemic agents, such as sulfonylureas. Vascular diseases are 
the major cause of diabetes-associated death and a large body of research 
has sought to elucidate the cellular and molecular mechanisms underlying the 
vascular complications associated with diabetes.
One of the hallmarks of diabetic vascular disease is endothelial 
dysfunction - failure of the endothelium to subserve its normal role in 
vasodilation and/or vascular homeostasis. Reduced bioavailability of NO 
appears to be common to all forms of endothelial dysfunction (Drexler and 
Hornig, 1999), but the underlying mechanism of this reduced bioavailability of 
NO is incompletely defined. In the prior chapters of this thesis, evidence was 
provided for the role of BH4 oxidation in the development and progression of 
endothelial dysfunction associated with elevated glucose levels. Diminished 
levels of vasodilating NO promotes vasoconstriction and contributes to 
diabetes-associated blindness, peripheral neuropathy and peripheral artery 
disease (insufficient blood blow to the limbs), the latter of which often results 
in amputations. Thus, complications arising from diabetic vasculopathies are 
a major clinical problem that demands an understanding of the underlying 
mechanisms.
Several recent studies have sought to elucidate the in vivo 
mechanisms relating BH4 availability to eNOS uncoupling in vascular 
diseases. Ex vivo studies involving coronary blood vessels from human
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patients who underwent bypass surgery demonstrated that NO-mediated 
endothelial function was attenuated and endothelial O2' production was 
increased (Guzik et al., 2002). Although there have only been a limited 
number of human studies reported, similar observations were made in many 
studies of animal models with endothelial dysfunction. Diabetes can be 
induced in rats by treatment with streptozotocin (STZ), an agent that destroys 
the insulin-producing beta cells of the pancreas; STZ-treated rats exhibit 
hyperglycemia, endothelial dysfunction and elevated vascular O2' production. 
This increased O2' production was reported to be mediated by a PKC- 
dependent pathway that resulted in activation of NADPH oxidase (Hink et al.,
2001). Paradoxically, eNOS mRNA and protein expression were increased 
while NO production was diminished.
Evidence for endothelial dysfunction and eNOS uncoupling has also 
been observed in the ApoE knockout mouse model of atherosclerosis. 
Elevated 3-NT incorporation into proteins, a hallmark of peroxynitrite 
formation, was observed in atherosclerotic vascular lesions. This requires the 
simultaneous production of NO and O2', as would be expected under 
conditions that elicit BH4 deficiency, owing to BH2 accumulation (Laursen et 
al., 2001). In ApoE knockout mice, both endothelial function and 
atherosclerotic lesion progression were worsened by transgenic eNOS 
overexpression. This was found to be associated with a further reduction in 
relative BH4 availability that was acutely reversed by BH4 supplementation 
(Ozaki et al., 2002). Although circumstantial evidence supports a role for BH4 
oxidation in these animal models, the extent of pterin oxidation has never
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been directly assessed in either the ApoE knockout mouse or ZDF diabetic rat 
models.
Support for a role of eNOS dysregulation in vascular disease has come 
from both eNOS knockout and eNOS transgenic mice. A generally protective 
role for eNOS in atherogenesis is inferred by the observation that 
atherosclerotic plaque formation and the proliferative response to vascular 
injury are both enhanced in eNOS knockout mice (Knowles et al., 2000; Rudic 
et al., 1998). Endothelium-targeted overexpression of eNOS would therefore 
be predicted to reduce atherosclerosis. Paradoxically, eNOS overexpression 
in ApoE knockout mice caused an exacerbation of atherosclerotic vascular 
dysfunction. Although transgenic overexpression of eNOS promoted an 
increase in NO production, a much larger increase in endothelial O2* 
production was observed (Ozaki et al., 2002). These features of elevated 
ROS formation where reversed by BH4 supplementation, suggesting that 
BH4-deficient eNOS accumulates in the endothelium of blood vessels during 
atherogenesis.
More mechanistic insights into the role of BH4 insufficiency and eNOS 
uncoupling in endothelial dysfunction came from recent studies in mice 
rendered hypertensive by deoxycorticosterone acetate-salt (DOCA-salt) 
feeding (Landmesser et al., 2003). These animals developed endothelial 
dysfunction and features of eNOS uncoupling, including BH4 oxidation. 
Notably, eNOS knockout mice were protected from the adverse vascular 
effects of DOGA salt feeding, implicating eNOS-derived ROS in the promotion 
of endothelial dysfunction.
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The importance of BH4 as a regulator of eNOS function/dysfunction is 
under active investigation by several groups. Two alternative therapeutic 
approaches have been explored in an attempt to redress the perceived BH4 
insufficiency. One approach seeks to elevate cellular BH4 levels by direct 
administration or gene therapy with the rate-limiting BH4 biosynthetic enzyme, 
GTPCH. A second approach seeks to re-couple eNOS and protect BH4 from 
oxidation. For both cultured EC and DOCA-salt induced hypertensive mice, 
enhancement of intracellular BH4 synthesis via GTPCH gene transfer was 
shown to greatly increase BH4 levels without an apparent change in BH4:BH2 
ratio (Cai et al., 2002). A substantial increase in both intracellular BH4 levels 
and eNOS activity was observed when GTPCH was constitutively 
overexpressed in the endothelium of transgenic mice (Alp et al., 2003). 
Crossing of GTPCH transgenic mice with ApoE knockout mice was shown to 
improve endothelial function and reduce plaque formation, in comparison to 
ApoE mice that express lower endogenous levels of GTPCH (Alp et al., 
2004). In cultured EC, addition of ascorbic acid maintains eNOS activity by 
stabilizing BH4 against oxidation to BH2 by peroxynitrite (Kuzkaya et al.,
2003). In ApoE knockout mice, supplementation with ascorbic acid was 
shown to increase BH4:BH2 ratios in the aortic endothelium, restore eNOS 
activity and improve endothelial function (d'Uscio et al., 2003). Oral BH4 
supplementation has been reported to increase tissue BH4 levels although 
this may have unpredictable effects due to the underlying oxidative stress 
(Vasquez-Vivar et al., 2002a). Experiments were performed to elucidate 
potential in vivo changes in NOS coupling and BH4 oxidation in association 
with endothelial dysfunction in animal models of diabetes and atherosclerosis.
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4.2 Methods
All chemicals, unless otherwise stated were purchased from Sigma 
Chemical Co (St. Louis, MO). Water used for HPLC mobile phase and 
sample preparation was from a MilliQ water purification system (Millipore, MA) 
and >18 MQ resistance.
Experimental Animals 
The ZDF model of type II diabetes
Studies were carried out on Zucker diabetic fat (ZDF) and non-diabetic 
lean control (ZL) rats (Charles River Laboratories Inc., MA), aged 8-9, 16 and 
22 weeks. Through genetic mutation and a managed diet, the ZDF rat 
developed a phenotype that closely mimics human metabolic syndrome and 
type II diabetes with related complications (Clark et al., 1983). ZDF animals 
which are homozygous for non-functional leptin receptors (fa/fa), when fed a 
regular chow diet (Purina 5008), develop obesity, hyperlipidemia, 
hyperglycemia, hyperinsulinemia and mild hypertension. Rats homozygous 
for wild type leptin receptors (+/+ or Zucker Lean, ZL) remain lean and 
normoglycemic with ageing.
Animals were housed in animal quarters kept at 20-22°C with a 12-h 
light/dark cycle and were allowed free access to rat chow and water 
throughout the study. ZDF rats were randomly divided into three groups. The 
first group was treated daily with ebselen, administered by gavage in two daily 
doses of 10 mg/kg body weight (Alexis Corporation, Lausen, Switzerland)
104
Mark J. Crabtree BH4 oxidation in models of vascular disease 2005
dissolved in 5% CM-cellulose (Sigma, St. Louis, MO, USA) starting at of 8-10 
weeks of age. The second group received the same treatment starting from 
the age of 16 weeks. The third (vehicle) group of ZDF rats were treated with 
5% CM-cellulose. A group of ZL control animals were similarly treated with 
5% CM-cellulose.
The ApoE knockout model of Atherosclerosis
Studies described herein employ the extensively characterized, ApoE 
knockout murine model of atherogenesis - through genetic mutation and a 
managed diet these animals develop vascular lesions and complications that 
closely mimic human atherosclerosis (Daugherty, 2002; Meir and Leitersdorf,
2004). Disease has been shown to be associated with an increased 
production of ROS in the blood vessel wall (Dhalla et al., 2000). When fed a 
diet of standard chow, proximal aortae of ApoE knockout mice exhibit fatty 
streaks and foam cell lesions by 12 wks, intermediate lesions containing foam 
cells and smooth muscle cells by 15 weeks and fibrous plaques by 20 weeks. 
This process is greatly accelerated when animals are fed a high-fat “western 
diet”, consisting of food pellets containing 21% fat/15% cholesterol from 6 
weeks of age (Daugherty, 2002; Meir and Leitersdorf, 2004). Notably, LDL 
receptor knockout mice offer an alternative genetic model of atherogenesis 
and possess a lipid profile quite similar to the human condition (Daugherty,
2002), however lesion composition and progression in these animals is less 
representative of that seen in humans, compared with the lesions in ApoE null 
mice (Daugherty, 2002).
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Blood pressure and serum chemistry profiting
For blood pressure monitoring, a mid-laparotomy was performed, the 
abdominal aorta was cannulated with a P-50 catheter, and mean BP (MBP) 
was measured using a pressure monitor BP-1 (World Precision Instruments, 
FL). Subsequently, blood was collected, and subject to analysis by standard 
profiling for triglycerides and cholesterol. Glucose concentration in the blood 
was measured using the modified Trinder color reaction according to the 
manufacturer’s protocol (Raichem, CA). Rats were anesthetized by 
intraperitoneal injection of Ketamin-Xylazin (60 and 7.7 mg/kg body wt, 
respectively) prior to sacrifice and harvest of the aortae. These experiments 
were carried out by Dr. Sergey Brodsky in the laboratory of Dr. Michael 
Goligorsky (New York Medical College, Valhalla, NY).
Acetyichoiine-induced vasorelaxation
Aortas were cleared of periadventitial tissue and cut transversely into 
rings, 1.5 to 2.0 mm in diameter. Vascular rings were handled carefully to 
avoid damage to the inner surface and mounted on wires in the chambers of a 
multivessel myograph (J.P. Trading, Denmark) containing Krebs’ buffer. The 
buffer was gassed with 95% O2 and 5% CO2 and maintained at 37°C (pH 7.4). 
After equilibration (30 minutes), the rings were set to an internal circumference 
equivalent to 90% of full relaxation under a transmural pressure of 100 mm Hg 
and allowed to stabilize for 20 to 30 minutes. The rings were then depolarized 
with potassium chloride (KOI; 60 mM) to evaluate maximal contraction. After 
washing with Krebs’ buffer, the vascular rings were contracted with
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phenylephrine (10 pM) and, when the contractile response was stabilized 
(steady-state phase, 12 to 15 minutes), vasorelaxing responses to cumulative 
increments in the concentration of acetylcholine or NONOate were examined 
(Li et al., 2002). These experiments were carried out by Dr. Sergey Brodsky 
in the laboratory of Dr. Michael Goligorsky (New York Medical College, 
Valhalla, NY).
Measurement of NO production by aortic rings obtained from 
ZL and ZL rats
The full length of the thoracic aorta was aseptically removed and 
immediately placed into EC Basal Medium-2 (EBM-2) (Clonetics, CA). After 
removal of the periaortic fibroadipose tissue with fine microsurgical forceps 
under a dissecting microscope, the aortae were placed in fresh EBM-2 
medium and cut into 1.2- to 1.5-mm ring segments. NO production by ring 
segments was tested using a porphyrin-electroplated, nafion-coated, carbon- 
fiber electrode (30 pm) daily, prepared according to Bio-Logic Instruments’ 
instructions. Calibration of the electrode was performed before each 
experiment using dilutions of freshly prepared nitrogen-sparged, NO-saturated 
Krebs-Ringer solution.
Aortic rings were placed into 100 pL of Krebs buffer and, after obtaining 
a stable baseline, 1 to 5 pM calcium ionophore A23187 was added and the 
electrochemical response was continuously recorded. A/°-nitro-L-arginine 
methyl ester (L-NAME) (2 mM) was used to define the NO dependence of the 
recorded electrode current at the end of each experiment. On completion of
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each experiment, electrode calibration was reconfirmed by evaluating 
responses to reference NO solutions. These experiments were carried out by 
Dr. Sergey Brodsky in the laboratory of Dr. Michael Goligorsky (New York 
Medical College, Valhalla, NY).
3-nitrotyrosine staining of aortic sections from ZL and ZDF 
animais
Immunohistochemical procedures were performed on aortic cross 
sections by Dr. Michael Goligorsky (New York Medical College, Valhalla). 
Aortae were fixed in PLP solution (2% paraformaldehyde, 10 mmol/L sodium 
meta-periodate in PBS, pH 6.2) overnight at 4°C, washed in PBS, immersed in 
35% sucrose overnight, embedded in OCT (Optimal Cutting Temperature 
compound), frozen and then cut into 10-pm sections. Indirect 
immunoperoxidase staining was performed using biotin-labeled secondary 
antibodies and a streptavidin-peroxidase complex with di-aminobenzidine as a 
chromogenic substrate, according to the manufacturer’s protocol (Dako 
Cytomation, CA). Rabbit polyclonal anti-nitrotyrosine (Upstate Biotechnology, 
VA, 1:100), and a rabbit polyclonal antibody for the major membrane lipid 
peroxidation product, 4-hydroxy-2-nonenal (anti-HNEJ-2: a gift from Dr 
Tanaka, Institute for Virus Research, Kyoto University, Sakyo-ku, Kyoto, 
Japan, 1:100) were used. Nonspecific protein binding was blocked by 
incubation in 1% BSA/PBS for 30 minutes. Controls included omission of 
primary antibodies. For nitrotyrosine and HNEJ-2 analysis, sections were 
counterstained with hematoxylin.
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Determination of protein content using the BioRad assay
Protein was measured using the BioRad Dc protein assay reagent 
(BioRad, CA). 5 pi samples of tissue homogenates were transferred to a 96 
well plate and BioRad reagents were added as per the manufacturer’s 
instructions. Unknown protein levels were quantified by comparison with a 
bovine serum albumin (BSA) standard curve, ranging from 20 -  1000 pg/ml. 
The plate was then read at ODysonm using a Versa MAX spectrophotpmetric 
plate reader (Molecular Devices, CA).
Western biotting
Cells were suspended in RIPA lysis buffer (20 mM Tris-HCI, 150 mM 
NaCI, 1 mM Na2 EDTA, 1 mM EGTA, 1% Triton, 0.1% SDS, 0.1 sodium 
deoxycholate, pH 7.4), that additionally contained a cocktail of protease 
inhibitors and lysed by four sequential freeze-thaw cycles in liquid nitrogen. 
Sample proteins (30 pg) were resolved by polyacrylamide gel electrophoresis 
(10-20%) and transferred to nitrocellulose membranes by wet electroblotting 
for 90 min. Nonspecific protein binding was blocked by incubation of the 
membranes with blocking buffer (10 mM Tris, 150 mM NaCI, 0.05% Tween 
20, 5% nonfat milk, pH 7.4). After washes in TBS, rabbit polyclonal IgG to 
eNOS (Transduction Laboratories) was incubated with membranes overnight, 
at 4°C. Membranes were washed in TBS and then incubated with HRP- 
conjugated anti-rabbit secondary antibody (1:1000) for 60 min at room 
temperature. Membranes were rewashed and visualized using LumiGLO 
Chemiluminescent Substrate (Cell Signaling Technology, Inc., MA).
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Pterin analysis by CouiArray eiectrochemicai detection
Tissue: Tissues were rinsed of blood using ice cold phosphate-
buffered saline solution (pH 7.2-7.4) and then homogenized in 10 ml per g wet 
weight of tissue in a buffer consisting of 50 mM Tris, 150 mM NaCI, 0.1 mM 
EDTA and 20 mM CHAPS (pH 7.4). Ice cold acid precipitation buffer (0.1 M 
Phosphoric acid, 0.23 M TCA) was added to a 100 pi portion of the sample 
(3:1 v/v) followed by centrifugation for 1 min at 12,000 x g at 4°C. Two 
aliquots of supernatant (120 pi) were transferred into HPLC vials for analysis 
of total biopterin, BH4, q-BH2 and 7,8-BH2, as described in Chapter 3 (page 
49).
Protein incorporated 3~nitrotyrosine quantification by 
CouiArray eiectrochemicai detection
Tissues (heart, lung, liver, kidneys and brain) were rinsed of blood 
using ice cold phosphate-buffered saline solution (pH 7.2-7.4), minced with a 
pair of scissors, and then homogenized in 10 ml per g wet weight of tissue in 
a buffer consisting of 50 mM Tris, 150 mM NaCI, 0.1 mM EDTA and 20 mM 
CHAPS (pH 7.4). Ice cold acid precipitation buffer (0.1 M phosphoric acid, 
0.23 M TCA) was added to a 100 pi portion of the sample (3:1 v/v), allowed to 
set for 5 min at room temperature, and then centrifuged for 15 min at 12,000 x 
g at 4°C. The supernatant was removed and placed in HPLC autoinjector 
vials.
A second aliquot of the tissue homogenate (100 pi) was subjected to 
proteolytic digestion before the extent of protein incorporated 3-NT was
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quantified. Proteinase K (1U/10 mg protein) was added to the tissue 
homogenate and incubated for 8 hours at 55°C. Samples were allowed to 
come to room temperature before the addition of the precipitation buffer and 
further preparation as above. Samples were then injected and 3-NT 
quantified using the isocratic HPLC system with multi-channel electrochemical 
CoulArray (ESA inc., MA) as described in Chapter 3 (page 54)
Statistics
Data are expressed as mean ± SEM. All data were analyzed and 
compared using either an unpaired Student’s t-test or a one way AN OVA with 
Tukey’s post hoc test, where appropriate. Differences are considered to be 
significant when P<0.05.
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4.3 Results 
ZDF rat model of type II diabetes
Characterization o f diabetes in ZDF vs. ZL rats
Unlike ZL control rats, ZDF rats develop moderate hyperglycemia by 
the age of 8 weeks, with glucose levels of 197.9 ± 11.7 mg/d I (vs. 144.8 ±
26.2 mg/dl) in age-matched ZL controls (Figure 4.3À and Table 4.1). By 16 
weeks of age, ZDF rats become severely hyperglycemic with resting glucose 
levels of 341.6 ± 35.9 mg/dl (vs. 162.8 mg/dl ± 8.2 mg/dl in ZL) that reach
400.2 ± 33.6 mg/dl by 22 weeks (vs. 180.9 ± 17.8 in ZL). Similarly, levels of 
blood triglycerides and cholesterol are significantly elevated in ZDF animals 
after 8 weeks of age compared to age-matched ZL controls. Treatment with 
ebselen, a scavenger of peroxynitrite (Masumoto et al., 1996) had no effect 
on any of these parameters (Table 4.1).
NO production by aortic endothelium. Ex vivo NO production by 
aortic rings obtained from 22-week-old ZDF and ZL rats was measured using 
an NO-selective microelectrode. As summarized in Figure 4.1 A, responses to 
A23187 were significantly blunted in ZDF rats. In rats receiving ebselen 
treatment, A23187-elicited NO production by aortic endothelium was partially 
restored, with values of approximately 70% of those observed in age-matched 
ZL rats.
Vasodilation in response to acetylcholine. To examine whether 
NO-dependent endothelial function was attenuated in the ZDF diabetic rat.
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ACh-induced vasodilation was assessed in excised aortic rings from animals 
at 7-8 weeks and 22 weeks of age, prior to and approximately 16 weeks after 
the onset of hyperglycemia, respectively. As expected, ACh was equi- 
effective at eliciting vasorelaxation in normoglycemic 7- to 8-week-old ZDF 
and ZL rats. Moderately impaired responses to A23187 were already evident 
in 9- to 10-week-old ZDF rats and responses become severely impaired in 22- 
week-old ZDF rats, compared to age-matched ZL counterparts (Figure 4.1 A). 
As shown in Figure 4.1 B, ACh-induced relaxation was almost abolished in 
ZDF rats at 22 wks, however, responsivity to Ach was preserved in ZDF rats 
that received ebselen from 6 weeks prior to sacrifice. As vessels from all 
experimental groups showed an equally robust relaxation in response to an 
NO donor (NONOate), the observed differences in ACh-induced relaxation 
could not be ascribed to the differing sensitivities or responsiveness of the 
vascular smooth muscle to NO.
eNOS protein expression remains unchanged. The observed 
vascular dysfunction and suppressed NO levels in the aorta of the ZDF animal 
may arise from diminished expression of eNOS protein. This was tested by 
Western blotting using a specific eNOS antibody. As shown in Figure 4.2, 
and replicated in three additional experiments, eNOS expression levels 
remained constant in both ZL and ZDF rats from ages 8-22 weeks. Moreover, 
no effect of ebselen on eNOS protein expression was found.
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Parameter
Z L Z D F Z L Z L ZDF ZD F
(8 wks) (8 wks) (22 wks) (22 wks) +  E (22 wks) (22 wks ) +  E
Body Weight
(g)
2 1 4 ± 9 332 ±  7^ 358 ±  12 365 ±1 6 4 3 2 ± 1 4 t 410 ±2 8
Mean Blood
Pressue 105 ± 4 98 ±  12 103 ± 3 105 ± 8 108 ± 5 10 1±6
(mm Hg)
Blood Glucose
(mg/dl) 144 ± 1 6
198± 11^ 181±17 167±15 400 ± 3 3 * 395± 18*
Triglycerides
(mg/dl)
35 ± 8 241 ±41 2 5 ± 1 3 3 0 ± 4 281 ± 2 3 * 253 ± 4 3 *
Cholesterol
(mg/dl)
71 ± 8 115±13 6 9 ± 6 68 ±1 4 2 1 6 ± 2 6 * 183 ± 1 7 *
^P<0.05 vs. ZL 8 wks 
tP<0.05 vs. ZL 22 wks 
*P<0.001 vs. ZL 22 wks
Table 4.1. Serum profiling o f ZDF and ZL rats in the absence and 
presence o f ebselen (Ebs). Body weight, mean blood pressure, blood 
glucose, triglycerides and cholesterol, were all measured as indicators of 
vascular condition and general animal health. All values are means ± SEM 
(n=5).
114
Mark J. Crabtree BH4 oxidation in models of vascular disease 2005
400
d 300
Ç 200
0}D)Cm
Ü 100
□  ZL 
■ Z D F  
n Z D F  + E
X
*
1
22
Age (wks)
B 75- ZL
ZDF
ZDF + Ebselen
co
1
25-
■7-10 9 -8 -6
Log (Acetylcholine mol/l)
Figure 4.1. A) NO production Is significantly attenuated In ZDF vs. ZL 
rats at 22 weeks o f age and prophylactic administration o f the ONOO' 
scavenger ebselen prevents this attenuation. NO production by ex vivo 
aortic rings was measured using an NO-selective microelectrode technique 
after stimulation with A23187 (5 pg/ml). Responses to A23187 were 
significantly blunted in ZDF rats at 22 weeks (*P<0.05), but restored by 
ebselen treatment (#P<0.05: n=6-8 in each group). B) Acetylcholine- 
Induced vasorelaxation In Intralobular arteries was severely Impaired In 
ZDF rats, but completely Intact In ZDF rats receiving ebselen treatment. 
ZDF rats showed significantly decreased responses to acetylcholine after 22 
weeks, compared to age matched ZL animals (P<0.05). These impaired 
responses were totally prevented by ebselen treatment and relaxations were 
restored to levels comparable with ZL rats of the same age (n=4-5).
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Figure 4.2. eNOS expression remains unchanged with ageing o f ZDF 
and ZL animals. Lysates were prepared from tissue homogenates and 
equivalent protein amounts (50 pg) were subjected to Western blot analysis 
with an anti-eNOS (1:2500) antibody. Blots show tissue lysates from A) 
control untreated and B) Ebselen-fed ZDF and ZL rats. eNOS protein 
expression is unchanged by the ZDF vs. ZL control animal phenotype. 
Ebselen had no effect on eNOS protein expression levels after treatment for 
4, 8 or 14 wks duration. Blots shown are representative and were repeated in 
at least two replicate experiments.
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BH4 oxidation in vivo. To assess whether the observation of BH4 
oxidation with elevated glucose in cultured cells manifests in the in vivo 
setting, experiments measured changing levels of plasma glucose and pterin 
redox status associated with the progression of diabetes in the ZDF rat model 
vs. age-matched ZL rats. As previously described and shown in Table 4.1, 
ZDF rats develop moderate hyperglycemia by the age of 8 weeks and 
become severely hyperglycemic by 16 weeks with resting glucose levels of 
341.6 ± 35.9 mg/dl (vs. 162.8 ± 8.2 mg/dl in ZL) that reach 400.2 ± 33.6 mg/dl 
by 22 weeks (vs. 180.9 ± 17.8 in ZL, Figure 4.3A). These increases in plasma 
glucose were mirrored by a progressive oxidation of BH4 to BH2, without any 
detected change in total tissue pterin content, as shown for lung in Figure 
4.3B. Similar increases in BH4 oxidation were observed in all other tissues 
studied (heart, kidney and liver; Figure 4.5). This age-associated decrease in 
BH4:BH2 ratio in ZDF rat lung was apparent by 16 weeks (Figure. 4.3C: 
P<0.001) and was not observed in ZL controls. As shown in Figure 4.3B, 
ebselen similarly protected BH4 against oxidation in 22 wk old ZDF rats 
(despite having no effect on glucose levels), consistent with a role for 
peroxynitrite or a related oxidant in the mediation of hyperglycemia-elicited 
BH4 oxidation.
A correlation between blood glucose and both the decrease in BH4 
levels and increase in BH2 accumulation is indicated in Figure 4.4 for animals 
that did not receive ebselen treatment. Notably, in ZL control animals, no 
significant change in either BH4 or BH2 amounts was observed with age and 
glucose elevation was insignificant (Figure 4.4A and 4.4C). In contrast, a 
marked decrease in BH4 and a considerable accumulation of BH2 was
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demonstrated in the ZDF rat with progressive age-dependent increases in 
blood glucose levels (Figure 4.4B and 4.4D).
Amelioration o f markers o f oxidative and nitrosative stress by 
ebselen. As noted previously, ebselen-treated rats showed the same degree 
of hyperglycemia as the vehicle-treated age-matched ZDF and ZL 
counterparts. Both ZDF and ZL rats had unaltered levels of mean blood 
pressure throughout the observation period (107.6 ± 4.8 versus 103.4 ± 3.2 
mm Hg, respectively) and ebselen treatment did not affect blood pressure 
(Table 4.1). Thus, ebselen treatment changed neither the severity of diabetes 
nor the systemic blood pressure of ZDF rats. Measurement of the abundance 
of 3-NT-modified proteins in the plasma of experimental animals showed 
comparably low levels in ZDF and ZL rats at age 8 weeks (3.17 ± 4.54 and 
2.18 ± 2.1 pmol/mg protein, respectively), but a 6-fold increase in the 
accumulation of 3-NT-modified proteins in ZDF rats at age 22 weeks (19.43 ± 
6.04 pmol/mg protein) while levels of 3-NT accumulation in ZL rats at the 
same age were unchanged (Figure 4.6A). Treatment of ZDF rats with 
ebselen resulted in a significant protection against plasma 3-NT-modified 
protein accumulation at 22 weeks (5.69 ± 3.37 pmol/mg protein; n=4 to 5, 
P<0.05). A similar dynamic was observed in aortic immunostaining studies: 3- 
NT-modified proteins were faintly detected in 8-week-old ZDF rats compared 
with ZL animals of the same age, but levels were dramatically increased at 22 
weeks of age. Ebselen treatment significantly diminished the abundance of 3- 
NT-modified proteins in the vascular wall of ZDF rats (Figures 4.6B and 
4.6C). HNE staining revealed lipid peroxidation products in the vascular wall
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to be increased significantly by 22 weeks of age in ZDF rats and this was also 
reduced by ebselen treatment (Figures 4.6B and 4.6C). Collectively, these 
data indicate the progressive accumulation of oxidative (lipid peroxidation) 
and nitrosative (3-NT-modified proteins) stress markers in plasma and aortae 
of ZDF rats and that both were prevented by the peroxynitrite scavenger, 
ebselen.
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Figure 4.3. Oxidation o f BH4 in association with increasing plasma 
glucose levels in the Zucker Diabetic Fatty (ZDF) rat model o f type II 
diabetes and metabolic syndrome. Comparison between age-dependent 
changes in plasma glucose and pterin redox status in ZDF, ZDF plus ebselen- 
treated (Ebs; 5 mg/kg by gavage twice daily) and ZL control rats. Panel A: 
Progressive increase in plasma glucose levels as ZDF rats age, while no 
significant change is observed in age-matched ZL rats. Increased plasma 
glucose in ZDF rats is unaffected by the peroxynitrite-scavenger, ebselen. 
Panel B: Progressive oxidation of BH4 is evident in lungs of aging ZDF rats, 
but not ZL controls. Ebselen, affords significant protection against BH4 
oxidation in ZDF rats. Panel C: Relationship between age and ratio of 
BH4:BH2 in ZDF, compared to control ZL rats. (*P<0.05 after 16 weeks). At 
22 weeks the BH4:BH2 ratio is significantly decreased in ZDF, compared to 
ZL rats (n=6). Points and bars represent means ± SEM (n= 6).
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Figure 4.4. BH4 oxidation and BH2 accumuiation directiy correiates with 
biood giucose ieveis in the iungs o f ZDF rats. Correlation between 
changes in plasma glucose and pterin redox status in ZDF and ZL control 
rats. A and 0) ZL rats exhibit no significant change in BH4 or BH2 levels, as 
blood glucose rises slightly with age. B and D) Lungs of ZDF rats exhibit a 
progressive increase in BH2 accumulation (*P<0.01) and reciprocal decrease 
in BH4 levels as blood glucose rises markedly with ageing (*P<0.05: n=6). 
Points represent means ± SEM (n= 6).
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Figure 4.5. Widespread oxidation o f BH4 to BH2 and evidence o f 
peroxynitrite formation in tissues from ZDF, but not ZL rats. ZL (green) 
and ZDF (blue) animals were fed on a regular diet, for 6 months. Animals 
were sacrificed, organs harvested and analyzed for pterin and 3NT content by 
HPLC-EC. Panel A: Pterin redox status in organs ZDF and ZL animals. BH2 
levels are low, or undetectable in organs from ZL animals. In contrast, 
significant accumulation of BH2 is observed in organs from ZDF animals at 22 
weeks of age (P<0.05 vs. control in all tissues). Panel B: Protein 3-NT 
accumulation in tissue proteins was uniformly low in proteins from ZL vs. ZDF 
rats. After 22 weeks, substantial 3NT accumulation is observed in all tissues. 
(P<0.05 in heart, lung and liver; P<0.01 in kidney) (n= 4 or 5).
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Figure 4.6. ZDF rats are characterized by the accumulation o f 3-NT- 
modified proteins and the iip id  peroxidation product, 4-hydroxy-2- 
nonenai (HNE) as a consequence o f combined oxidative and nitrosative  
stress. A) Concentration of 3-NT-modified proteins in the plasma of 
experimental animals as a function of age (*P<0.05 vs. 8-week old ZDF; 
#P<0.05 vs. 22-week old ZDF. Ebs indicates ebselen). B) Abundance of 
lipid peroxidation products (FINE staining) and 3-NT-modified proteins in the 
aortic wall of experimental animals. Aortae were obtained from the indicated 
groups of animals, sectioned, and immunostained. Representative images 
are shown. 0) Results of quantitative image analysis of the intensity of 
staining. Top panel, 3-NT, *P<0.05 vs. ZL 8 w; **P<0.01 vs. ZL 22 w; 
***p<0 001 vs. ZDF 22 w. Bottom panel, FINE, *P<0.05 vs. ZL 22 w; **P<0.01 
ZDF 22 w Ebs.
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ApoE knockout model of atherosclerosis
Widespread oxidation o f BH4 to BH2 and evidence o f peroxynitrite 
formation in tissues from ApoE knockout mice. It is well established that 
NO insufficiency is a characteristic of atherosclerotic lesions in ApoE knockout 
mice fed a high-cholesterol, western type diet. Although BH4 deficiency has 
been implicated, it is not known whether BH4 oxidation to BH2 is a 
widespread feature of this model and whether NOS itself contributes to BH4 
oxidation. As shown in Figure 4.7A, when ApoE knockout mice were fed a 
normal low cholesterol diet, BH4 (filled segment, black bars) was detected to 
a varying extent in all organ lysates studied (heart, lung, kidney and brain) 
while BH2 was essentially undetected (open segment, black bars); an 
exception is the liver, where BH2 comprised 12% of total biopterin. In these 
animals protein 3-NT accumulation in heart, lung, liver and brain revealed 
uniformly low levels (black bars. Figure 4.7B). These BH4 and protein 3-NT 
measurements suggest little oxidative or nitrosative stress in ApoE knockout 
mice when fed a low cholesterol, normal chow diet. Nonetheless, after 6 
months on a western (high cholesterol) chow diet, BH2 accumulation became 
substantial (equaling BH4 in some organs e.g. heart, lung and kidney; open 
segment of red bars in Figure 4.7A), and protein 3-NT accumulation in all 
tissues was marked (red bars, Figure 4.7B). Notably, 6 months on a western 
diet also resulted in atherosclerotic lesion development and loss of vascular 
NO bioactivity (not shown).
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Figure 4.7 Widespread oxidation o f BH4 to BH2 and evidence o f  
peroxynitrite formation in tissues from ApoE knockout mice. ApoE 
knockout animals were fed on either a control (black bars: low cholesterol) or 
western style (red bars: high cholesterol) diet, for 6 months. Animals were 
sacrificed, organs harvested and analyzed for pterin and 3-NT content by 
HPLC-EC. Panel A: Pterin redox status in organs of ApoE knockout animals. 
BH2 levels are low, or undetectable in organs from animals fed on the regular 
chow diet. In contrast, significant accumulation of BH2 is observed after 
feeding on western diet (P<0.05 vs. control in all tissues). Panel B: Protein 3- 
NT accumulation in tissue proteins was uniformly low in proteins from animals 
on normal chow diet. After 6 months on western diet, substantial 3-NT 
accumulation was observed in most tissues. (P<0.05 in liver and kidney, 
P<0.01 in heart and lung) (n= 8 or 9).
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4.4 Discussion
This study describes endothelial dysfunction in two animal models 
where NO deficiency and BH4 insufficiency are prevalent. The ZDF rat model 
of type II diabetes and the atherosclerotic ApoE knockout mouse were used to 
investigate potential changes in BH4 oxidation in endothelial dysfunction 
associated with vascular diseases in vivo. Previous studies have reported 
increased O2' production, potentially arising from uncoupled eNOS, in the 
aorta of ApoE knockout mice (d'Uscio et al., 2001; Laursen et al., 2001) 
diabetic rats (Hink et al., 2001) and hyperlipidémie rabbits (Oelze et al., 2000). 
In agreement with these studies, BFI4 oxidation in association with 
widespread 3-NT modification of proteins (indicative of elevated oxidative and 
nitrosative stress) was observed in our genetic animal models of diabetes and 
atherosclerosis.
Jn the ZDF rat, ebselen, a peroxynitrite scavenger and antioxidant, had 
no effect on the severity of diabetes mellitus per se, but significantly 
attenuated the accumulation of 3-NT-modified proteins in the plasma and 
aortic wall when administered to ZDF rats starting at 8 weeks of age (the time 
when there are no detectable signs of vasculopathy). Animals were 
reexamined at age 22 weeks for signs of endothelial dysfunction and 
developing vasculopathy; both were manifest in the absence of therapy with 
ebselen. Ebselen treatment improved ionophore-stimulated NO production by 
aortic rings (Figure 4.1), as well as the acetylcholine-induced NO-dependent 
vasorelaxation by aortic rings (Figure 4.2) while eNOS protein levels remain 
unchanged.
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Accelerated peroxynitrite formation, inferred from accumulated 3-NT 
modification of proteins, provides further support for a switch in eNOS toward 
oxidant generation, rather than NO. Concomitant increases in plasma 
glucose and tissue levels of BH2 in ZDF diabetic rats provide In vivo 
validation of results obtained with EC in culture (Chapter 3). The data shows 
that ebselen similarly attenuates the progressive accumulation of tissue BH2. 
Protection against BH2 accumulation provides a likely explanation for the 
effectiveness of ebselen in limiting the progressive hyperglycemia-associated 
loss of endothelium-dependent vasodilatation and diminished NO bioactivity in 
ZDF rat blood vessels (Brodsky et al., 2003; Chander et al., 2004). Similarly, 
in the atherosclerotic ApoE knockout mouse model, significant BFI2 and 3-NT 
accumulation were observed in all tissues after feeding a high-cholesterol 
western diet, compared to control litter mates fed a diet of normal chow.
The exact mechanisms underlying the apparent loss of BH4 availability 
in vascular disease remains unknown. Intracellular BH4 concentration is 
regulated by the enzyme GTPCH and the feedback regulatory protein, GFRP. 
There is no compelling evidence for major changes in endothelial GTPCH 
expression and BH4 synthesis in the setting of vascular disease. These data 
suggest that oxidative degradation of BH4 by peroxynitrite provides a 
mechanistic explanation for reduced BH4 levels in the setting of 
atherosclerosis and diabetes. In accord with this view, it has been shown that 
eNOS overexpression in atherosclerosis has detrimental effects because of 
O2* generated by eNOS uncoupling. This may be corrected by high-dose BH4 
supplementation (Ozaki et al., 2002), however, high pharmacological doses of 
sepiapterin or BH4 may also increase NO bioactivity via nonspecific
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antioxidant effects. Benefits of BH4 supplementation may therefore only be 
acute, due to ongoing oxidative processes. Therapies to reduce the 
underlying oxidative stress and protect BH4 from oxidation, preserving eNOS 
coupling, offer potential therapeutic utility in chronic vascular disease states.
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5.0 Restoration of glucose-induced NO deficiency by 
N°’-hydroxyarginine (NOHA)
5.1 Introduction
Nitric oxi(de synthases catalyze the five-electron oxidation of arginine to 
citrulline and nitric oxide (Marietta, 1993; Nathan, 1992) and require BH4 as a 
cofactor (Kwon et al., 1989b; Tayeh and Marietta, 1989). This NADPH- and
02-dependent reaction (Figure 5.2A) proceeds via the formation of a 
releasable reaction intermediate, AT-hydroxyarginine (NOHA) (Stuehr et al., 
1991b). The first step in NOS catalysis is the two-electron oxidation of 
arginine to form NOHA. In the process, one mole of NADPH and one mole of 
O2 are consumed and water is formed as a product (Kwon et al., 1990). The 
second step, conversion of NOHA to citrulline and NO, involves a three 
electron oxidation of nitrogen and 0 -0  bond formation, with the consumption 
of 0.5 moles of NADPH and 1 mol of O2 , again with water as a product (Kwon 
et al., 1990; Leone et al., 1991).
Following the discovery of BH4 as an essential cofactor in NOS 
catalysis, it was assumed that the redox function in oxygen activation was 
conserved in NOS enzymes in accord with the established function in AAAH. 
However, it became clear that BH4 adopted a different role in NOS catalysis 
when it was discovered that NOS contained a P450-type heme, a moiety able 
to support the activation of oxygen without the need for a pterin cofactor. 
Although the exact role of BH4 in NOS catalysis is incompletely solved, 
studies have demonstrated a multiplicity of roles. BH4 functions as an 
allosteric modulator of arginine binding (Klatt et al., 1994; Liu and Gross,
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1996) and contributes to tight dimer assembly (Ghosh and Stuehr, 1995; Klatt 
et al., 1995). Electron donation from BH4 to the heme iron also appears to be 
fundamental for NOS catalysis. Accordingly, only fully reduced pterins, such 
as BH4, have been shown to support NO synthesis (Presta et al., 1998; 
Riethmuller et al., 1999; Vasquez-Vivar and Kalyanaraman, 2000). Moreover, 
tetrahydropterins with modifications that would cause them to be redox silent 
are unable to catalyze NO synthesis (Hevel and Marietta, 1992; Werner et al., 
1996). Spectral and EPR studies have revealed the presence of a 
trihydrobiopterin (.BHs) radical intermediate, which could explain the need for 
BH4 to prevent premature release of oxygen as O2' (Bee et al., 1998), as 
observed with eNOS in the absence of bound BH4.
Published reports indicate that an optimal cellular concentration of 
tetrahydrobiopterin is of fundamental importance for full eNOS activity and 
may be deficient in animal disease models and human patients. Under 
conditions of BH4 insufficiency, both eNOS (Vasquez-Vivar et al., 1999) and 
nNOS (Kotsonis et al., 2000) become ‘uncoupled’ and produce O2 ' instead of 
NO (Katusic, 2001). As noted previously, in vascular disease conditions 
associated with oxidative stress BH4 may become oxidized to BH2 and if so, 
NO insufficiency/endothelial dysfunction may ensue. As in Figure 3.3, BH4 
and BFI2 bind eNOS with equal affinity and BH2 can displace BH4-bound 
eNOS resulting in elevated O2' production. Therapeutic approaches that can 
transiently recouple eNOS would provide a means to break the cycle of 
endothelial dysfunction and lead to long-term reinstatement of vascular 
health.
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Existing NOS-related therapies are largely centered on BH4 or arginine 
supplementation. Stroes et al demonstrated that intra-arterial administration 
of BH4 reverses the impairment in NO-dependent vasodilation in 
hypercholesterolemic patients (Stroes et al., 2000). Similarly, administration 
of BH4 has been shown to restore endothelium-dependent vasodilation in 
experimental diabetes (Pieper, 1997; Shinozaki et al., 2000a), smoking 
related vascular complications (Higman et al., 1996) and reperfusion injury 
(Tiefenbacher et al., 1996). Sepiapterin, which is converted to intracellular 
BH4 via the pterin salvage pathway also restores endothelial function 
following reperfusion injury (Tiefenbacher et al., 1996). Therapeutic 
administration of antioxidants, such as vitamin C has also been studied: In 
the ApoE knockout mouse model of atherosclerosis, long-term treatment with 
vitamin C increased BH4 levels in the vascular wall and enhanced NO 
synthesis (d'Uscio et al., 2003). Although many therapies appear to have 
acute positive effects on endothelial function, the effects of such agents may 
be transient and require frequent redosing if they fail to alleviate the 
underlying oxidative stress that initiates BH4 oxidation.
It is well established that BH2 does not support eNOS-mediated 
metabolism of arginine to NO and citrulline. Nonetheless, since NO synthesis 
occurs in two sequential steps, it was questioned whether BH2-bound eNOS 
is capable of catalyzing the second NOS-mediated catalytic step, conversion 
of NOHA to NO and citrulline. Experiments confirmed this possibility (Figure 
5.1, experiment done by Dr. Caroline Smith), although the mechanism of 
NOHA metabolism by BH2-bound eNOS was found to differ fundamentally 
from that catalyzed by BH4-bound eNOS. Indeed, in vitro studies indicated
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that while NOHA conversion to NO and citrulline by BH4-bound eNOS 
requires NOHA binding in the active (arginine binding) site, conversion of 
NOHA by BH2-bound eNOS depends on eNOS derived O2" and does not 
require NOHA binding (Figure 5.3). Thus, although arginine is only a 
substrate for NO production by BH4-bound eNOS, NOHA can be converted to 
NO and citrulline by either BH4-bouhd (coupled) or BH2-bound (uncoupled) 
eNOS. While the levels of NOHA in the circulation are significant (10-20 pM) 
(Wigand et al., 1997), a significant physiological role as a precursor for NO 
biosynthesis had not been considered, presumably because arginine is 
available in such great excess. In the setting of endothelial dysfunction, it is 
speculated that NOHA may serve a unique role in supporting NO production 
by EC that possess insufficient BH4 (or excess BH2) and are therefore unable 
to utilize arginine for adequate NO production.
In summary, while unable to synthesize NO from its normal substrate 
arginine, BH2-bound eNOS is still able to synthesize NO from the reaction 
intermediate NOHA. Conversion of NOHA to NO occurs both via the 
established enzyme-catalyzed reactions and by a 0 2 '-dependent reaction that 
can be promoted by uncoupled eNOS. Therefore, administration of NOHA 
would predictably accelerate NO synthesis in the presence of uncoupled 
(BH2-bound) eNOS, while at the same time reducing the levels of O2" and 
alleviating both NO scavenging and ONOO' formation. The diminished 
oxidative stress afforded by this reaction may allow cellular antioxidant 
mechanisms to restore the BH4/BH2 ratio toward normal levels and 
reestablish conventional, eNOS-mediated NO synthesis. Studies described in 
this chapter were performed to test the hypothesis that NOHA can effectively
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scavenge ROS in vitro for generation of NO or a related species. Follow on 
studies sought to investigate the therapeutic potential of NOHA administration 
in a cell based model of endothelial dysfunction.
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Figure 5.1. Cataiysis o f arginine and hydroxyarginine (NOHA) by BH4- 
bound and BH2-bound eNOS. In the presence of BH4 (10 pM), but not BH2 
(10 pM), eNOS (10 pmol) catalyzes the production of nitrite/nitrate (N0%) from 
arginine, as measured by Griess assay. In contrast, eNOS produces NOx 
from NOHA in the presence of either BH4 or BH2. Bars are means ± SEM 
(n=4).
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Figure 5.2. Alternative routes fo r NO synthesis from NOHA. Panel A: 
Hydroxylation of L-arginine generates NOHA as an intermediate in the 
formation of NO and citruiline. Panel B: NOHA supports the production of 
NO, or a related species by BH2-bound eNOS from O2' or H2O2 . Notably, O2 ' 
and H2O2 are products of uncoupled eNOS.
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5.2 Methods
All chemicals, unless otherwise stated were purchased from Sigma 
Chemical Go (St. Louis, MO). Water used for HPLC mobile phase and 
sample preparation was from a MilliQ water purification system (Millipore, MA) 
and >18 MQ resistance.
Synthesis of Ni^-Hydroxyarginine
NOHA was custom synthesized by Prof. Vladimir Krai (Department of 
Analytical Chemistry, ICT Prague, Czech Republic) using an improvement of 
the reported 5-step synthetic route (Stuehr et al., 1991a). Modification of the 
synthetic protocol and optimization of purification steps produced >98% purity 
material with a >40% yield.
Cell culture
Murine endothelial (sEnd.1) cells and RFL-6 cell lines were cultured in 
DMEM and Ham’s F-12 media (Invitrogen, CA) as previously described.
Nitrite quantification by Griess assay
NO production was quantified as NO2' in culture medium using the 
Griess assay (Green et al., 1982; Kilbourn et al., 1992). Cell culture mediunri 
(100 pi) was removed from cells in 6 well plates and added to 100 pi Griess 
reagent (1:1 sulfanilamide (1%) in ortho-phosphoric acid (50%) and N-(1-
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napthyl) ethylenediamine dihydrochloride (1%)) in a 96 well plate. The plate 
was read at A550/650 in a microplate spectrophotometer (Molecular Devices, 
CA) and nitrite was quantified by comparison with sodium nitrite standards.
Electrochemical detection of NO
Cells were seeded into 96-well culture plates and after 24 hours the 
media was replaced with media containing either low (5 mM) or high (30 mM) 
concentrations of D-glucose, in the presence or absence of NMA (3 mM). 
After a further 48 hours, the medium was removed and cells were gently 
washed with Dulbecco's phosphate-buffered saline and then incubated in 100 
pL of Krebs Ringer buffer (145 mM NaCI, 4.86 mM KCI, 0.54 mM CaCl2 , 1.22 
mM MgS0 4 , 5.7 mM Na2 HP0 4 , and 5.5 mM glucose) for 60 minutes at 37°C. 
NO concentration in the media was measured as a change in electric current 
as detected by an NO-sensitive electrode (World Precision Instruments, FL). 
Calibration of the electrode was performed using varying concentrations of the 
NO donor SNAP, as recommended by the electrode manufacturer.
Detection of endothelial-derived NO using an RFL-6 cell cGMP 
reporter bioassay
After treatment with drugs or NOHA as described, endothelial-derived 
NO bioactivity was measured based on the increase in cGMP elicited in RFL- 
6 reporter cells, after exposure to pre-conditioned media from sEnd.1 EC as 
described previously (Ishii et al., 1991). RFL-6 cell extracts were harvested
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and analyzed for cGMP content using an ELISA kit (Cayman Chemical, Ml) as 
per the manufacturers instructions.
Pterin analysis by CoulArray electrochemical detection
Cells: An immortalized murine EC line (sEnd.1) was used. After 
treatment, cells were harvested into PBS buffer and spun at 2000 x g for 1 
min. The supernatant was discarded and 300 pi ice-cold, acid precipitation 
buffer (0.1 M Phosphoric acid, 0.23 M TCA) was added followed by 
recentrifugation (12,000 x g at 4°C) for a further 1 min. Two aliquots of 
supernatant (120 pi) were transferred to HPLC vials for the analysis of total 
biopterin, BH4, qBH2 and 7,8-BH2 (Heales and Hyland, 1989).
To the first vial, 1 pi Sodium bisulfite (final concentration 3 mM) was 
added immediately followed by 1 pi Dithioerythritol (DTE, 6 mM final). To the 
second vial, DTE (6 mM final) only was added. Samples were then injected 
onto an isocratic HPLC system with multi-channel electrochemical Coul Array 
detection (ESA inc., MA) and biopterins were quantified as described 
previously (page 49).
Protein incorporated 3-nitrotyrosine quantification by 
CoulArray electrochemical detection
Cells were washed three times and harvested into ice cold phosphate- 
buffered saline solution (pH 7.2-7.4). Samples were centrifuged (2,000 x g) 
and supernatants were discarded. Pellets were resuspended in a buffer 
consisting of 50 mM Tris, 150 mM NaCI, 0.1 mM EDTA and 20 mM CHAPS,
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pH 7.4 (300 pi). After centrifugation, (12,000 x g for 5 min) ice cold acid 
precipitation buffer (0.1 M Phosphoric acid, 0.23 M TCA), was added to a 100 
pi portion of the sample (3:1 v/v), which was then incubated for 5 min at room 
temperature and centrifuged for 15 min (12,000 x g at 4°C). The supernatant 
was removed and placed in HPLC vials for the analysis of biopterin content.
A second 100 pi aliquot of the cell homogenate was subjected to 
proteolytic digestion for analysis of the extent of protein incorporated 3-NT. 
Proteinase K (1U/10 mg protein) was added to the tissue homogenate 
followed by incubation for 8 hours at 55°C. Samples were allowed to come to 
room temperature before the addition of precipitation buffer and subsequent 
analysis for 3-NT content by HPLC as described above (page 54).
Superoxide quantitation by iuminoi chemiiuminescence
The production of ROS in response to elevated levels of glucose was 
measured by luminol (5-amino-2,3-dihydro-1,4-phthalazinedione) dependent 
chemiiuminescence. After incubation of sEnd.1 cells in high or low glucose 
media for 48 hours, cells were washed with modified Krebs buffer (145 mM 
NaCI, 5.7 mM sodium phosphate, 4.86 mM KCI, 0.54 mM CaClz, 1.22 mM 
MgS0 4 , 5.5 mM glucose, pH 7.35) and fresh medium was added that was 
either unmodified or contained L-NAME (3 mM), DPI (10 pM), or CuZn-SOD 
(1000 U/ml). After 2 hours further incubation, cells were washed and 
harvested in modified Krebs buffer. Cell suspensions (100 pi) were added to 
Krebs buffer containing luminol (100 pM; 100 pi) and placed in a luminometer 
cuvette. After 5 minutes, luminol-enhanced chemiiuminescence was 
quantified using a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA).
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eNOS knockdown by RNAi
siRNA duplexes were designed, synthesized and transfections were 
performed as described in Chapter 3.
Analysis of ROS and NOHA reaction products by LCMS/MS
Nanoflow liquid chromatography-tandem mass spectrometry (nLC- 
MS/MS) was employed to obtain peptide sequence information and identify 
cognate proteins of origin. LC-MS/MS was performed using an 1100 series 
LC/MSD XCT plus ion trap mass spectrometer (Agilent Technologies, NY). 
Eight microliters of reaction mixture was injected onto a 0.3 x 5 mm Zorbax 
300SB-C18 sample-enrichment column, at a flow rate of 10 pL/min. Small 
molecules were resolved on a 0.075 x 150 mm Zorbax 300SB-C18 analytical 
column at a flow rate of 0.3 pL/min with a gradient of 15-40% solvent B for 50 
min and 40-85% solvent B for 30 min. Mobile phase solvent A comprised 
0.1% formic acid in 3% acetonitrile and solvent B was 0.1% formic acid in 
100% acetonitrile. The LC column eluate was introduced into the mass 
spectrometer via nanospray, using a 15 pm diameter silica emitter needle. 
Mass spectra were acquired in positive-ion mode with automated data- 
dependent MS/MS on the four most intense ions from a precursor MS scan. 
The fragmentation amplitude was 1.15V, MS scan rates were 8100 m/z per 
sec, capillary voltage was 1800 and the skimmer voltage was 30 V.
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Statistics
Data are expressed as means ± SEM. All data were analyzed and 
compared using either an unpaired Student’s t-test or one way AN OVA, with 
Tu key’s post hoc test where required. Differences were considered to be 
significant when P<0.05.
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5.3 Results
L-NAME and NMA inh ib it the production o f NOHA-derived NOx 
from BH4-bound eNOS, but enhance the production by BH2-bound 
eNOS. in prior experiments, carried out by a previous member of the 
laboratory (Dr. Caroline Smith), the effects of L-NAME (1 mM) and NMA (1 
mM) on eNOS (1 pmol)-catalyzed conversion of NOHA to NOx were tested in 
the presence of either BH4 or BH2 (10 pM). As expected, both L-NAME and 
NMA inhibited the BH4-bound eNOS reaction with NOHA (Figure 6.3A). 
Paradoxically, in the presence of BH2, NMA and L-NAME markedly enhanced 
NOx generation from NOHA (Figure 5.3B). The failure of arginine analogue 
inhibitors (at concentrations that bind to the active site of eNOS) to effectively 
attenuate NOx formation from NOHA suggests that NO production by BH2- 
eNOS does not require NOHA binding to the arginine site.
eNOS does not support NO production from hydroxy guanidine.
NOHA-derived NOx production by eNOS originates from the hydroxyguanidine 
group. Hence, the ability of hydroxyguanidine to be converted to NOx by 
eNOS was investigated. Various concentrations of hydroxyguanidine were 
incubated with eNOS in the presence of BH4 or BH2. As shown in Figure 5.4, 
NOx was undetectable after incubation of hydroxyguanidine (1 mM) with either 
BH4- or BH2-bound eNOS.
NOHA is an oxidant-dependent NO donor. As eNOS-derived O2' 
was thought to be the reactant in NOHA-derived NOx synthesis, the ability of 
ROS to support NO production from NOHA was evaluated. Hence, these
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experiments investigated whether xanthine/xanthine oxidase generated O2 ' 
and H2O2 are capable of supporting NOx production from NOHA (Figure 5.6). 
Both of these oxidants were found to support the synthesis of NOx from 
NOHA, as assessed by nitrate/nitrite accumulation. In order to confirm that 
reactive oxygen species could directly mediate the conversion of NOHA to 
NO, NO production was measured in vitro using an NO-selective electrode 
(Figure 5.5). Notably, in the presence of xanthine/xanthine oxidase generated 
O2', H2O2 and SIN-1, a concentration-dependent conversion of NOHA into NO 
was observed. However, in the presence of H2O2 , although a similar 
accumulation of nitrate/nitrite was observed, levels of NO detected by the 
specific electrode were extremely low, indicating the production of an N0-1 ike 
intermediate species that decays to NOx. The literature would suggest 
nitroxyl (NO ) as the likely identity of the H202-derived product of NOHA 
(Pufahl et al., 1995). These data support the view that if uncoupled eNOS is 
manifest, eNOS-derived ROS are capable of supporting the conversion of 
NOHA to NO, or a related species.
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Figure 5.3. Effect o f NMA and L-NAME on eNOS-mediated conversion o f 
NOHA to nitrite/nitrate (NOx). NOHA was added to eNOS (10 pmol) alone, 
or with either L-NAME (1 mM) or NMA (1 mM) in the presence of 10 pM BH4 
{Upper Panel) or 10 pM BH2 {Lower Panel). BH4-bound eNOS supported 
NOx production which was inhibited by L-NAME and NMA (P<0.05). In 
contrast, BH2-bound eNOS supported NOx production that was significantly 
enhanced by L-NAME and NMA (P<0.05). Points are means ± SEM (n=4).
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Figure 5.4. eNOS does not support NO production from  
hydroxyguanidine. In the presence of either BH4 or BH2, eNOS (10 pmol) 
fails to support NO production from hydroxyguanidine. Points are means ± 
SEM (n=3).
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Figure 5.5. O i, and to a lesser extent, H2O2 and SIN-1 (a peroxynltrite  
donor) catalyze NOHA-derived NO production. A NO-selective electrode 
was used to detect NO production from NOHA in the presence of a O2 ' 
generating system, H2O2 or peroxynltrite derived from SIN-1. A) 
Concentration-dependent conversion of NOHA to NO by O2' derived from 
xanthine (100 pM)/xanthine oxidase (0.1 U). B) NO production from xanthine 
increases with increasing amounts of xanthine oxidase, and therefore O 2" 
concentration. Varying amounts of xanthine oxidase were added to NOHA 
(30 pM) and xanthine (100 pM). B) and 0) Conversion of NOHA to NO in the 
presence of H2O2 (100 pM) and the peroxynltrite donor, SIN-1. Note the 
difference in scale between x-axes relative to panel A, indicating less efficient 
NO production by H2O2 and peroxynltrite compared with superoxide. Points 
are means ± SEM (n=3).
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Figure 5.6. Both H2O2 and O2' support NOx production from NOHA.
NOHA (300 pM) was added to either H2O2 (1 mM) or O2' (xanthine oxidase, 
0.1 U, in the presence of 100 pM xanthine which produces approximately 10 
nmole/ml/min of O2' for over 20 minutes) and NOx generation was quantified 
using the Griess assay. Catalase (2000 U/ml) and SOD (2000 U/ml) 
abolished NOx production from NOHA in the presence of H2O2 and O2 ', 
respectively. Bars are means ± SEM (n=4).
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NOHA administration restores BH4 ieveis and release o f bloactlve 
NO by high glucose treated EC. As it was observed that NOHA can utilize 
reactive oxygen species to support NO production, the ability of NOHA to 
restore endothelial function and NO production in high-glucose treated EC 
was tested. Since biopterin oxidation and diminished NO synthesis were both 
evident in sEnd.1 EC following exposure to hyperglycemic levels of glucose, 
the potential of NOHA (vs. arginine) to reconstitute NO synthesis in these 
cells was studied. Hence, experiments assessed the ability of low glucose (5 
mM) vs. high glucose (30 mM) treated cells to synthesize NO from NOHA.
Using a highly selective NO electrode, addition of NOHA to high and 
low glucose treated EC was observed to significantly increase NO production 
(P<0.05). Interestingly, high glucose-treated EC produced NOHA-derived NO 
at a markedly greater rate than low glucose control cells. This finding 
supports the view that elevated levels of reactive oxygen species produced by 
high glucose treated EC is responsible for accelerated NO production from 
NOHA vs. low glucose-treated control cells (Figure 5.7).
lonophore-induced NO production was impaired in high glucose 
treated EC in the presence of arginine as compared with low glucose control 
cells. However, NOHA addition increased NO synthesis to a greater degree 
in high vs. low glucose treated cells, eliciting 3- and 1.7-fold increases, 
respectively (Figure 5.8).
The ability of NOHA to reverse high glucose-induced biopterin 
oxidation was assessed (Figure 5.9). Cells were exposed to low or high 
glucose treatment for a period of 48 h. After 24 h NOHA (30 pM), arginine (30 
pM) or vehicle was added to the culture medium and the level of pterin
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oxidation assessed after a further 24 h incubation. NOHA, but not arginine, 
was found to completely reverse glucose-induced pterin oxidation and restore 
BH4 levels to those observed in low glucose treated cells (P<0.05). When 
hydroxyguanidine was added (OHG, 30 pM), previously shown not to support 
NO synthesis from BH2-bound eNOS, no protective effect was observed 
(Figure 5.10). This is consistent with a role for the differing side chains in 
NOHA and OHG in dictating reactivity with ROS (resulting in NO release) and 
the protective properties of NOHA against BH4 oxidation.
The protective effect o f NOHA is dependent on eNOS-derived O2 .
It was hypothesized that conversion of NOHA to NO by high-glucose treated 
EC relies on generation of reactive oxygen species. Experiments sought to 
elucidate the nature of the eNOS-derived ROS that mediate the conversion of 
NOHA to NO, sustaining protective effects of NOHA against BH4 oxidation in 
vitro. Toward this end, the ability of superoxide dismutase (SOD) and 
catalase to prevent NOHA-mediated protection against BH4 oxidation was 
tested. Selective removal of O2' or H2O2 would allow the elucidation of a 
mechanism by which NOHA is protective, i.e. whether O2' or H2O2 is the 
principal mediator of NOHA elicited protection against BH4 oxidation. As 
shown in Figure 5.7, SOD, but not catalase, abrogated the ability of NOHA to 
prevent high glucose-induced pterin oxidation. Hence, these data suggest 
that O2', in addition to being highly effective in mediating conversion of NOHA 
to NO, is required for the protective effect of NOHA against BH4 oxidation and 
BH2 accumulation in EC (Figure 5.11).
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It was previously observed that eNOS is the sole source of O2' 
production after 48 h incubation of EC with elevated levels of glucose. To 
affirm that eNOS-derived O2' also supports NO synthesis from NOHA (Figure
5.12) eNOS gene silencing experiments were attempted, as previously 
applied to high glucose-treated EC and described in Chapter 3. It was 
hypothesized that knockdown of eNOS-derived O2' would attenuate or even 
abrogate the protective effect of NOHA against pterin oxidation. However, 
eNOS gene silencing in high glucose treated EC was sufficient on its own to 
prevent pterin oxidation; therefore, effects of NOHA upon this system could 
not be simply evaluated. Pterin redox status, and specifically BH2 
accumulation (Figure 5.12B), remained unchanged versus NOHA treatment 
alone. As the siRNA approach lacked utility, studies also tested whether 
pharmacological inhibition of eNOS-derived O2' blocks the ability of NOHA to 
protect against BH4 oxidation. Paradoxically, in the presence of L-NAME, the 
protective effect of NOHA on BH4 oxidation was diminished to the lesser 
protective levels observed with L-NAME alone. Removal of eNOS-derived O2' 
and subsequent attenuation of the protective effect of NOHA, suggest that the 
protective effect of NOHA is dependent on eNOS-derived O2'.
Taken together, these data identify eNOS as the major source of ROS 
for conversion of NOHA to NO in high glucose treated EC. Moreover, the 
identity of the catalytic ROS was confirmed as O2', or a 0 2  -derived species, 
probably peroxynltrite.
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Figure 5.7. NO production from NOHA by EC is accelerated by high 
glucose treatment. NOHA elicits concentration-dependent NO production 
from both low and high glucose treated EC cells. NOHA was added to EC 
media and NO production measured using an Apollo 4000 NO electrode (WPI 
instruments, Sarasota, FL). NOHA produced significantly more NO from high 
glucose, compared to low glucose treated cells (P<0.01). Points are means ± 
SEM (n=3).
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Figure 5.8. NOHA is more effective in restoring NO bioactivity in EC that 
express elevated levels o f Og". High glucose treatment diminished basal NO 
production by 50%. NOHA significantly increased NO production in both high 
and low glucose treated cells. Importantly, eNOS derived O2 , from high 
glucose treated cells, supported NO production from NOHA to a greater 
extent than in low glucose treated cells following activation with A23187 for 20 
min (*P<0.05). Bioactive NO was measured indirectly by cGMP accumulation 
in RFL-6 reporter cells. Bars are means ± SEM (n=3).
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Figure 5.9. NOHA, but not arginine, protects against glucose-induced 
oxidation o f BH4 in EC. EC were cultured in low or high glucose containing 
medium for 48 hours. NOHA (30 pM) and arginine (30 pM), or an equivalent 
volume of vehicle (BASAL) were added at 24 hours and pterin oxidation 
status measured by HPLC-EC. NOHA, but not arginine, attenuated glucose- 
induced BH4 (filled bars) oxidation to BH2 (open bars) in EC. Bars are means 
± SEM (n=8).
154
Mark J. Crabtree BH4 oxidation in models of vascular disease 2005
125
LOW
HIGH
BASAL OHG
Figure 5.10. N-hydroxyguanidine (OHG) has no protective effect against 
pterin oxidation. EC were cultured in low or high glucose containing medium 
for 48 hours. OHG (30 pM) was added at 24 hours and pterin oxidation status 
measured by HPLC-EC. OHG had no effect on glucose induced BH4 (filled 
bars) oxidation to BH2 (open bars) in EC. Values are means ± SEM (n=5).
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Figure 5.11. Protection against BH4 oxidation by NOHA depends on O2 , 
but not H2O2. EC were cultured in low or high glucose containing medium for 
48 hours. NOHA (30 pM), SOD (2000 U/ml) or catalase (2000 U/ml) were 
added alone, or in combination at 24 hours and pterin oxidation was 
measured by HPLC-EC. NOHA alone prevented high-glucose induced BH4 
oxidation in EC. The protective effect of NOHA was attenuated by SOD, but 
not catalase. Bars are means ± SEM (n=6).
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Figure 5.12. The protective effect o f NOHA is dependent on O i derived 
from eNOS. EC were cultured in low or high glucose containing medium for 
48 hours. After 24 hours, NOHA (30 pM) was added alone (black bars), or in 
combination with either eNOS-specific siRNAs (blue bars), or L-NAME (3 mM: 
red bars). Panel A: Effect of treatments on total EC pterin content. Panel B: 
Replot of data from panel A, depicting the effect of treatments on absolute 
BH2 levels. NOHA and eNOS siRNA exhibited significant protective effects 
on BH4 (filled bars) oxidation to BH2 (open bars). L-NAME significantly 
attenuated the protective effect of NOHA (*P<0.05). Bars are means ± SEM 
(n=8).
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NOHA prevents high glucose-induced formation of O2 and 
accumuiation of protein incorporated 3-NT. If NOHA reacts with O2' to 
cause NO release, as the data indicates, it is conceivable that significant 
amounts of O2' are consumed in the process. NOHA therefore has potential 
antioxidant effects in addition to restoring NO synthesis. To test this 
possibility, EC were cultured in low or high glucose containing medium for 48 
hours. NOHA (30 pM) was added at 24 h and release of O2' and 3-NT 
incorporation into cellular protein was measured by luminol 
chemiiuminescence and HPLC-EC, respectively (Figure 5.13). NOHA 
markedly suppressed O2' levels and significantly diminished the accumulation 
of 3-NT in endothelial proteins (indicative of attenuated peroxynitrite 
formation).
The reaction between NOHA and O2 results in the formation of 
different products than those observed after NOHA reaction with H2O2.
The reactions between NOHA and either O2', H2O2 or peroxynitrite each 
appear to yield some NO as a reaction product, as detected by an NO- 
sensitive electrode. However, at least in the case of H2O2 and peroxynitrite, it 
is apparent that NO-like products (i.e. nitroxyl) predominate. Identification of 
the citruiline like co-products may inform on the reaction mechanism and 
chemistry by which NOHA gives rise to NO and relates species. To gain 
insight into the reaction, NOHA was incubated for 30 minutes in the presence 
of O2' (derived from the xanthine/xanthine oxidase system) or H2O2 (100 pM) 
and the reaction products were analyzed by LC-MS/MS as outline in Materials 
and Methods. The alternative reaction products derived in the presence of
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the alternative oxygen species were found to be significantly different as 
shown in Figure 5.14. Although definitive identification of the reaction 
products was not obtained by this experiment, it is apparent that the reaction 
products, and hence reaction mechanism of NOHA with O2' and H2O2 are 
different. Notably, previous published reports suggested the identity of these 
co-products and possible mechanisms by which they may be formed. 
Marietta et al studied the formation of a carbodiimide and cyanoornithine from 
the reaction of NOHA with O2 and H2O2 , respectively, as shown in Figure 
5.15A (Pufahl and Marietta, 1993; Pufahl et al., 1992; Pufahl et al., 1995). It 
is also notable that Southan et al carried out related experiments looking at 
the ability of NOHA to donate NO in the presence of peroxynitrite and 
suggested the formation of a NO donating intermediate, similar to those of the 
NON Oates depicted in Figure 5.15B (Southan et al., 1998).
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Figure 5.13. NOHA prevents high glucose-induced formation o f O i and 
3-NT. EC were cultured in low or high glucose containing medium for 48 h. 
NOHA (30 pM) or ARG (30 pM) was added at 24 h and production of O2 ' and 
3-NT protein incorporation were measured by luminol chemiiuminescence and 
HPLC-EC, respectively. NOHA, but not ARG diminished O2' production 
toward normal levels {Panel A) and prevented 3-NT accumulation in 
endothelial proteins {Panel B). Bars are mean ± SEM (n=6). .
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Figure 5.14. LC-MS/MS analysis of NOHA reaction products with O2 or 
H2O2- NOHA (30 jjM) was incubated with O2 ' (0.1 U xanthine oxidase, plus 
100 pM xanthine, or 100 pM H2 O2 . Although product identification was not 
definitive, reactions of NOHA with O2 ' and H2 O2 clearly resulted in different 
co-products with NO. Similar results were obtained two other experiments.
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Figure 5.15. Possible reaction mechanisms for the reaction o f NOHA 
with superoxide, hydrogen peroxide and peroxynitrite. Panel A: 
Predicted formation of carbodiimide and cyanoornithine products from the 
reaction of NOHA with O2 and H2O2 , respectively (Pufahl et al., 1995). Panel 
B: Potential formation of an NO donor from the reaction of NOHA with 
peroxynitrite (Southan et al., 1998).
162
Mark J. Crabtree BH4 oxidation In models of vascular disease 2005
5.4 Discussion
Endothelial dysfunction, characterized by deficient NO bioactivity, has 
been implicated in the etiology and progression of a number of major vascular 
disorders, including atherosclerosis and diabetic vasculopathy. Previous 
studies have implicated simple BH4 insufficiency as a primary basis for the 
observed deficiency in endothelial-derived NO. Studies outlined in previous 
chapters implicate a molecular basis for BH4 insufficiency in which the 
oxidation of BH4 to BH2 by eNOS-derived ROS leads to an accumulation of 
BH2 and a mixed population of BH2-bound and BH4-bound eNOS. This BH2 
bound eNOS is incapable of NO synthesis, but produces O2" and can thereby 
facilitate further BH4 oxidation. The simultaneous production of NO and O2' 
by eNOS leads to the formation of the more potent oxidant, peroxynitrite, 
scavenging NO in the process. Data described herein demonstrates that 
NOHA, has the potential to consume superoxide (or a derived oxidant), 
deliver NO, restore cellular pterin to its fully reduced form, and thus end the 
futile cycle, BH2 accumulation and NO insufficiency outlined above.
BH2 is unable to support eNOS-mediated metabolism of arginine to 
NO and citrulline (Vasquez-Vivar et al., 2002). However, since NO synthesis 
occurs in two sequential steps, and BH4 cycling to the BH3 radical seems to 
be involved in the first of these steps (i.e. formation of NOHA), whether BH2- 
eNOS is capable of catalyzing the second catalytic step -  the conversion of 
NOHA to NO and citrulline was questioned. Experiments confirmed this 
hypothesis (Figure 5.1), although the mechanism was found to differ markedly 
from the orthodox BH4-bound eNOS catalyzed reaction. In vitro studies 
indicated that NOHA is a substrate for NO production by BH4-bound eNOS,
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by conventional conversion at the active site, and BH2-bound eNOS, by a 
ROS-dependent mechanism that is promoted by the release of O2' 
independent of NOHA-binding to the arginine binding site. Notably, arginine 
is only a substrate for NO production by BH4-bound eNOS.
It is now appreciated that BH4 occupancy determines whether eNOS 
catalyses the production of O2 ' or NO. In BH4 deficient NOS, L-arginine 
oxidation becomes uncoupled from O2 reduction, resulting in the production of 
O2' rather than NO, as detected by electron paramagnetic resonance (ERR) 
(Pou et al., 1992; Vasquez-Vivar et al., 1998). Moreover, addition of BH4 to 
purified eNOS has been shown to simultaneously enhance NO production 
and decrease O2* generation (Wever et al., 1997). In chapters three and four 
experiments confirmed that BH4 levels do influence the identity of eNOS- 
derived products, but suggest that it is the ratio of reduced:oxdized pterin 
(BH4:BH2) that is the determining factor of whether NO or O2' is produced 
(not strictly BH4 amount as previously thought). Simultaneous production of 
NO and O2 ' by NOS and the near diffusion-limited rate of reaction between 
O2" and NO, resulting in the formation of peroxynitrite, can elicit further BH4 
oxidation and BH2 accumulation. In accord with this model, these studies 
have observed BH4 oxidation in three independent models of endothelial 
dysfunction: vascular cells exposed to high levels of glucose (Figure 3.10), the 
ZDF rat model of type II diabetes (Figure 4.3) and the ApoE knockout model 
of atherosclerosis (Figure 4.6).
Studies described herein, follow on from previous investigations carried 
out by a previous graduate student. Dr. Caroline Smith (described in part in 
figures 5.2 and 5.3). These prior experiments illustrated that while NMA and
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L-NAME inhibited NOx generation by BH4-eN0S, these NOS inhibitors 
potentiate NOx generation by BH2-eN0S. This finding indicates that 
interaction of NOHA with the arginine binding site is not required for the 
reactions catalyzed by BH2-eN0S and are consistent with the view that NMA 
and L-NAME potentiate eNOS uncoupling (Figure 5.5). It was also found that 
NOx generation from BH2-bound eNOS is blocked by a flavin inhibitor, DPI 
and is suppressed in the absence of Ca^Vcalmodulin, further implicating 
electron flux through eNOS as causal (not shown).
In sufficient quantity, both O2 ' (Everett et al., 1996; Modolell et al., 
1997; Vetrovsky et al., 1996) and hydrogen peroxide (Pufahl et al., 1995) can 
support the non-enzymatic conversion of NOHA to citrulline and a product 
with NO bioactivity that decays to NOx (NO2/NO3). Thus, the capacity of BH2- 
bound eNOS to produce either O2' or hydrogen peroxide could mediate NOHA 
metabolism in vivo. Alternatively, akin to the finding that NOS is the principal 
“paraquat diaphorase” (Day et al., 1999), an NADPH oxidase activity that 
preferentially functions to toxify paraquat by reducing it to the reactive free- 
radical intermediate, BH2-bound eNOS could directly provide electrons for 
reduction of NOHA to NOx and citrulline. When NOHA was incubated in the 
presence of xanthine/xanthine oxidase (O2' generating system), H2O2 or SIN- 
1 (a peroxynitrite donor), O2 ' and H2O2 were shown to generate NOx (as 
measured by the Griess assay. Figure 5.6) and «NO (measured by the NOS 
selective electrode. Figure 5.5). When repeated in the presence of SOD or 
catalase, NOx/NO formation was attenuated by xanthine/xanthine oxidase and 
H2O2 systems, respectively. Marietta et ai previously reported that H2O2 could 
form citrulline from NOHA, but were unable to detect the formation of NOx,
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perhaps due to the micromolar detection limit of the Griess assay. The 
marked inhibition of NO production by SOD or catalase suggests that the 
major route for conversion of NOHA is by eNOS-derived oxidants, rather than 
the direct donation of electrons between eNOS and NOHA, although a minor 
role for this paraquat-like mechanism cannot be ruled out.
SIN-1 was observed to promote NO production from NOHA as 
assessed by a selective NO electrode (Figure 5.3), whereas NOx formation 
was undetectable by the Griess assay. Reaction of NOHA with known 
amounts of actual peroxynitrite, rather than continual generation from SIN-1, 
also gave a negative result by the Griess assay and, due to the extremely 
short lifetime of peroxynitrite at physiological pH, measurement of NO with the 
electrode was not feasible. Colorimetric detection of NO by the Griess assay 
relies upon a colorimetric diazotization reaction at low pH. Hence, the 
addition of peroxynitrite, in 2 M NaOH (necessary for preservation of 
peroxynitrite), interferes with the Griess methodology. Surprisingly, unlike the 
O2 /H2O2 catalyzed reaction, SIN-1-mediated NO production from NOHA 
appears to be quantitative (i.e. 30 pmoles of NOHA should yield a maximum 
of 30 pmoles of NO) (Pufahl et al., 1995). However, Southan et al proposed 
the formation of a NONOate like NO donor during the reaction of SIN-1 with 
NOHA (as shown in Figure 5.14) and observe the concomitant release of NO 
and N2O upon reaction of NOHA and peroxynitrite (Southan et al., 1998). 
According to this view, NO would be an indirect product of NOHA.
As the formation of either NO or its one electron reduced form, NO* 
would give rise to NO2/NO3 in physiological buffers, the identity of the reaction 
product as NO is verified using an NO-selective electrode which fails to detect
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NO'. To further confirm NO as the dominant product, incubates were subject 
to LC-MS/MS analysis. Although inconclusive, mass spec chromatograms do 
reveal that the reaction products of NOHA with H2O2 and O2 ' are significantly 
different. Further analysis will be required to conclusively identify the 
citrulline-like product of the NOHA reaction which should shed light on the 
nature of the oxidant that supports NO production from NOHA in v/vo (Figure
5.13).
In the setting of endothelial dysfunction, NOHA may serve a unique 
role in supporting NO production by EC that are BH4 deficient (or which 
possess excess BH2), therefore over produce O2 ' and are unable to utilize 
arginine as a NO precursor. Having characterized the ability of NOHA to 
donate NO, and in the process consume 0 2 ', H2O2 and peroxynitrite, the 
possible therapeutic benefits of NOHA administration in alleviating oxidative 
stress and BH4 deficiency in an EC model of diabetes were investigated. 
NOHA (30 pM) was added to cells grown in high glucose containing media 
and NO production was quantified using an NO selective electrode. In 
support of our hypothesis, high glucose treated, oxidatively stressed cells 
supported the production of «50% more NOHA-derived NO, in comparison to 
low glucose treated cells (Figure 5.7). This result was confirmed by the 
detection of similarly increased cGMP production in RFL-6 reporter cells in the 
presence of conditioned media from high glucose treated cells, compared to 
media from low glucose controls (Figure 5.8). Notably, in both experiments 
NOHA was found to fully restore NO production to levels detected with low 
glucose. Additionally, levels of cGMP produced in the presence of NOHA 
were 3- and 4-fold greater than observed with arginine controls under low
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glucose and high glucose treatment. This finding may be explained by 
knowledge that NOHA is actually a more productive substrate for all NOS 
isoforms, exhibiting a Vmax that is 3-fold greater than that with arginine.
As NOHA was able to reinstate NO synthesis via a process in which it 
was hypothesized was by the removal of ROS, the ability of NOHA to protect 
intracellular BH4 against oxidation was evaluated. Hence, the degree of BH4 
oxidation in cells exposed to high levels of glucose in the absence and 
presence of NOHA was compared. Notably, Figure 5.9 shows that NOHA 
was able to fully prevent BH4 oxidation by elevated glucose (P<0.05), while 
arginine offered no protective effect. Furthermore, when compared to the 
degree of BH4 oxidation observed at 24 hours (Figure 3.10), NOHA was 
found to reverse BH2 accumulation in EC. SOD, but not catalase prevented 
the protective effect of NOHA, implicating O2', or a 02'-derived species (i.e. 
peroxynitrite) as the radical that reacts with NOHA to form NO in the high 
glucose tissue culture model of oxidative stress. Reactions of NOHA with 
H2 O2 in the protection against BH4 oxidation are ruled out in this model 
system. Indeed, catalase had little effect on NOHA-mediated cellular pterin 
restoration and the addition of SOD, which increases levels of H2 O2 , 
diminished the protective effect of NOHA. Silencing eNOS protein expression 
using eNOS-specific siRNA, thereby attenuating both eNOS-derived NO and 
O2', elicited a profound protective effect on glucose-induced pterin oxidation. 
However, when high glucose stressed EC were exposed to a combination of 
NOHA (30 pM) and L-NAME (3 mM), the protective effect of NOHA was 
prevented. Taken together, these data identify eNOS as the major source of 
ROS that mediates conversion of NOHA to NO in high glucose treated EC.
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Furthermore these data confirm the mediation of eNOS-derived O2 ', or a O2 - 
derived species, probably peroxynitrite, in NOHA elicited protection against 
BH4 oxidation. Separately, these experiments have demonstrated that both 
O2 ' and peroxynitrite are able to support NO synthesis from NOHA. As NO 
and O2' react at a near-diffusion limited rate (6.7 x 10® mol-L'^-s'^) (Huie and 
Padmaja, 1993), it is extremely unlikely that O2 ' would react with NOHA when 
NO is available. Indeed, the rate of degradation of NOHA by O2 ' has been 
measured at 200-500 M’^s*\ far too slow to compete with either NO or SOD 
under physiological conditions. Therefore, the most likely scenario in 
oxidatively stressed EC is that eNOS-derived O2 ' and NO react together to 
form peroxynitrite and that peroxynitrite, not 0 2 ', mediates the conversion of 
NOHA to NO.
Physiological serum concentrations of arginine and NOHA in humans 
have been measured as 91 pM and 9.1 pM, respectively (Meyer et al., 1997). 
In patients exhibiting diseases where oxidative stress is prominent, such as 
rheumatoid arthritis and systemic lupus erythrematosis, levels of serum 
NOHA are reported to be increased (Wigand et al., 1997). This is indicative of 
elevated NO synthase activity in response to acute or chronic inflammation 
(Wigand et al., 1997). Circulating levels of NOHA may therefore serve as a 
substrate for BH2-eN0S, particularly under pathophysiological conditions in 
which oxidative stress is evident. It is hypothesized that elevated levels of 
NOHA may occur in vascular conditions exhibiting oxidative stress-induced 
endothelial dysfunction. The molecular basis for NOHA accumulation in such 
settings is not known.
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NOHA can potentially target the delivery of NO in a peroxynitrite- 
dependent manner to sites of oxidative stress-mediated NO deficiency, while 
simultaneously diminishing harmful levels of ROS. This possibility is 
supported by our observation that NOHA efficiently attenuated glucose- 
induced elevations in both O2 ' (Figure 5.12A) and 3-NT (Figure 5.12B).
In summation, as outlined in Figure 5.16, these studies suggest that in 
healthy endothelium, BH4-bound eNOS produces sufficient levels of NO and 
promotes optimal endothelial function/vasorelaxation. Under conditions of 
oxidative stress, as evident for cultured EC when exposed to elevated levels 
of glucose, BH4 becomes oxidized to BH2 causing eNOS uncoupling, O2" 
production, endothelial dysfunction and subsequent impaired vasodilation. 
Studies described herein provide evidence for a beneficial effect of NOHA, 
restoring endothelial function in oxidatively stressed cells. NOHA can react 
with and remove 0 2 ', re-coupling eNOS and donating NO specifically at sites 
of deficiency. This putative therapeutic effect of re-coupling eNOS, by 
reversal of pterin oxidation has potential for development as an alternative or 
supplement to therapies that aim to increase BH4 levels. Notably, increasing 
levels of BH4 in the setting of underlying oxidative stress could offer a short­
term therapeutic remedy and may ultimately worsen existing dysfunction. 
Attenuated oxidative stress by NOHA administration is anticipated to restore 
the normally high BH4:BH2 ratio (typically >10 in healthy EC), reverse 
endothelial dysfunction and reinstate antioxidant defenses. Accordingly, 
NOHA has potential to serve as a generic approach for therapeutic treatment 
of vascular complications in which oxidative stress plays a predominant role. 
The ability of NOHA and potentially other superoxide-dependent NO donors to
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reverse pterin oxidation and endothelial dysfunction could prove to be very 
therapeutically important. As an endogenous product, NOHA is likely to be 
safe and may be taken either prophylactically in asymptomatic subjects with a 
familial history of vascular disorders (with a high risk profile), or it could be 
used therapeutically, to reverse existing endothelial dysfunction and re-instate 
normal vascular function.
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Figure 5.16. ROS-elicited NO donation by NOHA. It is hypothesized that in 
normal healthy endothelium, BH4-bound eNOS produces optimal levels of NO 
and promotes good endothelial function/vasorelaxation. Under conditions of 
oxidative stress BH4 becomes oxidized to BH2 causing eNOS uncoupling, O2 ' 
production and impaired vasodilation. NOHA is proposed to restore healthy 
endothelial function by reacting with and removing ROS, re-coupling eNOS 
and donating NO specifically at sites of deficiency.
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6.0 Concluding remarks and future work
The goal of this thesis research project was to elucidate the 
mechanisms by which oxidative stress, such as associated with diabetes and 
other chronic vascular diseases, lead to endothelial dysfunction and 
impairment of NO bioactivity. These investigations have advanced our 
understanding of the role and relative contribution of BH4 oxidation and 
uncoupled eNOS to the pathogenesis of chronic vascular diseases. In the 
course of these investigations, it was discovered that NOHA has potential for 
therapy of endothelial dysfunction, donating NO, while simultaneously 
scavenging O2' at sites where the production of ROS attenuates NO 
bioavailability.
In the healthy endothelium, BH4-bound eNOS produces sufficient 
levels of NO to promote normal endothelial function and vasorelaxation 
(Figure 6.1: Top). Under conditions of oxidative stress, as evident in both our 
in vitro and in vivo models of hyperglycemia/diabetes, BH4 becomes oxidized 
to BH2, causing eNOS uncoupling, O2' production, endothelial dysfunction 
and impaired vasodilation (Figure 6.1: Middle). Studies described herein lead 
to the speculation that in regions of most severe oxidative stress, NOHA can 
efficiently scavenge O2' (or derived oxidants), donating NO in the process; this 
leads to restoration of cellular BH4:BH2 ratios, re-coupling of eNOS and 
restoration of normal endothelial NO production (Figure 6.1 : Bottom).
Several key questions remain unanswered while many new lines of 
investigation have emerged. Future research directions of this project will 
include in vitro and in vivo studies, not limited to those described below.
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It is hypothesized that it is the intracellular ratio of BH4:BH2, rather 
than the absolute amount of BH4, that determines the balance between the 
alternative eNOS products, NO and O2'. In cultured cells in which oxidative 
stress was induced by high levels of glucose, eNOS was largely responsible 
for the production of O2' and the oxidation of BH4 after 48 hours. The 
resulting BH2 accumulation may displace BH4 from its binding site on eNOS, 
promoting eNOS uncoupling and a futile cascade of BH4 oxidation, BH2 
accumulation, further eNOS-derived O2' production and ultimately, 
compromised endothelial function. Studies in which intracellular pterin levels 
were manipulated by supplementation with exogenous BH4, BH2 or 
sepiapterin confirmed our hypothesis. In cells exhibiting improved BH4:BH2 
ratio following pterin supplementation, NO production was markedly increased 
and O2' production was attenuated. Importantly, these changes occurred 
whilst absolute BH4 levels remained constant. Although our studies support 
this model, further work will be needed to more definitively distinguish whether 
absolute amount of BH4 or the ratio of BH4:BH2 dictates the identity of the 
eNOS product formed and whether BH4 oxidation occurs in all vascular 
conditions associated with oxidative stress. These follow on experiments 
would involve manipulating intracellular BH4 and BH2 levels in EC by 
transfection with GTPCH or pterin supplementation, in the setting of varying 
oxidative conditions (e.g. oxLDL), together with pterin analysis by HPLC-EC. 
If our theory is correct that BH4:BH2 ratio, not BH4 amount dictates the 
ultimate product of eNOS, it would be predicted that NO production would not 
correlate with total BH4 amount, but with the BH4:BH2 ratio in vivo. Under 
oxidative conditions where BH2 accumulation is manifest, manipulation of
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BH4:BH2 ratio and total BH4 amounts with subsequent correlation of vascular 
function, NO production and O2 ' synthesis, should further elucidate the role of 
BH4 oxidation in the progression of vascular disease.
Although our studies suggest that following 48 hours of high glucose 
treatment, eNOS is largely responsible for pterin oxidation, the initial trigger of 
BH4 oxidation is still undefined. Our investigations are consistent with the 
view that increased flux through the mitochondrial electron transport chain 
and promotion of mitochondrial ROS production play a significant role in BH4 
oxidation and eNOS uncoupling. Unexpectedly, no contribution of NADPH 
oxidase to biopterin oxidation was observed in our high glucose EC model. 
This is in contrast to another report in which significant activity of NADPH 
oxidase was observed in response to elevated levels of glucose (Cosentino et 
al., 2003). These discrepant findings may be explained by differences in cell 
lines and the duration of glucose exposure. It is conceivable that NADPH 
oxidase activation, giving a superoxide “burst”, may contribute to BH4 
oxidation during a brief interval and for certain cell types. Future in vitro cell 
culture experiments, elucidating the relative contribution of NADPH oxidase-, 
mitochondrial- and eNOS-derived O2'w ill be illuminating.
Having previously found that a subpopulation of eNOS specifically 
associates with the outer membrane on the mitochondria (Gao et al., 2004), 
and that mitochondrial O2' is necessary for glucose-induced oxidation 
(described herein), it is hypothesized that peroxynitrite is formed at the 
mitochondrial surface and may play an initiating role for BH4 oxidation, 
leading to eNOS uncoupling. Since peroxynitrite is predicted to react within 1- 
2 pm of the site of its synthesis (Jourd'heuil et al., 2001), mitochondrial eNOS
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may be preferentially uncoupled. Uncoupling of mitochondria-associated 
eNOS would then elicit a feed forward cascade, ubiquitous BH4 oxidation and 
propagation of significant O2 ' production by eNOS throughout the whole cell, 
scavenging of bioavailable NO and ultimately, transcellular NO insufficiency. 
Mammalian vectors allowing the overexpression of mitochondrial-targeted 
eNOS have been recently developed and are now available in our laboratory. 
Comparison of cells expressing eNOS-WT and eNOS-Cox (containing the 
cytochrome oxidase peptide that specifically targets eNOS to the 
mitochondrial outer membrane), following exposure of cells to oxidative stress 
conditions, will enable the differential effect of mitochondrial vs. wild type 
eNOS-derived O2' on pterin redox status and NO production to be elucidated. 
Conditions that accelerate or attenuate mitochondrial-derived O2' production 
on BH4 redox status, 3-NT accumulation, eNOS and GTPCH protein 
expression in oxLDL and high glucose-induced oxidatively stressed EC will be 
investigated. These experiments should allow us to ascertain whether 
mitochondrial eNOS is a dominant generator of the NO and O2 ' that promotes 
BH4 oxidation and NO sufficiency, and if facilitating mitochondrial association 
of eNOS accelerates ROS-induced endothelial dysfunction.
An obvious translation of the studies described herein, is the evaluation 
of the therapeutic potential of NOHA in animal models of vascular disease. 
From the data presented herein, it is hypothesized that NOHA can retard, or 
reverse, the progression of endothelial dysfunction associated with type II 
diabetes and atherosclerosis in ZDF rat and ApoE knockout mouse models, 
respectively.
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The potential utility of NOHA will be tested in ApoE knockout mice fed 
a western diet and ZDF rat models of atherosclerosis or chronic 
hyperglycemia, respectively. Since pharmacokinetics of NOHA are 
undefined, in initial experiments animals would be continually infused with 
either NOHA or arginine (as control), at equivalent concentrations and rates 
using Alzet miniosmotic pumps. A control group would receive an equivalent 
infusion dose of mannitol as an osmotic control. Due to the asymptomatic 
nature of atherosclerosis and diabetes (patients are not typically diagnosed 
until vascular complications are profound), the study will not only focus on the 
ability of NOHA to protect against the appearance of vascular complications, 
but also the potential of NOHA to reverse advanced-stage endothelial 
dysfunction in ApoE knockout mice and ZDF rats. In the ApoE knockout 
mouse model, NOHA administration will therefore be given to two separate 
animal groups, starting at 8 weeks (with the initiation of the western diet) and 
after 16 weeks (8 weeks after the initiation of the western diet where oxidative 
stress and endothelial dysfunction is already manifest). The ZDF rat becomes 
hyperglycemic with age so no western diet is required. A similar regime, 
comparing early and late initiation of NOHA treatment at 8 and 16 weeks, 
respectively, would also be evaluated. After sacrifice, oxidant stress and 
severity of vasculopathies would be assessed using many of the biochemical, 
physiological and histological procedures outlined in Chapters 3 and 4. These 
experiments are currently in the planning phase, but are soon to be initiated.
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Figure 6.1. Schematic representation depicting the roie o f eNOS 
uncoupling and BH4 oxidation in endothelial dysfunction. These data 
suggest that NOHA can react with and efficiently remove 0 { ,  re-coupie 
eNOS and donate NO preferentially at sites o f deficiency.
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